Compositions and methods for inhibiting MASP-1 and / or MASP-2 and / or MASP-3
By using MASP-3 and MASP-2 inhibitor compositions, the activation of the complement system is inhibited, and the problem of difficulty in effectively inhibiting the activation of the complement system in the prior art is solved, and treatment options are provided for specific diseases to reduce tissue damage.
Patent Information
- Application Number
- CN202410989581.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2012-06-18
- Filing Date
- 2013-06-18
- Publication Date
- 2024-11-12
AI Technical Summary
The prior art is difficult to effectively inhibit the activation of the complement system, resulting in tissue damage in various diseases, especially the role of classical pathways, lectin pathways and alternative pathways in disease pathogenesis is not fully understood and inhibited.
Develop compositions containing MASP-3 inhibitors and MASP-2 inhibitors for inhibiting MASP-3-dependent and MASP-2-dependent complement activation by specific binding or competition with MASP-3 or MASP-2 Sex-bound antibody fragments reduce the activation of the complement system, especially for diseases such as paroxysmal nocturnal hemoglobinuria and age-related macular degeneration.
Effectively inhibit MASP-3-dependent and MASP-2-dependent complement activation, reduce tissue damage, and provide potential treatment options for diseases such as paroxysmal nocturnal hemoglobinuria, age-related macular degeneration, etc.
Smart Images

Figure BDA0004958491900000361 
Figure BDA0004958491900001051 
Figure BDA0004958491900001061
Abstract
Description
[0001] The present application is a continuation-divisional application of invention application No. 201380044434.5, which is filed on June 18, 2013 and entitled “Compositions and methods for inhibiting MASP-1 and / or MASP-2 and / or MASP-3 for treating various diseases and conditions”, and divisional application No. 201811331359.1, which is filed on June 18, 2013.
[0002] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit of application No. 61 / 661,167, filed June 18, 2012. Technical Field The present application relates to inhibitors of the complement system and their use in various clinical conditions. Background Art The complement system provides an early mechanism of action (MK Liszewski and JP Atkinson, 1993, in Fundamental Immunology, 3rd edition, WE Paul edited, Raven Press, Ltd., New York) for initiating, amplifying and arranging immune responses against microbial infections and other acute injuries in humans and other vertebrates. Although complement activation provides an important first line of defense against potential pathogens, the complement activity that promotes protective immune responses can also show potential threats to the host (KR Kalli et al., Springer Semin. Immunopathol. 15: 417-431, 1994; BP Organ, Eur. J. Clinical Investig. 24: 219-228, 1994). For example, C3 and C5 protein hydrolysis products recruit and activate neutrophils. Although essential for host defense, activated neutrophils are indiscriminate in the release of their destructive enzymes and can cause organ damage. Furthermore, complement activation can result in the deposition of lytic complement components on nearby host cells as well as microbial targets, leading to host cell lysis.
[0005] The complement system has also been implicated in the pathogenesis of many acute and chronic disease states, including myocardial infarction, stroke, ARDS, reperfusion injury, septic shock, capillary leakage following thermal burns, inflammation after cardiopulmonary bypass, transplant rejection, rheumatoid arthritis, multiple sclerosis, myasthenia gravis, and Alzheimer's disease. In almost all of these conditions, complement is not the cause, but rather one of several factors involved in the pathogenesis. Nevertheless, complement activation can be an important pathological mechanism and has been shown to be effective in the clinical management of many of these disease states. The increasing recognition of the importance of complement-mediated tissue damage in various disease states has emphasized the need for effective complement inhibitory drugs. To date, Eculizumab has been shown to be an effective and promising complement inhibitor. An antibody targeting C5 is the only complement-targeted drug approved for human use. However, C5 is one of several effector molecules located "downstream" of the complement system, and blockade of C5 does not inhibit complement activation. Therefore, inhibitors of the initial steps of complement activation would have significant advantages over "downstream" complement inhibitors.
[0006] At present, it is generally accepted that the complement system can be activated by three distinct pathways: the classical pathway, the lectin pathway, and the alternative pathway. The classical pathway is usually triggered by a complex composed of host antibodies binding to foreign particles (i.e., antigens), and therefore requires prior exposure to antigens to produce specific antibody responses. Because the activation of the classical pathway depends on the host's previous acquired immune response, the classical pathway is part of the acquired immune system. In contrast, both the lectin pathway and the alternative pathway are independent of acquired immunity and are part of the innate immune system.
[0007] Activation of the complement system leads to the continuous activation of serine protease zymogens. The first step in the activation of the classical pathway is the binding of the specific recognition molecule C1q to antigen-bound IgG and IgM molecules. C1q combines with C1r and C1s serine protease zymogens to form a complex called C1. When C1q binds to the immune complex, the Arg-Ile site of C1r undergoes autoproteolytic cleavage, followed by C1r-mediated C1s cleavage and activation, which thereby acquires the ability to cleave C4 and C2. C4 is cleaved into two fragments, called C4a and C4b, and, similarly, C2 is cleaved into C2a and C2b. The C4b fragment can form a covalent bond with an adjacent hydroxyl or amino group and generates the C3 convertase (C4b2b) by non-covalently interacting with the C2a fragment that activated C2. C3 convertase (C4b2b) activates C3 by proteolytic cleavage into C3a and C3b subcomponents, leading to the generation of C5 convertase (C4b2a3b), which cleaves C5, leading to the formation of a membrane attack complex (C5b in combination with C6, C7, C8, and C9, also known as "MAC") that can disrupt the cell membrane and cause cell lysis. The activated forms of C3 and C4 (C3b and C4b) are covalently deposited on the surface of foreign targets, where they are recognized by complement receptors on various phagocytes.
[0008] Independently, the first step in the activation of the complement system through the lectin pathway is also the binding of a specific recognition molecule, which is followed by the activation of the bound serine protease zymogen. However, the recognition molecules in the lectin pathway include a group of sugar-binding proteins collectively known as lectins (mannan-binding lectin (MBL), H-ficolin, M-ficolin, L-ficolin, and C-type lectin CL-11), rather than binding immune complexes through C1q. See J. Lu et al., Biochim. Biophys. Acta 1572: 387-400, (2002); Holmskov et al., Annu. Rev. Immunol. 21: 547-578 (2003); Teh et al., Immunology 101: 225-232 (2000)). See also J. Luet et al., Biochim Biophys Acta 1572:387-400 (2002); Holmskov et al., Annu Rev Immunol 21:547-578 (2003); Teh et al., Immunology 101:225-232 (2000); Hansen et al., J. Immunol 185(10):6096-6104 (2010).
[0009] Ikeda et al. first demonstrated that, similar to C1q, MBL can activate the complement system in a C4-dependent manner after binding to yeast mannan-coated erythrocytes (Ikeda et al., J. Biol. Chem. 262:7451-7454, (1987)). MBL is a member of the collectin protein family and a calcium-dependent lectin that binds to carbohydrates with 3-hydroxy and 4-hydroxy groups oriented in the equatorial plane of the pyranose ring. Therefore, the important ligands for MBL are D-mannose and N-acetyl-D-glucosamine, while carbohydrates that do not meet this steric requirement have no detectable affinity for MBL (Weis et al., Nature 360:127-134, (1992)). The interaction between MBL and monovalent sugars is quite weak, with dissociation constants typically in the single-digit millimolar range. MBL achieves specific and tight binding to glycan ligands by avidity, i.e., by simultaneously interacting with multiple monosaccharide residues located in close proximity to one another (Lee et al., Archiv. Biochem. Biophys. 299: 129-136, (1992)). MBL recognizes carbohydrate patterns that commonly modify microorganisms such as bacteria, yeast, parasites, and certain viruses. In contrast, MBL does not recognize D-galactose and sialic acid, the penultimate and penultimate sugars that typically modify "mature" complex glycoconjugates found on mammalian plasma and cell surface glycoproteins. This binding specificity is thought to facilitate recognition of "foreign" surfaces and help protect against "autoactivation." However, MBL does bind with high affinity to high-mannose "precursor" glycan clusters located on N-linked glycoproteins and glycolipids sequestered in the endoplasmic reticulum and Golgi apparatus of mammalian cells (Maynard et al., J. Biol. Chem. 257: 3788-3794, (1982)). In addition, MBL has been shown to bind to polynucleotides, DNA, and RNA, which may be exposed on necrotic and apoptotic cells (Palaniyar et al., Ann. NY Acad. Sci., 1010:467-470 (2003); Nakamura et al., J. Leuk. Biol. 86:737-748 (2009)). Therefore, damaged cells are potential targets for activation of the lectin pathway via MBL binding.
[0010] Ficolin has a different type of lectin domain from MBL, called a fibrinogen-like domain. ++In humans, three types of ficolins have been identified (L-ficolin, M-ficolin, and H-ficolin). Two serum ficolins, L-ficolin and H-ficolin, share specificity for N-acetyl-D-glucosamine; however, H-ficolin also binds N-acetyl-D-galactosamine. The differences in carbohydrate specificity among L-ficolin, H-ficolin, CL-II, and MBL suggest that different lectins may be complementary, targeting different glycoconjugates despite overlap. This notion is supported by the recent report that, among the known lectins of the lectin pathway, only L-ficolin specifically binds to lipoteichoic acid, a cell wall glycoconjugate found on all Gram-positive bacteria (Lynch et al., J. Immunol. 172:1198-1202, (2004)). In addition to acetylated sugar moieties, ficolin can also bind acetylated amino acids and peptides (Thomsen et al., Mol. Immunol. 48(4):369-81 (2011)). Collectins (i.e., MBL) and ficolin do not share significant amino acid sequence similarities. However, these two groups of proteins have similar domain organization and, like C1q, assemble into oligomeric structures, maximizing the potential for multisite binding.
[0011] Serum concentrations of MBL are highly variable in healthy individuals and are genetically controlled by polymorphisms / mutations in both the promoter and coding regions of the MBL gene. As an acute phase protein, MBL expression is further upregulated during inflammation. L-ficolin is present in serum at concentrations similar to those of MBL. Therefore, the L-ficolin branch of the lectin pathway may be comparable in strength to the MBL branch. MBL and ficolin may also function as opsonins, allowing phagocytes to target MBL- and ficolin-modified surfaces (see Jack et al., J Leukoc Biol., 77(3):328-36 (2004), Matsushita and Fujita, Immunobiology, 205(4-5):490-7 (2002), Aoyagi et al., J Immunol, 174(1):418-25 (2005)). This opsonization requires interaction of these proteins with phagocyte receptors (Kuhlman et al., J. Exp. Med. 169:1733, (1989); Matsushita et al., J. Biol. Chem. 271:2448-54, (1996)), the identity of which has not been determined.
[0012] Human MBL forms specific and high-affinity interactions through its collagen-like domain with unique C1r / C1s-like serine proteases, termed MBL-associated serine proteases (MASPs). Three MASPs have been described to date. First, a single enzyme, "MASP," was identified and characterized as the enzyme responsible for initiating the complement cascade (i.e., cleaving C2 and C4) (Matsushita et al., J Exp Med 176(6):1497-1502 (1992); Ji et al., J. Immunol. 150:571-578, (1993)). Subsequently, it was determined that MASP activity is actually a mixture of two proteases, MASP-1 and MASP-2 (Thiel et al., Nature 386:506-510, (1997)). However, the MBL-MASP-2 complex alone has been shown to be sufficient for complement activation (Vorup-Jensen et al., J. Immunol. 165:2093-2100, (2000)). Furthermore, only MASP-2 cleaves C2 and C4 at high rates (Ambrus et al., J. Immunol. 170:1374-1382, (2003)). Thus, MASP-2 is the protease responsible for activating C4 and C2 to produce the C3 convertase, C4b2a. This is a significant difference from the C1 complex in the classical pathway, in which two specific serine proteases (C1r and C1s) act synergistically to activate the complement system. In addition, a third novel protease, MASP-3, has been isolated (Dahl, MR et al., Immunity 15:127-35, 2001). MASP-1 and MASP-3 are alternatively spliced products of the same gene.
[0013] MASPs share the same domain organization with the enzymatic components of the C1 complex, C1r and C1s (Sim et al., Biochem. Soc. Trans. 28:545, (2000)). These domains include an N-terminal C1r / C1s / sea urchin VEGF / bone morphogenetic protein (CUB) domain, an epidermal growth factor-like domain, a second CUB domain, tandem complement regulatory protein domains, and a serine protease domain. As in the C1 protease, activation of MASP-2 occurs through cleavage of an Arg-Ile bond near the serine protease domain, which separates the enzyme into a disulfide-linked A chain and a B chain, the latter of which is composed of the serine protease domain.
[0014] MBL also associates with an alternatively spliced form of MASP-2, called the 19 kDa MBL-associated protein (MAp19) or small MBL-associated protein (sMAP), which lacks the catalytic activity of MASP-2 (Stover, J. Immunol. 162:3481-90, (1999); Takahashi et al., Int. Immunol. 11:859-863, (1999)). MAp19 comprises the first two domains of MASP-2, followed by an additional sequence of four unique amino acids. The function of MAp19 is unclear (Degn et al., J. Immunol. Methods, 2011). The MASP-1 and MASP-2 genes are located on human chromosomes 3 and 1, respectively (Schwaeble et al., Immunobiology 205:455-466, (2002)).
[0015] Several lines of evidence suggest that different MBL-MASP complexes exist and that the majority of MASPs in serum are not complexed with MBL (Thiel et al., J. Immunol. 165:878-887, (2000)). Both H-ficolin and L-ficolin bind to all MASPs and activate the lectin complement pathway, as does MBL (Dahl et al., Immunity 15:127-35, (2001); Matsushita et al., J. Immunol. 168:3502-3506, (2002)). Both the lectin and classical pathways form a common C3 convertase (C4b2a), and the two pathways converge at this step.
[0016] It is generally believed that the lectin pathway was first used experimentally MBL plays an important role in the host's defense against infection. Strong evidence for its involvement in host defense comes from an analysis of patients with reduced serum levels of functional MBL (Kilpatrick, Biochim. Biophys. Acta 1572: 401-413, (2002)). These patients exhibit susceptibility to recurrent bacterial and fungal infections. These symptoms are usually evident early in life, during the window of vulnerability, as maternally acquired antibody titers decrease, but before the development of a full antibody repertoire. This syndrome is often caused by mutations at several sites in the collagen portion of MBL that interfere with the proper formation of MBL oligomers. However, since MBL can function as a complement-independent opsonin, it is not known to what extent the increased susceptibility to infection is due to impaired complement activation.
[0017] In contrast to the classical and lectin pathways, no initiator has been identified that performs the recognition function in the alternative pathway, whereas in the other two pathways, C1q and lectins perform the recognition function. It is currently generally accepted that the alternative pathway spontaneously undergoes low-level turnover activation, which can be easily amplified on foreign or other abnormal surfaces (bacteria, yeast, virus-infected cells, or damaged tissue) that lack the appropriate molecular elements to maintain controlled spontaneous complement activation. Four plasma proteins are directly involved in the activation of the alternative pathway: C3, factor B, factor D, and properdin.
[0018] Although a wealth of evidence indicates that both the classical and alternative complement pathways are involved in the pathogenesis of non-infectious human diseases, the role of the lectin pathway has only just begun to be evaluated. Recent studies have provided evidence that activation of the lectin pathway may be responsible for complement activation and associated inflammation in ischemia / reperfusion injury. Collard et al. (2000) reported that cultured endothelial cells subjected to oxidative stress bind MBL and exhibit C3 deposition upon exposure to human serum (Collard et al., Am. J. Pathol. 156:1549-1556, (2000)). Furthermore, treatment of human serum with a blocking anti-MBL monoclonal antibody inhibited MBL binding and complement activation. These findings were extended to a rat model of myocardial ischemia-reperfusion, where rats treated with a blocking antibody against rat MBL exhibited significantly less myocardial injury upon coronary artery occlusion than rats treated with a control antibody (Jordan et al., Circulation 104:1413-1418, (2001)). The molecular mechanism of MBL binding to the vascular endothelium after oxidative stress is still unclear; recent studies suggest that activation of the lectin pathway after oxidative stress may be mediated by MBL binding to endothelial cytokeratin rather than binding to glycoconjugates (Collard et al., Am. J. Pathol. 159: 1045-1054, (2001)). Other studies have shown that the role of the classical and alternative pathways in the pathogenesis of ischemia / reperfusion injury, as well as the role of the lectin pathway in this disease, remains controversial (Riedermann, NC et al., Am. J. Pathol. 162: 363-367, 2003).
[0019] Recent studies have shown that MASP-1 and MASP-3 convert the alternative pathway activating enzyme factor D from its zymogen form to its enzymatically active form (see Takahashi M. et al., J Exp Med 207(1):29-37 (2010); Iwaki et al., J. Immunol. 187:3751-58 (2011)). The physiological importance of this process is emphasized by the absence of alternative pathway functional activity in the plasma of MASP-1 / 3-deficient mice. For the alternative pathway to function, C3b, generated by proteolysis of native C3, is required. Because the alternative pathway C3 convertase (C3bBb) contains C3b as an essential subunit, the question of the source of the first C3b via the alternative pathway has raised puzzling questions and has prompted considerable research efforts.
[0020] C3 belongs to a family of proteins (along with C4 and alpha-2 macroglobulin) that contain a rare post-translational modification known as a thioester bond. The thioester group consists of a glutamine whose terminal carbonyl forms a covalent thioester linkage with the sulfhydryl group of a cysteine three amino acids away. This bond is unstable, and the electrophilic glutamyl-thioester can react with nucleophilic moieties such as hydroxyl or amino groups and thereby form covalent bonds with other molecules. When sequestered inside the hydrophobic pocket of intact C3, the thioester bond is quite stable. However, C3 is proteolytically cleaved into C3a and C3b, resulting in the exposure of the highly reactive thioester bond on C3b, which covalently binds to the target following nucleophilic attack by adjacent moieties including hydroxyl or amino groups. In addition to its well-documented role in the covalent binding of C3b to complement targets, the C3 thioester is also believed to have a key role in triggering the alternative pathway. According to the generally accepted "tick-over theory," the alternative pathway is initiated by the generation of the fluid-phase convertase iC3Bb, which is formed from C3, a hydrolyzed thioester (iC3; C3(HO)), and factor B (Lachmann, PJ et al., Springer Semin. Immunopathol. 7:143-162, (1984)). C3b-like C3(HO) is produced by the slow, spontaneous hydrolysis of an internal thioester in the protein from native C3 (Pangburn, MK et al., J. Exp. Med. 154:856-867, 1981). Through the activity of the C3(HO)Bb convertase, C3b molecules are deposited on the target surface, thereby initiating the alternative pathway.
[0021] Prior to the discoveries described herein, little was known about the initiators of alternative pathway activation. Activators are thought to include yeast cell walls (zymosan), many pure polysaccharides, rabbit erythrocytes, certain immunoglobulins, viruses, fungi, bacteria, animal tumor cells, parasites, and damaged cells. The only characteristic shared by these activators is the presence of carbohydrates, but the complexity and diversity of carbohydrate structures make it difficult to identify shared molecular determinants. It is widely accepted that alternative pathway activation is controlled by a fine balance between inhibitory regulatory components of the pathway, such as factor H, factor I, DAF and CR 1, and properdin, the latter being the only positive regulator of the alternative pathway (see Schwaeble WJ and Reid KB, Immunol Today 20(1):17-21 (1999)).
[0022] In addition to the apparent unregulated activation mechanism described above, the alternative pathway can also provide a powerful amplification loop for the lectin / classical pathway C3 convertase (C4b2a), as any C3b generated can join with factor B to form additional alternative pathway C3 convertase (C3bBb). The alternative pathway C3 convertase is stabilized by binding properdin. Properdin extends the half-life of the alternative pathway C3 convertase by six to ten times. Addition of C3b to the alternative pathway C3 convertase leads to the formation of the alternative pathway C5 convertase.
[0023] It has long been believed that all three pathways (i.e., classical, lectin, and alternative pathways) converge at C5, which is cleaved to form products with various proinflammatory effects. The convergent pathway is known as the terminal complement pathway. C5a is the most potent anaphylatoxin, causing changes in smooth muscle and vascular tone and vascular permeability. It is also a powerful chemotactic factor and activator for both neutrophils and monocytes. C5a-mediated cell activation can significantly amplify the inflammatory response by inducing the release of a variety of additional inflammatory mediators, including cytokines, hydrolases, arachidonic acid metabolites, and reactive oxygen species. C5 cleavage leads to the formation of C5b-9, also known as the membrane attack complex (MAC). There is now strong evidence that sub-cleaved MAC deposition, in addition to serving as a pore-forming complex for cleavage, may also play an important role in inflammation.
[0024] In addition to its important role in immune defense, the complement system also contributes to tissue damage in many clinical conditions. Therefore, there is an urgent need to develop therapeutically effective complement inhibitors to prevent these adverse effects. Summary of the Invention In one aspect, the present invention provides methods for inhibiting MASP-3-dependent complement activation in a subject suffering from paroxysmal nocturnal hemoglobinuria (PNH), age-related macular degeneration (AMD), ischemia-reperfusion injury, arthritis, disseminated intravascular coagulation, thrombotic microangiopathy, asthma, dense deposit disease, microimmunonecrotizing crescentic glomerulonephritis, traumatic brain injury, aspiration pneumonia, endophthalmitis, neuromyelitis optica, or Behcet's disease. The methods comprise the step of administering to the subject a composition comprising an amount of a MASP-3 inhibitory agent effective to inhibit MASP-3-dependent complement activation. In certain embodiments, the methods further comprise administering to the subject a composition comprising a MASP-2 inhibitory agent.
[0026] In another aspect, the present invention provides a method for inhibiting MASP-2-dependent complement activation in a subject having or at risk for developing a disease or condition selected from dense deposit disease, microimmunonecrotizing crescentic glomerulonephritis, traumatic brain injury, aspiration pneumonia, endophthalmitis, neuromyelitis optica, or Behcet's disease. The method comprises administering to the subject a composition comprising an amount of a MASP-2 inhibitory agent effective to inhibit MASP-2-dependent complement activation. In some embodiments, the MASP-2 inhibitory agent is a MASP-2 antibody or fragment thereof. In some embodiments, the MASP-2 inhibitory agent is a MASP-2 monoclonal antibody or fragment thereof that specifically binds to a portion of SEQ ID NO:5. In some embodiments, the MASP-2 antibody is a chimeric, humanized, or human antibody.
[0027] In another aspect, the present invention provides pharmaceutical compositions comprising at least one inhibitory agent and a pharmaceutically acceptable carrier, wherein the at least one inhibitory agent comprises a MASP-2 inhibitory agent and a MASP-3 inhibitory agent.
[0028] In another aspect, the invention provides pharmaceutical compositions comprising a MASP-3 inhibitory agent bound to a portion of MASP-1 (SEQ ID NO: 10: full length) and also bound to a portion of MASP-3 (SEQ ID NO: 8) and a pharmaceutically acceptable carrier.
[0029] In another aspect, the invention provides pharmaceutical compositions comprising a MASP-3 inhibitory agent bound to a portion of MASP-2 (SEQ ID NO: 5: full length) and also bound to a portion of MASP-3 (SEQ ID NO: 8) and a pharmaceutically acceptable carrier.
[0030] In another aspect, the invention provides pharmaceutical compositions comprising a MASP-3 inhibitory agent bound to a portion of MASP-1 (SEQ ID NO: 10: full length) and also bound to a portion of MASP-2 (SEQ ID NO: 5) and a pharmaceutically acceptable carrier.
[0031] In another aspect, the invention provides pharmaceutical compositions comprising a MASP-3 inhibitory agent bound to a portion of MASP-1 (SEQ ID NO: 10 full length), bound to a portion of MASP-2 (SEQ ID NO: 5 full length), and further bound to a portion of MASP-3 (SEQ ID NO: 8), and a pharmaceutically acceptable carrier.
[0032] In another aspect, the present invention provides a method for preparing a medicament for inhibiting MASP-3-dependent complement activation in a living subject in need thereof, the method comprising combining a therapeutically effective amount of a MASP-3 inhibitory agent in a pharmaceutical carrier. In some embodiments, the method according to this aspect of the invention comprises preparing a medicament for inhibiting MASP-3-dependent complement activation in a subject suffering from or at risk for developing a disease or condition selected from paroxysmal nocturnal hemoglobinuria (PNH), age-related macular degeneration (AMD), ischemia-reperfusion injury, arthritis, disseminated intravascular coagulation, thrombotic microangiopathy, asthma, dense deposit disease, microimmunonecrotizing crescentic glomerulonephritis, traumatic brain injury, aspiration pneumonia, endophthalmitis, neuromyelitis optica, or Behcet's disease. In some embodiments, the method further comprises combining a therapeutically effective amount of a MASP-2 inhibitory agent into a medicament comprising a MASP-3 inhibitory agent or combining a therapeutically effective amount of a MASP-2 inhibitory agent with a medicament comprising a MASP-3 inhibitory agent.
[0033] In another aspect, the present invention provides methods for preparing a medicament for inhibiting MASP-2-dependent complement activation in a living subject in need thereof, the methods comprising combining a therapeutically effective amount of a MASP-2 inhibitory agent in a pharmaceutical carrier. In some embodiments, the methods according to this aspect of the invention comprise preparing a medicament for inhibiting MASP-2-dependent complement activation in a subject suffering from or at risk for developing a disease or condition selected from dense deposit disease, microimmunonecrotizing crescentic glomerulonephritis, traumatic brain injury, aspiration pneumonia, endophthalmitis, neuromyelitis optica, or Behcet's disease. In some embodiments, the methods further comprise combining a therapeutically effective amount of a MASP-3 inhibitory agent with a medicament comprising a MASP-2 inhibitory agent or combining a therapeutically effective amount of a MASP-3 inhibitory agent with a medicament comprising a MASP-2 inhibitory agent.
[0034] As described herein, various embodiments of MASP-3 inhibitory agents and / or various embodiments of MASP-2 inhibitory agents can be used in the pharmaceutical compositions of the present invention.
[0035] As described herein, the pharmaceutical compositions of the present invention can be used according to the methods of the present invention.
[0036] These and other aspects and embodiments of the invention described herein will become apparent with reference to the following detailed description of the invention and the accompanying drawings. All U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications, and non-patent publications referred to in this specification are incorporated herein by reference in their entirety, as if each were individually incorporated herein. BRIEF DESCRIPTION OF THE DRAWINGS The foregoing aspects of the present invention and many of the attendant advantages will be more readily understood by reference to the following detailed description of the invention taken in conjunction with the accompanying drawings, in which: Figure 1 describes a new understanding of the lectin pathway and the alternative pathway; Figure 2 is a schematic diagram adapted from Schwaeble et al., Immunobiol 205:455-466 (2002), modified by Yongqing et al., BBA 1824:253 (2012), indicating the MASP-2 and MAp19 protein domains and the exons encoding them; Figure 3 Schematic diagram adapted from Schwaeble et al., Immunobiol 205:455-466 (2002), modified by Yongqing et al., BBA 1824:253 (2012), showing the MASP-1, MASP-3, and MAp44 protein domains and the exons encoding them; Figure 4 An alignment of the amino acid sequences of the MASP-1, MASP-2, and MASP-3 proteins is shown and the consensus regions among them are indicated; Figure 5 An alignment of the amino acid sequences of the MASP-1, MASP-2, and MASP-3 alpha chains is shown; Figure 6 An alignment of the amino acid sequences of the MASP-1, MASP-2, and MASP-3 beta chains is shown; Figure 7A Pairwise alignment of the amino acid sequences of the MASP-1 and MASP-2 protease domains (β-chains) is shown; Figure 7B Pairwise alignment of the amino acid sequences of the MASP-1 and MASP-3 protease domains (β-chains) is shown; Figure 7C A pairwise alignment of the amino acid sequences of the MASP-2 and MASP-3 protease domains (β-chains) is shown; FIGURE 8 is a Kaplan-Meier curve graphically showing the percent survival of MASP-2 KO and WT mice following administration of an infectious dose of 2.6 x 107 cfu of N. meningitidis serogroup A Z2491, demonstrating that MASP-2-deficient mice are protected from N. meningitidis-induced mortality, as described in Example 1; Figure 9 is a Kaplan-Meier curve graphically representing the percent survival of MASP-2 KO and WT mice following administration of an infectious dose of 6 x 10<6 > cfu of N. meningitidis serogroup B strain MC58, demonstrating that MASP-2-deficient mice are protected from N. meningitidis-induced mortality, as described in Example 1; Figure 10 The graphic representation shows the log cfu / mL of N. meningitidis serogroup B strain MC58 recovered per mL of blood from MASP-2 KO and WT mice at various time points following i.p. infection with 6 x 10<6 > cfu of N. meningitidis serogroup B strain MC58 (n=3, at various time points for both groups of mice), demonstrating that MASP-2 KO mice have increased bacteremia clearance compared to WT mice, even though MASP-2 KO mice were infected with the same dose of N. meningitidis serogroup B strain MC58 as used for WT mice, as described in Example 1; Figure 11 The graph shows the mean disease scores of MASP-2 KO and WT mice at 3, 6, 12, and 24 hours after infection with 6 x 10<6 > cfu of Neisseria meningitidis serogroup B strain MC58, demonstrating that MASP-2-deficient mice exhibit much lower disease scores at 6, 12, and 24 hours post-infection compared to WT mice, as described in Example 1; Figure 12 is a Kaplan-Meier curve graphically representing the percent survival of mice following administration of an infectious dose of 4 x 10<6 > cfu of Neisseria meningitidis serogroup B strain MC58, followed by administration of an inhibitory MASP-2 antibody (1 mg / kg) or a control isotype antibody 3 hours post-infection, demonstrating that MASP-2 antibodies are effective in treating and improving survival in subjects infected with Neisseria meningitidis, as described in Example 2; Figure 13The graph shows the log cfu / mL of viable counts of Neisseria meningitidis serogroup B strain MC58 recovered at different time points in human serum samples as shown in Table 5 collected at different time points after incubation with Neisseria meningitidis serogroup B strain MC58, as described in Example 3; Figure 14 The graph shows the log cfu / mL of viable counts of N. meningitidis serogroup B-MC58 recovered at different time points in the human serum samples shown in Table 7, demonstrating that complement-dependent killing of N. meningitidis in human 20% (v / v) serum is MASP-3 and MBL-dependent, as described in Example 3; Figure 15 The graph shows the log cfu / mL of viable counts of N. meningitidis serogroup B-MC58 recovered at different time points in the mouse serum samples shown in Table 9, demonstrating that serum from MASP-2- / - knockout mice (referred to as "MASP-2- / -") has a higher level of bactericidal activity against N. meningitidis compared to serum from WT mice, while serum from MASP-1 / 3- / - mice lacks any bactericidal activity, as described in Example 3. Figure 16 The graph shows the kinetics of C3 activation in sera from WT, C4- / -, MASP-1 / 3- / -, Factor B- / -, and MASP-2- / - mice under lectin pathway-specific conditions (1% plasma), as described in Example 4. Figure 17 The graphic shows the expression of MASP-3-deficient, C4-deficient, and MBL-deficient serum samples under "traditional" alternative pathway-specific (AP-specific) conditions (i.e., BBS / EGTA / Mg ++ No Ca ++ ), the level of alternative pathway-driven (AP-driven) C3b deposition on zymosan-coated microtiter plates as a function of serum concentration, as described in Example 4; Figure 18 The graph shows the expression of AP in 10% human serum samples from MASP-3-deficient, C4-deficient, and MBL-deficient human subjects under "traditional" AP-specific conditions (i.e., BBS / EGTA / Mg ++ No Ca ++ ) under conditions of AP-driven C3b deposition over time on zymosan-coated microtiter plates, as described in Example 4; Figure 19AThe graph shows the expression of AP in serum samples from WT, MASP-2-deficient, and MASP-1 / 3-deficient mice under "traditional" AP-specific conditions (i.e., BBS / EGTA / Mg ++ No Ca ++ ) or under physiological conditions that allow both the lectin pathway and the alternative pathway (AP) to function (BBS / Mg ++ / Ca ++ ) under the condition of C3b deposition level on mannan-coated microtiter plates as a function of serum concentration, as described in Example 4; Figure 19B The graph shows the expression of AP in serum samples from WT, MASP-2-deficient, and MASP-1 / 3-deficient mice under conventional AP-specific conditions (i.e., BBS / EGTA / Mg ++ No Ca ++ ) or under physiological conditions that allow both the lectin pathway and the alternative pathway to function (BBS / Mg ++ / Ca ++ ) under the condition of C3b deposition on zymosan-coated microtiter plates as a function of serum concentration, as described in Example 4; Figure 19C The graph shows the expression of AP in serum samples from WT, MASP-2-deficient, and MASP-1 / 3-deficient mice under conventional AP-specific conditions (i.e., BBS / EGTA / Mg ++ No Ca ++ ) or under physiological conditions that allow both the lectin pathway and the alternative pathway to function (BBS / Mg ++ / Ca ++ ) under the condition of S. pneumoniae D39-coated microtiter plates, the level of C3b deposition varies with serum concentration, as described in Example 4; Figure 20A The figure shows that under traditional AP-specific conditions (i.e. BBS / EGTA / Mg ++ No Ca ++ ) or under physiological conditions that allow both the lectin pathway and the alternative pathway to function (BBS / Mg ++ / Ca ++ ) , the results of a C3b deposition assay in highly diluted serum on mannan-coated microtiter plates using serum concentrations ranging from 0% to 1.25%, as described in Example 4; Figure 20B The figure shows that under traditional AP-specific conditions (i.e. BBS / EGTA / Mg ++ No Ca ++) or under physiological conditions that allow both the lectin pathway and the alternative pathway to function (BBS / Mg ++ / Ca ++ ) under the conditions of C3b deposition assays performed on zymosan-coated microtiter plates using serum concentrations ranging from 0% to 1.25%, as described in Example 4; Figure 20C The figure shows that under traditional AP-specific conditions (i.e. BBS / EGTA / Mg ++ No Ca ++ ) or under physiological conditions that allow both the lectin pathway and the alternative pathway to function (BBS / Mg ++ / Ca ++ ) under conditions of C3b deposition assays performed on S. pneumoniae D39-coated microtiter plates using serum concentrations ranging from 0% to 1.25%, as described in Example 4; Figure 21 The graph shows the effect of a series of serum dilutions on the expression of serum from MASP-3- / -, heat-inactivated normal human serum (HI NHS), MBL- / -, NHS+MASP-2 monoclonal antibody, and NHS control under physiological conditions (i.e., at Ca ++ The level of hemolysis of mannan-coated murine erythrocytes (measured by the release of hemoglobin from lysed mouse erythrocytes (Crry / C3- / -) into the supernatant, which was measured photometrically), as described in Example 5; Figure 22 The graph shows the expression of a range of serum concentrations of human serum under physiological conditions (i.e., at Ca2+) in serum from MASP-3- / -, heat-inactivated (HI) NHS, MBL- / -, NHS+MASP-2 monoclonal antibody, and NHS control. ++ The level of hemolysis of mannan-coated murine erythrocytes (measured by the release of hemoglobin from lysed mouse erythrocytes (Crry / C3- / -) into the supernatant, which was measured photometrically), as described in Example 5; Figure 23 The graph shows the expression of a range of serum concentrations of human serum under physiological conditions (i.e., at Ca2+) in serum from 3MC (MASP-3- / -), heat-inactivated (HI) NHS, MBL- / -, NHS+MASP-2 monoclonal antibody, and NHS control. ++ the level of hemolysis of non-coated murine erythrocytes (measured by release of hemoglobin from lysed WT mouse erythrocytes into the supernatant, which was measured photometrically) as described in Example 5; Figure 24The graph shows the expression of a range of serum concentrations of human serum under physiological conditions (i.e., at Ca ++ Hemolysis of non-coated murine erythrocytes (measured by release of hemoglobin from lysed mouse erythrocytes (CD55 / 59- / -) into the supernatant, which was measured photometrically) was performed as described in Example 5; Figure 25 The graph shows the effect of a range of serum concentrations on serum from MASP-1 / 3- / - mice and serum from WT control mice under physiological conditions (i.e., at Ca ++ hemolyzed mannan-coated rabbit erythrocytes (measured by the release of hemoglobin from the lysed rabbit erythrocytes into the supernatant, which was measured photometrically) as described in Example 6; Figure 26 Graph showing the level of C3b deposition (OD 405 nm) on zymosan-coated microtiter plates as a function of serum concentration in serum samples from Factor D- / -, MASP-2- / -, and WT mouse serum in a C3 deposition assay performed under AP-specific conditions, as described in Example 7; Figure 27 The diagram shows that under physiological conditions (in Ca ++ In a C3 deposition assay performed in the presence of 5-MASP-2 (F- / -), the level of C3b deposition (OD 405 nm) on zymosan-coated microtiter plates in serum samples from Factor D- / -; MASP-2- / - and WT mouse serum varied as a function of serum concentration, as described in Example 7; Figure 28 The diagram shows that under physiological conditions (in Ca ++ In a C3b deposition assay performed in the presence of 5-nitro-2amin (1:1), the level of C3b deposition (OD 405 nm) on zymosan-coated microtiter plates in serum samples obtained from Factor D- / -; Factor B- / -; plus and minus MASP-2 monoclonal antibodies was determined as a function of serum incubation time (minutes), as described in Example 7. Figure 29A The graph shows lectin pathway-specific C4b deposition on zymosan-coated microtiter plates as measured ex vivo in undiluted serum samples collected from mice (n=3 mice / group) at various time points following subcutaneous administration of 0.3 mg / kg or 1.0 mg / kg of mouse MASP-2 MoAb, as described in Example 13; Figure 29BThe graph shows the time course of lectin pathway recovery over 3 weeks following a single intraperitoneal dose of 0.6 mg / kg mouse MASP-2 MoAb in mice, as described in Example 13; Figure 30A is a FACS histogram of MASP-3 antigen / antibody binding for clone M3J5, as described in Example 15; Figure 30B is a FACS histogram of MASP-3 antigen / antibody binding for clone M3M1, as described in Example 15; Figure 31 The graph shows the saturation binding curve of clone M3J5 (clone 5) for the MASP-3 antigen, as described in Example 15; Figure 32A is an amino acid sequence alignment of the VH regions of M3J5, M3M1, D14, and 1E10 with the chicken DT40 VH sequence, where dots indicate amino acid identity with the DT40 sequence and bars indicate gaps introduced to maximize the alignment, as described in Example 15; Figure 32B is an amino acid sequence alignment of the VL regions of M3J5, M3M1, D14, and 1E10 with the chicken DT40 VL sequence, where dots indicate amino acid identity with the DT40 sequence and bars indicate gaps introduced to maximize the alignment, as described in Example 15; Figure 33 is a bar graph showing the inhibitory activity of mAb 1E10 in the MBL pathway screen in the Wieslab complement system compared to the positive serum provided in the assay kit and an isotype control antibody, demonstrating that mAb 1E10 partially inhibits LEA-2-dependent activation (by inhibiting MASP-1-dependent activation of MASP-2), while the isotype control antibody does not, as described in Example 15; Figure 34 The graph shows the level of C3b deposition at concentrations ranging from 0.15 to 1000 nM for 1% normal human serum plus isotype control, SGMI-1Fc, or SGMI-2Fc, demonstrating that both SGMI-1Fc and SGMI-2Fc inhibit C3b deposition from normal serum in mannan-coated ELISA wells, IC 50 The values were approximately 27 nM and 300 nM, respectively, as described in Example 16; Figure 35A The results of flow cytometric analysis of C3b deposition on heat-killed Staphylococcus aureus are presented, demonstrating that in the presence of EDTA (which is known to inactivate lectins and the alternative pathway) in normal human serum, no C3b deposition was observed (panel 1). ++In normal human serum treated with EGTA, alternative pathway-driven C3b deposition was observed (Panel 2), and in factor B-depleted, factor D-depleted, and properdin (factor P)-depleted sera, as shown in Panels 3, 4, and 5, respectively, alternative pathway-driven C3b deposition was not observed, as described in Example 17; Figure 35B The results of flow cytometric analysis of C3b deposition on heat-killed S. aureus are presented, demonstrating that, as in EDTA-treated normal serum (panel 1), in 3MC serum, C3b deposition on Mg ++ AP-driven C3b deposition was absent in the presence of Mg / EGTA (panel 3), whereas panels 4 and 5 show that AP-driven C3b deposition in 3MC serum was restored to that in the presence of Mg / EGTA. ++ The levels observed in normal serum treated with EGTA (panel 2) were comparable to those observed in normal serum treated with EGTA, whereas neither inactive rMASP-3(S679A) (panel 6) nor wild-type rMASP-1 (panel 7) restored AP-driven C3b deposition in 3MC serum, as described in Example 17; Figure 36 Shown are the results of a Western blot analysis measuring factor B cleavage in the presence or absence of rMASP-3 in 3MC serum in response to S. aureus, demonstrating that factor B cleavage is significantly increased in 3MC serum relative to that in Mg ++ Compared to normal human serum in the presence of Mg / EGTA (as shown in lane 2 (positive control)), normal human serum in the presence of EDTA (negative control, lane 1) showed very little factor B cleavage, as further shown in lane 3. ++ EGTA showed very little Factor B cleavage. However, as shown in lane 4, Factor B cleavage was restored by adding full-length, recombinant MASP-3 protein to 3MC serum and preincubating, as described in Example 17; Figure 37 A Coomassie-stained protein gel is shown in which Factor B cleavage was analyzed, demonstrating that Factor B cleavage is optimal in the presence of C3, MASP-3, and pro-factor D (Lane 1); as shown in Lanes 4 and 5, either MASP-3 alone or pro-factor D alone can mediate Factor B cleavage, as long as C3 is present, as described in Example 17; Figure 38The graph shows the mean fluorescence intensity (MFI) of C3b staining of S. aureus obtained from mAbD14 (which binds MASP-3), mAb1A5 (negative control antibody), and an isotype control antibody plotted against mAb concentration in the presence of rMASP-3 in 3MC serum, demonstrating that mAbD14 inhibits MASP-3-dependent C3b deposition in a concentration-dependent manner, as described in Example 17; Figure 39 Western blot analysis of pro-factor D substrate cleavage is shown, wherein full-length wild-type recombinant MASP-3 (lane 2) and MASP-1 (lane 5) fully or partially cleave pro-factor D to produce mature factor D, compared to pro-factor D alone (lane 1) or inactive full-length recombinant MASP-3 (S679A; lane 3) or MASP-1 (S646A; lane 4), as described in Example 18; Figure 40 is a Western blot showing the inhibitory activity of MASP-3 binding mAbs D14 (lane 2) and M3M1 (lane 3) on MASP-3-dependent pro-factor D cleavage, as described in Example 18, compared to a control reaction containing only MASP-3 and pro-factor D (no mAb, lane 1) and a control reaction containing a mAb from the DTLacO library (which binds to MASP-1 but not MASP-3) (lane 4); Figure 41 The graph shows the level of AP-driven C3b deposition on zymosan-coated microtiter plates as a function of serum concentration in serum samples from MASP-3-deficient (3MC), C4-deficient, and MBL-deficient subjects, demonstrating that MASP-3-deficient sera from patients 2 and 3 had residual AP activity at high serum concentrations (25%, 12.5%, 6.25%), but significantly higher AP 50 (i.e., 8.2% and 12.3% serum were required to achieve 50% maximal C3 deposition), as described in Example 19; Figure 42A The graph shows the expression of AP in 10% human serum samples from MASP-3-deficient, C4-deficient, and MBL-deficient human subjects under "traditional" AP-specific conditions (i.e., BBS / EGTA / Mg ++ No Ca ++ ) under conditions of AP-driven C3b deposition over time on zymosan-coated microtiter plates, as described in Example 19; Figure 42BShown are Western blots of plasma obtained from 3MC patient #2 (MASP-3 (- / -), MASP-1 (+ / +)), 3MC patient #3 (MASP-3 (- / -), MASP-1 (- / -)), and serum from a normal donor (W), wherein human factor D (25040 Daltons) and / or mature factor D (24405 Daltons) were detected using human factor D-specific antibodies, as described in Example 19; Figure 42C The graph shows the results of Weislab classical, lectin, and alternative pathway assays for plasma obtained from 3MC patient #2, 3MC patient #3, and normal human serum, as described in Example 19; Figure 43 The graphic shows the expression of Ca in serum from two normal human subjects (NHS) and two 3MC patients (patients 2 and 3). ++ The percentage hemolysis of mannan-coated rabbit erythrocytes (measured by release of hemoglobin from lysed rabbit erythrocytes into the supernatant, which was measured photometrically) over a range of serum concentrations determined in the absence of MASP-3 demonstrates that MASP-3 deficiency reduces the percentage of complement-mediated lysis of mannan-coated erythrocytes compared to normal human serum, as described in Example 19; Figure 44 The graph shows the level of AP-driven C3b deposition on zymosan-coated microtiter plates following the addition of MASP-3 from human 3MC patient 2. - / - ), demonstrating that active recombinant MASP-3 protein reconstitutes AP-driven C3b deposition on zymosan-coated plates in a concentration-dependent manner compared to a negative control, inactive recombinant MASP-3 (MASP-3A; S679A), as described in Example 19; Figure 45 The diagram shows that in Ca ++ The percentage hemolysis of mannan-coated rabbit erythrocytes (measured by release of hemoglobin from lysed rabbit erythrocytes into the supernatant, which was measured photometrically) over a range of serum concentrations in the absence of: (1) normal human serum (NHS); (2) 3MC patient serum; (3) 3MC patient serum plus active full-length recombinant MASP-3 (20 μg / ml); and (4) heat-inactivated human serum (HIS) demonstrated that the percentage hemolysis of rabbit erythrocytes was significantly increased in 3MC serum containing rMASP-3 (p=0.0006) compared to the percentage hemolysis in 3MC serum without recombinant MASP-3, as described in Example 19; Figure 46The graph shows the activity of recombinant MASP-3 in BBS / MgSO4 solution at concentrations ranging from 0 to 110 μg / ml. ++ The percentage of rabbit erythrocyte lysis in 7% human serum from 3MC patient 2 and from 3MC patient 3 in 7% human serum (in 4% EGTA), demonstrating that the percentage of rabbit erythrocyte lysis increases with the amount of recombinant MASP-3 in a concentration-dependent manner, as described in Example 19; and Figure 47 The graph shows the level of LEA-2-driven C3b deposition on mannan-coated ELISA plates as a function of human serum concentration diluted in BBS buffer for sera from normal human subjects (NHS), from two 3MC patients (patient 2 and patient 3), from the parents of patient 3, and from an MBL-deficient subject.
[0038] Figure 48A Results presented show baseline VEGF protein levels in RPE-choroidal complexes isolated from wild-type (WT) (+ / +) and MASP-2 (- / -) mice, as described in Example 20; Figure 48B Results presented show VEGF protein levels in the RPE-choroidal complex of (WT) (+ / +) and MASP-2 (- / -) mice at day 3 following laser-induced injury in a macular degeneration model as described in Example 20; Figure 49 Results presented show mean choroidal neovascularization (CNV) volume at day 7 following laser-induced injury in (WT) (+ / +) and MASP-2 (- / -) mice, as described in Example 20; Figure 50 Graphed are the mean choroidal neovascularization (CNV) area on day 7 following laser-induced injury in WT (+ / +) mice pretreated with a single i.p. injection of 0.3 mg / kg or 1.0 mg / kg mouse MASP-2 monoclonal antibody, as described in Example 21; Figure 51A Results presented demonstrate reduced infarct size in WT (+ / +) and MASP-2 (- / -) mice following injury in a coronary artery occlusion and reperfusion model, as described in Example 22; Figure 51B The results presented show the distribution of individual animals tested in the coronary artery occlusion and reperfusion model, as described in Example 22; Figure 52AGraphed are the mean area at risk (AAR) and infarct volume (INF) as a percentage of total myocardial volume in WT (+ / +) and MASP-2 (- / -) mice subjected to left anterior descending coronary artery occlusion and reperfusion, as described in Example 23; Figure 52B Graphed is the relationship between infarct volume (INF) plotted against average area at risk (AAR) as a percentage of left ventricular myocardial volume in WT (+ / +) and MASP-2 (- / -) mice following arterial occlusion and reperfusion, as described in Example 23; Figure 52C Graphed are the infarct volumes (INF) of buffer-perfused hearts from WT (+ / +) and MASP-2 (- / -) mice prepared according to the Langendorff isolation-reperfusion mouse heart model, in which global ischemia and reperfusion are performed in the absence of serum, as described in Example 23; Figure 52D Graph showing the relationship between infarct volume (INF) and risk zone (RZ) in buffer-perfused hearts from WT (+ / +) and MASP-2 (- / -) mice prepared according to the Langendorff isolation-reperfusion mouse heart model, as described in Example 23; Figure 53A The graph shows the results of a C3b deposition assay on immune complex-coated plates, wherein the symbol "*" indicates serum from WT (MASP-2(+ / +)); the symbol "●" indicates WT serum (C1q depleted); the symbol "□" indicates MASP-2(- / -) serum; and the symbol "Δ" indicates MASP-2(- / -) serum (C1q depleted), indicating that MASP-2(- / -) mice retain a functional classical pathway, as described in Example 24; Figure 53B The graph shows the results of a C3b deposition assay on zymosan-coated plates, wherein the symbol "*" indicates serum from WT (MASP-2(+ / +)) and the symbol "□" indicates serum from MASP-2(- / -); this indicates that MASP-2(- / -) mice retain a functional alternative pathway, as described in Example 24; Figure 54A Graph depicting tissue loss induced by myocardial ischemia / reperfusion injury (MIRI) in C4(- / -) mice (n=6) and matched WT littermate controls (n=7) following ligation of the left anterior descending coronary artery (LAD) and reperfusion, showing area at risk (AAR) and infarct size (INF), as described in Example 24; Figure 54B The diagram shows Figure 42AInfarct size (INF) as a function of area at risk (AAR) in treated C4(- / -) and WT mice, demonstrating that C4(- / -) mice are equally susceptible to MIRI as WT controls (dashed line), as described in Example 24; Figure 55A The graph shows the results of a C3b deposition assay using WT mouse serum, C4(- / -) mouse serum, and C4(- / -) mouse serum pre-incubated with mannan, as described in Example 24; Figure 55B The graph shows the results of a C3b deposition assay using WT mouse serum, C4(- / -) mouse serum, and MASP-2(- / -) mouse serum mixed with varying concentrations of a murine MASP-2 monoclonal antibody (mAbM11), as described in Example 24; Figure 55C Graphs show the results of a C3b deposition assay using human sera from WT (C4-sufficient) and C4-deficient subjects, as well as sera from C4-deficient subjects pre-incubated with mannan, as described in Example 24; Figure 55D Graphed are the results of a C3b deposition assay using human serum from WT (C4-sufficient) and C4-deficient subjects mixed with human MASP-2 mAb (mAbH3), as described in Example 24; Figure 56A Graph depicting comparative analysis of C3 convertase activity of plasma from various complement-deficient mouse strains tested under lectin activation pathway-specific assay conditions or classical activation pathway-specific assay conditions, as described in Example 24; Figure 56B Graphed are the time-resolved kinetics of C3 convertase activity in the plasma of various complement-deficient mouse strains tested under lectin activation pathway-specific assay conditions, as described in Example 24; Figure 57A Graph showing the extent of tissue damage in WT and MASP-2(- / -) mice following transient ischemia / reperfusion injury induced in the gastrointestinal tract (GIRI), demonstrating a significant degree of protection in MASP-2(- / -) mice compared to WT controls, as described in Example 25; Figure 57B Graphs depict the results of a C4b deposition assay using serum obtained from mice (n=3) time after a single intraperitoneal dose of a recombinant murine MASP-2 antibody (mAbM11), demonstrating ablation of functional activity of the lectin pathway in vivo, as described in Example 25; Figure 57CGraph depicting the effect of MASP-2 mAb treatment on the severity of GIRI pathology, demonstrating that mice administered a murine MASP-2 monoclonal antibody (mAbM11) 24 hours prior to a transient ischemia / reperfusion injury in the gastrointestinal tract (GIRI) had significantly reduced tissue damage compared to mice administered saline (*P<0.05 when comparing animals treated with the MASP-2 inhibitory antibody mAbM11 or an irrelevant isotype control antibody), as described in Example 25; Figure 57D Shown are histopathological manifestations of GIRI-mediated small intestine in mice pretreated with a single intraperitoneal injection of saline, isotype control antibody, or recombinant murine MASP-2 antibody (mAbM11) 12 hours prior to induction of GIRI, as described in Example 25; Figure 58 Graph showing cerebral infarct volume in WT (MASP-2(+ / +)) and MASP-2(- / -) mice following 30 minutes of ischemia and 24 hours of reperfusion, as described in Example 26; Figure 59A Shown are a series of photographs of stained brain sections from WT (MASP-2+ / +) mice following 30 minutes of ischemia and 24 hours of reperfusion. Figure 52A Groups 1-8 of represent different slice regions of the brain, corresponding to bregma 1-8, respectively, relative to the outer lobe of the auditory nerve (bregma 0), as described in Example 26; Figure 59B Shown are a series of photographs of stained brain sections from MASP-2 (- / -) mice following 30 minutes of ischemia and 24 hours of reperfusion. Figure 52B Groups 1-8 of represent different slice regions of the brain, corresponding to bregma 1-8, respectively, relative to the outer lobe of the auditory nerve (bregma 0), as described in Example 26; Figure 60 Results presented show the mean clinical arthritis scores over time in (WT)(+ / +) and MASP-2(- / -) mice following Col2 mAb-induced rheumatoid arthritis, as described in Example 27; Figure 61 Graph depicting the results of a C3 deposition assay on serum samples obtained from WT mice in the presence of house dust mites or zymosan, as described in Example 28; Figure 62A and 62B The inhibition of C4b deposition ( Figure 62A ) and a dose-response curve for inhibition of thrombin activation, as described in Example 29; Figure 63A and 63BWe present platelet aggregation in a localized Shwartzman reaction model of disseminated intravascular coagulation compared to untreated wild-type mice and wild-type mice in which the complement pathway was inhibited by the depleting agent cobra venom factor (CVF) and a terminal pathway inhibitor (C5aR antagonist). Figure 63A ) compared with MASP-2(- / -) mice, the platelet aggregation ( Figure 63B ) (expressed as the aggregate area), as described in Example 30; Figure 64 illustrates the results of Western blot analysis showing that the thrombin substrate FXIa and FXa activate human C3, as indicated by the presence of the a' chain, as described in Example 31; Figure 65 Graphed are the results of a C3b deposition assay on serum samples obtained from WT, MASP-2(- / -), F11(- / -), F11(- / -) / C4(- / -), and C4(- / -) mice, demonstrating that there is a functional lectin pathway even in the complete absence of C4 or F11, while mice with combined F11-(- / -) / C4(- / -)-deficiency lack a functional lectin pathway, as described in Example 31; Figure 66 The graph shows the time to onset of microvascular occlusion following LPS injection in MASP-2(- / -) and WT mice, showing the percentage of mice with thrombosis as measured over 60 minutes, demonstrating that thrombosis was detectable in WT mice after 15 minutes, with up to 80% of WT mice showing thrombosis by 60 minutes; in contrast, none of the MASP-2(- / -) mice showed any thrombosis during the 60-minute period (log rank: P=0.0005), as described in Example 32; Figure 67 Graphing the percentage survival over time (hours) of saline-treated control mice (n=5) and MASP-2 antibody-treated mice (n=5) in the STX / LPS-induced HUS model, showing that all control mice died within 42 hours, while in contrast, 100% of the MASP-2 antibody-treated mice survived throughout the time course of the experiment, as described in Example 33; Figure 68 Graphed are the percentage of mice with microvascular occlusion in the FITC / dextran UV model as a function of time after injury induction following treatment with isotype control or human MASP-2 antibody mAbH6 (10 mg / kg) 16 hours and 1 hour prior to FITC / dextran injection, as described in Example 34; Figure 69The occlusion time in minutes for mice treated with human MASP-2 antibody (mAbH6) and isotype control antibody is shown, with data reported as a scatter plot with mean (horizontal bars) and standard error bars (vertical bars). The statistical test used for analysis was an unpaired t-test; where the symbol "*" indicates p value = 0.0129, as described in Example 34; and Figure 70 Graphed are the time to occlusion in minutes for wild-type mice, MASP-2 KO mice, and wild-type mice pretreated with human MASP-2 antibody (mAbH6) (administered at 10 mg / kg ip 16 hours before thrombosis induction and again 1 hour before thrombosis induction) in a FITC-dextran / light-induced endothelial cell injury model of thrombosis using low light intensity (800-1500), as described in Example 34.
[0039] Sequence Listing Description SEQ ID NO: 1 Human MAp19 cDNA SEQ ID NO: 2 Human MAp19 protein (with leader sequence) SEQ ID NO: 3 Human MAp19 protein (mature) SEQ ID NO: 4 Human MASP-2 cDNA SEQ ID NO: 5 Human MASP-2 protein (with leader sequence) SEQ ID NO:6 Human MASP-2 protein (mature) SEQ ID NO: 7 Human MASP-3 cDNA SEQ ID NO: 8 Human MASP-3 protein (w / leader sequence) SEQ ID NO:9 human MASP-1 cDNA SEQ ID NO: 10 Human MASP-1 protein (w / leader sequence) SEQ ID NO: 11 Human MAp44 protein (w / leader sequence) SEQ ID NO: 12 Rat MASP-2 cDNA SEQ ID NO: 13 Rat MASP-2 protein (with leader sequence) SEQ ID NO: 14 DNA encoding the heavy chain variable region (VH) of 17D20_dc35VH21N11VL (OMS646) (without signal peptide) SEQ ID NO:1517D20_dc35VH21N11VL(OMS646) heavy chain variable region (VH) polypeptide SEQ ID NO:1617N16mc heavy chain variable region (VH) polypeptide SEQ ID NO:1717D20_dc21N11VL(OMS644) light chain variable region (VL) polypeptide SEQ ID NO: 18 DNA encoding the light chain variable region (VL) of 17N16_dc17N9 (OMS641) (without signal peptide) SEQ ID NO:1917N16_dc17N9(OMS641) light chain variable region (VL) polypeptide SEQ ID NO: 20: scFv daughter clone 17N16m_d17N9 full-length polypeptide SEQ ID NO: 21: scFv subclone 17D20m_d3521N11 full-length polypeptide SEQ ID NO: 22: scFv subclone 17N16m_d17N9 DNA encoding the full-length polypeptide (without signal peptide) SEQ ID NO: 23: scFv subclone 17D20m_d3521N11 DNA encoding the full-length polypeptide (without signal peptide) SEQ ID NO: 24: Parental DTLacO heavy chain variable region (VH) polypeptide SEQ ID NO:25: MASP-3 specific clone M3J5 heavy chain variable region (VH) polypeptide SEQ ID NO:26: MASP-3 specific clone M3M1 heavy chain variable region (VH) polypeptide SEQ ID NO: 27: Parental DTLacO light chain variable region (VL) polypeptide SEQ ID NO:28: MASP-3 specific clone M3J5 light chain variable region (VL) polypeptide SEQ ID NO:29: MASP-3 specific clone M3M1 light chain variable region (VL) polypeptide SEQ ID NO:30: MASP-3 clone D14 heavy chain variable region (VH) polypeptide SEQ ID NO:31: MASP-3 clone D14 light chain variable region (VL) polypeptide SEQ ID NO:32: MASP-1 clone 1E10 heavy chain variable region (VH) polypeptide SEQ ID NO:33: MASP-1 clone 1E10 light chain variable region (VL) polypeptide SEQ ID NO: 34 SGMI-1 peptide SEQ ID NO:35 SGMI-2 peptide SEQ ID NO: 36 human IgG1-Fc polypeptide; SEQ ID NO: 37 Peptide linker #1 (12 aa); SEQ ID NO: 38: Peptide linker #2 (10 aa); SEQ ID NO: 39: Nucleic acid encoding a polypeptide fusion comprising human IL-2-signal sequence, SGMI-1, linker #1, and human IgG1-Fc; SEQ ID NO:40: Mature polypeptide fusion comprising SGMI-1, linker #1, and human IgG1-Fc (SGMI-1Fc); SEQ ID NO:41: Nucleic acid encoding a polypeptide fusion comprising human IL-2-signal sequence, SGMI-2, linker #1, and human IgG1-Fc; SEQ ID NO: 42: Mature polypeptide fusion comprising SGMI-2, linker #1 and human IgG1-Fc (SGMI-2Fc). DETAILED DESCRIPTION I. Definition Unless otherwise specified herein, all terms used herein have the same meaning as understood by one of ordinary skill in the art in the field of the present invention. The following definitions are provided to clarify the terms as they are used in the specification and claims to describe the present invention.
[0041] As used herein, lectin pathway effector arm 1 ("LEA-1") refers to the lectin-dependent activation of factor B and factor D by MASP-3.
[0042] As used herein, lectin pathway effector branch 2 ("LEA-2") refers to MASP-2-dependent complement activation.
[0043] As used herein, the term "MASP-3-dependent complement activation" comprises two components: (i) lectin MASP-3-dependent activation of Factor B and Factor D, which are involved in LEA-1-mediated complement activation in the Ca ++ occurs in the presence of Ca, typically resulting in the conversion of C3bB to C3bBb and pro-factor D to factor D; and (ii) lectin-independent conversion of factor B and factor D, which can occur in the presence of Ca ++In its absence, it typically results in the conversion of C3bB to C3bBb and pro-factor D to factor D. It has been determined that LEA-1-mediated complement activation and lectin-independent conversion of factor B and factor D lead to opsonization and / or cytolysis. While not wishing to be bound by any particular theory, it is believed that only when multiple C3b molecules associate and bind in close proximity does the C3bBb C3 convertase change its substrate specificity and cleave C5 to the alternative pathway C5 convertase, i.e., C3bBb(C3b)n.
[0044] As used herein, the term "MASP-2-dependent complement activation" is also referred to herein as LEA-2-mediated complement activation, and includes MASP-2 lectin-dependent activation, which is activated in the presence of Ca ++ This occurs in the presence of C3b, leading to the formation of the lectin pathway C3 convertase C4b2a and, following accumulation of the C3 cleavage product C3b, the subsequent formation of the C5 convertase C4b2a(C3b)n, which is determined to lead to opsonization and / or cytolysis.
[0045] As used herein, the term "traditional understanding of the alternative pathway," also referred to as the "traditional alternative pathway," refers to the alternative pathway that preceded the discoveries described herein, i.e., complement activation triggered by, for example, zymosan from the cell walls of fungi and yeast, lipopolysaccharide (LPS) from the Gram-negative outer membrane, and rabbit erythrocytes, as well as a variety of pure polysaccharides, viruses, bacteria, animal tumor cells, parasites, and damaged cells, and has traditionally been believed to be caused by C3b generated by spontaneous proteolysis of complement factor C3. As used herein, activation of the "traditional alternative pathway" (also referred to herein as the "alternative pathway") is initiated by Mg. ++ / EGTA buffer (i.e., in Ca ++ when it is not present).
[0046] As used herein, the term "lectin pathway" refers to complement activation that occurs through specific binding of serum and non-serum carbohydrate-binding proteins, including mannan-binding lectin (MBL), CL-11, and ficolins (H-ficolin, M-ficolin, or L-ficolin). As described herein, the inventors have discovered that the lectin pathway is driven by two effector branches: lectin pathway effector branch 1 (LEA-1), which is now known to be MASP-3-dependent; and lectin pathway effector branch 2 (LEA-2), which is MASP-2-dependent. As used herein, activation of the lectin pathway utilizes Ca-containing ++ buffer for evaluation.
[0047] As used herein, the term "classical pathway" refers to complement activation that is triggered by antibody binding to foreign particles and requires binding of the recognition molecule C1q.
[0048] As used herein, the term "HTRA-1" refers to serine peptidase high temperature requiring serine protease A1.
[0049] As used herein, the term "MASP-3 inhibitory agent" refers to any agent that directly or indirectly inhibits MASP-3-dependent complement activation, including agents that bind to or directly interact with MASP-3, including MASP-3 antibodies and MASP-3 binding fragments thereof, natural and synthetic peptides, competitive substrates, small molecules, expression inhibitors, and isolated natural inhibitors, and also includes peptides that compete with MASP-3 for binding to another recognition molecule in the lectin pathway (e.g., MBL, CL-11, H-ficolin, M-ficolin, or L-ficolin). In one embodiment, the MASP-3 inhibitory agent is specific for MASP-3 and does not bind to MASP-1 or MASP-2. Inhibitory agents that directly inhibit MASP-3 may be referred to as direct MASP-3 inhibitors (e.g., MASP-3 antibodies), while inhibitory agents that indirectly inhibit MASP-3 may be referred to as indirect MASP-3 inhibitors (e.g., MASP-1 antibodies that inhibit MASP-3 activation). Examples of direct MASP-3 inhibitory agents are MASP-3 specific inhibitors, e.g., MASP-3 inhibitors that specifically bind to a portion of MASP-3 (SEQ ID NO:8) with an affinity at least 10-fold greater than that of other components of the complement system. In one embodiment, MASP-3 inhibitory agents indirectly inhibit MASP-3 activity, e.g., inhibitors of MASP-3 activation, including inhibitors of MASP-1-mediated MASP-3 activation (e.g., MASP-1 antibodies or MASP-1-binding fragments thereof, natural and synthetic peptides, small molecules, expression inhibitors, and isolated natural inhibitors, and also peptides that compete with MASP-1 for binding to MASP-3). In another embodiment, MASP-3 inhibitory agents inhibit MASP-3-mediated maturation of Factor D. In another embodiment, MASP-3 inhibitory agents inhibit MASP-3-mediated activation of Factor B. The MASP-3 inhibitory agents used in the methods of the present invention can reduce MASP-3-dependent complement activation by greater than 10%, e.g., greater than 20%, greater than 50%, or greater than 90%. In one embodiment, a MASP-3 inhibitory agent reduces MASP-3-dependent complement activation by greater than 90% (i.e., results in MASP-3 complement activation of only 10% or less). MASP-3 inhibition is expected to block, in whole or in part, both LEA-1-associated cytolysis and opsonization and the lectin-independent conversion of Factor B and Factor D-associated cytolysis and opsonization.
[0050] As used herein, the term "MASP-1 inhibitory agent" refers to any agent that binds to or directly interacts with MASP-1 and inhibits at least one of: (i) MASP-3-dependent complement activation and / or (ii) MASP-2-dependent complement activation and / or (iii) lectin-independent or lectin-dependent MASP-1-mediated maturation of factor D, wherein lectin-dependent MASP-1 maturation of factor D involves direct activation of factor D, and includes MASP-1 antibodies and MASP-1 binding fragments thereof, natural and synthetic peptides, small molecules, expression inhibitors, and isolated natural inhibitors, and also includes peptides that compete with MASP-1 for binding to another recognition molecule in the lectin pathway (e.g., MBL, CL-11, H-ficolin, M-ficolin, or L-ficolin). In one embodiment, the MASP-1 inhibitory agents used in the methods of the invention reduce MASP-3-dependent complement activation by greater than 10%, e.g., greater than 20%, greater than 50%, or greater than 90%. In one embodiment, the MASP-1 inhibitory agents reduce MASP-3-dependent complement activation by greater than 90% (i.e., resulting in only 10% or less complement activation for MASP-3). In another embodiment, the MASP-1 inhibitory agents used in the methods of the invention reduce MASP-2-dependent complement activation by greater than 10%, e.g., greater than 20%, greater than 50%, or greater than 90%. In one embodiment, the MASP-1 inhibitory agents reduce MASP-2-dependent complement activation by greater than 90% (i.e., resulting in only 10% or less complement activation for MASP-2).
[0051] In another embodiment, the MASP-1 inhibitory agent used in the methods of the invention reduces MASP-3-dependent complement activation (LEA-1), lectin-independent conversion of Factor B and Factor D, and MASP-2-dependent complement activation (LEA-2) by greater than 10%, e.g., greater than 20%, greater than 50%, or greater than 90%. In one embodiment, the MASP-1 inhibitory agent reduces MASP-3-dependent complement activation (LEA-1), lectin-independent conversion of Factor B and Factor D, and MASP-2-dependent complement activation (LEA-2) by greater than 90% (i.e., resulting in MASP-3 complement activation of only 10% or less and MASP-2 complement activation of only 10% or less).
[0052] An example of a direct MASP-1 inhibitor is a MASP-1-specific inhibitor, such as a MASP-1 inhibitor that specifically binds to a portion of MASP-1 (SEQ ID NO: 10) with an affinity at least 10-fold greater than that of other components of the complement system. In many cases, given that MASP-1 can activate MASP-3, and given that MASP-1 can activate MASP-2, inhibition of MASP-1 would be expected to effectively inhibit MASP-3 and / or MASP-2. However, in some cases, inhibition of either MASP-1 or MASP-3 or MASP-2 may be a preferred embodiment over inhibition of other MASP targets. For example, in the case of Staphylococcus aureus infection, MASP-3 has been shown to be activated and responsible for opsonization of S. aureus in the absence of MASP-1 (see Iwaki D. et al., J Immunol 187(7):3751-8 (2011)). Therefore, in the treatment of, for example, paroxysmal nocturnal hemoglobinuria (PNH), it may be advantageous to directly inhibit MASP-1 rather than MASP-3, thereby reducing potential susceptibility to S. aureus during LEA-1 -inhibitory therapy of PNH.
[0053] As used herein, the term "MASP-2 inhibitory agent" refers to any agent that binds to or directly interacts with MASP-2 and inhibits at least one of: (i) MASP-2-dependent complement activation and / or (ii) MASP-1-dependent complement activation, including MASP-2 antibodies and MASP-2-binding fragments thereof, natural and synthetic peptides, small molecules, expression inhibitors, and isolated natural inhibitors, and also includes peptides that compete with MASP-2 for binding to another recognition molecule in the lectin pathway (e.g., MBL, CL-11, H-ficolin, M-ficolin, or L-ficolin). The MASP-2 inhibitory agent used in the methods of the present invention can reduce MASP-2-dependent complement activation by greater than 10%, such as greater than 20%, greater than 50%, or greater than 90%. In one embodiment, the MASP-2 inhibitory agent reduces MASP-2-dependent complement activation by greater than 90% (i.e., results in MASP-2 complement activation of only 10% or less). Examples of direct MASP-2 inhibitory agents are MASP-2-specific inhibitory agents, e.g., MASP-2 inhibitory agents that specifically bind to a portion of MASP-2 (SEQ ID NO:5) with an affinity at least 10-fold greater than to other components of the complement system.
[0054] As used herein, the term "antibody" includes antibodies and antibody fragments thereof that are obtained from any mammalian species that produces antibodies (e.g., mouse, rat, rabbit, and primate, including human), or from hybridomas, phage selection, recombinant expression, or transgenic animals (or other methods of producing antibodies or antibody fragments), and that specifically bind to a target polypeptide (e.g., a MASP-1, MASP-2, or MASP-3 polypeptide or portion thereof). The term "antibody" is not intended to be limited by the source of the antibody or the manner in which it is produced (e.g., by hybridoma, phage selection, recombinant expression, transgenic animals, peptide synthesis, etc.). Exemplary antibodies include polyclonal antibodies, monoclonal antibodies, and recombinant antibodies; pan-specific, multispecific antibodies (e.g., bispecific antibodies, trispecific antibodies); humanized antibodies; murine antibodies; chimeric mouse-human, mouse-primate, primate-human monoclonal antibodies; and anti-idiotypic antibodies, and can be any intact antibody or fragment thereof. The term "antibody" as used herein includes not only intact polyclonal or monoclonal antibodies, but also fragments thereof (e.g., dAb, Fab, Fab', F(ab')2, Fv), single chains (ScFv), synthetic variants thereof, naturally occurring variants, fusion proteins including antibody portions of antigen-binding fragments with the desired specificity, humanized antibodies, chimeric antibodies, and any other modified configuration of immunoglobulin molecules that contain an antigen-binding site or fragment (epitope recognition site) of the desired specificity.
[0055] "Monoclonal antibody" refers to a homogeneous antibody population, wherein the monoclonal antibody is composed of the amino acids (naturally occurring and non-naturally occurring) involved in the selection of binding epitopes. Monoclonal antibodies are highly specific to the target antigen. The term "monoclonal antibody" includes not only complete monoclonal antibodies and full-length monoclonal antibodies, but also fragments thereof (e.g., Fab, Fab', F(ab')2, Fv), single chains (ScFv), variants thereof, fusion proteins including antigen-binding portions, humanized monoclonal antibodies, chimeric monoclonal antibodies, and any other modified configurations of immunoglobulin molecules including antigen-binding fragments (epitope recognition sites) with the desired specificity and ability to bind epitopes. It is not intended to be limited according to the source of the antibody or its preparation method (e.g., by hybridoma, phage selection, recombinant expression, transgenic animals, etc.). The term includes complete immunoglobulins and fragments described according to the above definition of "antibody," etc.
[0056] As used herein, the term "antibody fragment" refers to a portion of a full-length antibody (e.g., an antibody to MASP-1, MASP-2, or MASP-3), generally including its antigen-binding region or its variable region. Illustrative examples of antibody fragments include Fab, Fab', F(ab)2, F(ab')2, and Fv fragments, scFv fragments, diabodies, linear antibodies, single-chain antibody molecules, and multispecific antibodies formed from antibody fragments.
[0057] As used herein, "single-chain Fv" or "scFv" antibody fragments comprise the VH and VL domains of an antibody, wherein these domains are present on a single polypeptide chain. Typically, the Fv polypeptide also includes a polypeptide linker between the VH and VL domains, which enables the scFv to form the desired antigen-binding structure.
[0058] As used herein, a "chimeric antibody" is a recombinant protein that contains the variable domains and complementarity determining regions of an antibody from a non-human species (eg, a rodent), while the remainder of the antibody molecule is derived from a human antibody.
[0059] As used herein, a "humanized antibody" is a chimeric antibody comprising minimal sequence consistent with a specific complementary determining region derived from a non-human immunoglobulin, which is implanted into a human antibody framework. Humanized antibodies are typically recombinant proteins (including antibodies produced from phage display or yeast) in which only the antibody complementary determining regions are of non-human origin.
[0060] As used herein, the term "mannan-binding lectin" ("MBL") is equivalent to mannan-binding protein ("MBP").
[0061] As used herein, "membrane attack complex" ("MAC") refers to the complex (also known as C5b-9) of the terminal five complement components (C5b, along with C6, C7, C8, and C9) that inserts into and disrupts membranes.
[0062] As used herein, "subject" includes all mammals, including but not limited to humans, non-human primates, dogs, cats, horses, sheep, goats, cows, rabbits, pigs, and rodents.
[0063] The abbreviations for amino acid residues used in this article are as follows: alanine (Ala; A), asparagine (Asn; N), aspartic acid (Asp; D), arginine (Arg; R), cysteine (Cys; C), glutamic acid (Glu; E), glutamine (Gln; Q), glycine (Gly; G), histidine (His; H), isoleucine (Ile; I), leucine (Leu; L), lysine (Lys; K), methionine (Met; M), phenylalanine (Phe; F), proline (Pro; P), serine (Ser; S), threonine (Thr; T), tryptophan (Trp; W), tyrosine (Tyr; Y) and valine (Val; V).
[0064] In the broadest sense, naturally occurring amino acids can be grouped according to the chemical properties of the individual amino acid side chains. A "hydrophobic" amino acid refers to any one of Ile, Leu, Met, Phe, Trp, Tyr, Val, Ala, Cys, or Pro. A "hydrophilic" amino acid refers to any one of Gly, Asn, Gln, Ser, Thr, Asp, Glu, Lys, Arg, or His. This grouping of amino acids can be further subdivided as follows. An "uncharged hydrophilic" amino acid refers to any one of Ser, Thr, Asn, or Gln. An "acidic" amino acid refers to any one of Glu or Asp. A "basic" amino acid refers to any one of Lys, Arg, or His.
[0065] As used herein, the term "conservative amino acid substitution" is described by substitutions between amino acids in each of the following groups: (1) glycine, alanine, valine, leucine, and isoleucine; (2) phenylalanine, tyrosine, and tryptophan; (3) serine and threonine; (4) aspartic acid and glutamic acid; (5) glutamine and asparagine; and (6) lysine, arginine, and histidine.
[0066] As used herein, the term "oligonucleotide" refers to an oligomer or polymer of ribonucleic acid (RNA) or deoxyribonucleic acid (DNA) or its mimetics. The term also includes oligonucleotide bases composed of naturally occurring nucleotides, sugars, and internucleotide (backbone) covalent bonds, as well as oligonucleotides with non-naturally occurring modifications.
[0067] As used herein, an "epitope" refers to a site on a protein (e.g., human MASP-3 protein) to which an antibody binds. An "overlapping epitope" comprises at least one (e.g., 2, 3, 4, 5, or 6) common amino acid residues and includes both linear and non-linear epitopes.
[0068] As used herein, the terms "polypeptide," "peptide," and "protein" are used interchangeably to refer to any peptide-linked chain of amino acids, regardless of length or post-translational modification. The MASP proteins described herein (MASP-1, MASP-2, or MASP-3) may contain or be wild-type proteins, or may be variants having no more than 50 (e.g., no more than 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 12, 15, 20, 25, 30, 35, 40, or 50) conservative amino acid substitutions. Conservative substitutions typically include substitutions within the following groups: glycine and alanine; valine, isoleucine, and leucine; aspartic acid and glutamic acid; asparagine, glutamine, serine, and threonine; lysine, histidine, and arginine; and phenylalanine and tyrosine.
[0069] The human MASP-1 protein (set forth in SEQ ID NO: 10), human MASP-2 protein (set forth in SEQ ID NO: 5), and human MASP-3 protein (set forth in SEQ ID NO: 8) described herein also include "peptide fragments" of the proteins, which are shorter than the full-length and / or immature (pre-pro) MASP proteins, including peptide fragments of the MASP proteins, including terminal and internal deletion variants of the proteins. Deletion variants can lack 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acid stretches (of two or more amino acids) or non-contiguous individual amino acids. In certain embodiments, the human MASP-1 protein can have an amino acid sequence that is equal to or greater than 70 (e.g., 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100)% identical to the human MASP-1 protein having the amino acid sequence set forth in SEQ ID NO: 10.
[0070] In certain embodiments, the human MASP-3 protein can have an amino acid sequence that is equal to or greater than 70 (e.g., 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100)% identical to the human MASP-3 protein having the amino acid sequence set forth in SEQ ID NO:8.
[0071] In certain embodiments, the human MASP-2 protein can have an amino acid sequence that is equal to or greater than 70 (e.g., 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, or 100)% identical to the human MASP-2 protein having the amino acid sequence set forth in SEQ ID NO:5.
[0072] In certain embodiments, the length of a peptide fragment can be at least 6 (e.g., at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 8, or 10). In certain embodiments, the length of the antigenic peptide fragment of a human MASP protein is less than 500 (e.g., less than 450, 400, 350, 325, 300, 275, 250, 225, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, 100, 95, 90, 85, 80, 75, 70, 65, 60, 55, 50 , 49, 48, 47, 46, 45, 44, 43, 42, 41, 40, 39, 38, 37, 36, 35, 34, 33, 32, 31, 30, 29, 28, 27, 26, 25, 24, 23, 22, 21, 20, 19, 18, 17, 16, 15, 14, 13, 12, 11, 10, 9, 8, 7, or 6) amino acid residues (e.g., less than 500 contiguous amino acid residues of any of SEQ ID NOs: 5, 8, or 10).
[0073] In certain embodiments, in the case of generating antibodies that bind to MASP-1, MASP-2, and / or MASP-3, the peptide fragments are antigenic and retain at least 10% (e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 50%, at least 55%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99%, at least 99.5%, or 100% or more) of the ability of the full-length protein to induce an antigenic response in a mammal (see "Methods of Generating Antibodies" below).
[0074] The percentage (%) of amino acid sequence identity is defined as the percentage of amino acids in the candidate sequence that are identical to the amino acids in the reference sequence, after aligning the sequences and introducing gaps (if necessary) to achieve maximum percentage sequence identity. Alignment for determining percentage sequence identity can be achieved in a variety of ways within the skill in the art, for example, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ALIGN-2, or Megalign (DNASTAR) software. Suitable parameters for determining the alignment, including any algorithm required to achieve maximum alignment across the full length of the sequences to be compared, can be determined by known methods.
[0075] In representative embodiments, human MASP-1 protein (SEQ ID NO: 10) is encoded by the cDNA sequence set forth in SEQ ID NO: 9; human MASP-2 protein (SEQ ID NO: 5) is encoded by the cDNA sequence set forth in SEQ ID NO: 4; and human MASP-3 protein (SEQ ID NO: 8) is encoded by the cDNA sequence set forth in SEQ ID NO: 7. Those skilled in the art will recognize that the cDNA sequences disclosed in SEQ ID NO: 9, SEQ ID NO: 4, and SEQ ID NO: 7 represent individual alleles of human MASP-1, MASP-2, and MASP-3, respectively, and that allelic variation and alternative splicing are expected. Allelic variants of the nucleotide sequences set forth in SEQ ID NO: 9, SEQ ID NO: 4, and SEQ ID NO: 7, including those containing silent mutations and those in which the mutations result in changes in the amino acid sequence, are within the scope of the present invention. Allelic variants of a MASP-1, MASP-2 or MASP-3 sequence can be cloned by probing cDNA or genomic libraries from different individuals according to standard procedures, or can be identified by homology comparison searches (e.g., BLAST searches) of databases containing such information.
[0076] II. Lectin pathway: new understanding i. Overview: The lectin pathway has been redefined As described herein, the inventors have made the surprising discovery that the lectin pathway of complement has two effector branches that activate complement, both of which are driven by the lectin pathway activation complex formed by carbohydrate recognition components (MBL, CL-11, and ficolins): i) an effector branch formed by the lectin pathway-associated serine proteases MASP-1 and MASP-3, referred to herein as "lectin pathway effector branch 1" or "LEA-1"; and (ii) a MASP-2-driven activation effector branch, referred to herein as "lectin pathway effector branch 2" or "LEA-2." Both LEA-1 and LEA-2 can exert cytolytic and / or opsonizing effects.
[0077] It has also been determined that MASP-3 is responsible for the lectin-independent conversion of factor B, and HTRA-1, MASP-1, and MASP-3 are responsible for the lectin-independent conversion of factor D, both of which can be detected in Ca ++ 1) typically results in the conversion of C3bB to C3bBb and pro-factor D to factor D. Thus, inhibition of MASP-3 can simultaneously inhibit LEA-1 and lectin-independent activation of factor B and / or factor D, which can lead to inhibition of cytolysis and / or opsonization.
[0078] Figure 1 This new understanding of the complement activation pathway is illustrated. Figure 1 As shown, LEA-1 is driven by lectin-bound MASP-3, which can activate Factor D zymogen to its active form and / or cleave C3b- or C3b(H20)-bound Factor B, resulting in conversion of the C3bB zymogen complex to its enzymatically active form, C3bBb. Activated Factor D generated by MASP-3 can also convert the C3bB or C3b(H20) zymogen complex to its enzymatically active form. MASP-1 is capable of rapid self-activation, while MASP-3 is not. In many instances, MASP-1 is an activator of MASP-3.
[0079] Although in many instances lectins (ie, MBL, CL-11, or ficolin) can direct activity to the cell surface, Figure 1 The lectin-independent functions of MASP-3, MASP-1, and HTRA-1 in factor B activation and / or factor D maturation are also summarized. As with the lectin-associated form of MASP-3 in LEA-1, the lectin-independent form of MASP-3 is capable of mediating the conversion of C3bB or C3b(H20) to C3bBb (see also Figure 36 and 37 ) and converting pre-factor D to factor D (see Figure 39 MASP-1 (see also Figure 39) and the non-MASP-associated protein HTRA-1 can also activate factor D (Stanton et al., Evidence That the HTRA1 Interactome Influences Susceptibility to Age-Related Macular Degeneration, presented at the Association for Research in Vision and Ophthalmology 2011 meeting on May 4, 2011), in a manner that does not require a lectin component.
[0080] Thus, MASP-1 (via LEA-1 and lectin-independent forms), MASP-3 (via LEA-1 and lectin-independent forms), and HTRA-1 (lectin-independent only) can be activated directly or indirectly at one or more points along the MASP-3-Factor D-Factor B axis. In this case, they produce C3bBb (the C3 convertase of the alternative pathway) and stimulate the production and deposition of C3b on microbial surfaces. C3b deposition plays a key role in opsonization, marking microbial surfaces for destruction by host phagocytes (e.g., macrophages). As an example herein ( FIG35 ), MASP-3 is crucial for opsonization of Staphylococcus aureus. C3b deposition occurs rapidly in a MASP-3-dependent manner on Staphylococcus aureus exposed to human serum ( FIG35 ).
[0081] However, the contributions of LEA-1 and MASP-3, MASP-1, or HTRA-1 to lectin-independent functions are not limited to opsonization. Figure 1 As shown, these three components can also cause cell lysis and the generation of C3b through indirect or direct activation of factor B. These components form a complex that produces the alternative pathway C5 convertase, C3bBb (C3b). n As further described herein, in the lysis of Neisseria meningitidis (see Figure 13 、 14 and 15) require MASP-3 and MBL, but not MASP-2 (and, therefore, not LEA-2 in this example), demonstrating a role for LEA-1 in cell lysis. Taken together, the opsonization results from the S. aureus studies and the cell lysis results observed in the N. meningitidis studies support a role for LEA-1 in both processes (e.g., Figure 1Furthermore, these studies demonstrate that both opsonization and cytolysis can result from the conversion of C3bB or C3b(H20) and / or the conversion of pro-factor D to factor D; thus, both processes may be the result of lectin-independent actions of MASP-3, MASP-1, or HTRA-1. Figure 1 The model developed by the inventors in supports the use of inhibitors of primarily MASP-3, as well as inhibitors of MASP-1 and / or HTRA-1, to block opsonization and / or cytolysis and treat pathologies resulting from dysregulation of these processes.
[0082] 1. Lectin pathway effector branch (LEA-1) The first effector branch of the lectin pathway, LEA-1, is formed by the lectin pathway-associated serine proteases MASP-1 and MASP-3. As described herein, the inventors have now demonstrated that in the absence of MASP-3 and in the presence of MASP-1, the alternative pathway is not effectively activated on surface structures. These results demonstrate that MASP-3 plays a previously undiscovered role in initiating the alternative pathway and were confirmed using MASP-3-deficient 3MC serum from a patient with the rare autosomal recessive disorder 3MC (Rooryck C, et al., Nat Genet. 43(3):197-203 (2011)), who harbors a mutation that renders the MASP-3 serine protease domain dysfunctional. Based on these novel findings, complement activation involving the alternative pathway, as conventionally defined, is expected to be MASP-3-dependent. In fact, MASP-3, and its LEA-1 activation, may represent a hitherto unidentified initiator of the alternative pathway.
[0083] As further described in Examples 1-4 herein, the present inventors observed a higher level of lectin-dependent alternative pathway activation in MASP-2-deficient serum, which resulted in higher bactericidal activity (i.e., cytolytic activity) against N. meningitidis. While not wishing to be bound by any particular theory, it is believed that in the absence of MASP-2, the carbohydrate recognition complex with MASP-1 is more likely to bind tightly to the carbohydrate recognition complex with MASP-3 to activate MASP-3. It is known that in many cases, the activation of MASP-3 is dependent on MASP-1 activity because MASP-3 is not a self-activating enzyme and often requires the activity of MASP-1 to convert from its zymogen form to its enzymatically active form. MASP-1 (like MASP-2) is a self-activating enzyme, while MASP-3 is not self-activating and, in many cases, requires the enzymatic activity of MASP-1 to convert to its enzymatically active form. See Zundel S, et al., J Immunol., 172(7):4342-50 (2004). In the absence of MASP-2, all lectin pathway recognition complexes are loaded with either MASP-1 or MASP-3. Thus, the absence of MASP-2 promotes MASP-1-mediated conversion of MASP-3 to its enzymatically active form. Once MASP-3 is activated, activated MASP-3 initiates alternative pathway activation (now referred to as "LEA-1" activation) through MASP-3-mediated conversion of C3bB to C3bBb and / or conversion of pro-factor D to factor D. C3bBb, also known as the alternative pathway C3 convertase, cleaves additional C3 molecules, resulting in a deposition of opsonized C3b molecules. If several C3b fragments come into close proximity and bind to the C3bBb convertase complex, this results in the formation of the alternative pathway C5 convertase, C3bBb(C3b), which promotes MAC formation. Additionally, C3b molecules are deposited on the surface, forming new sites for factor B binding, which can now be cleaved by factor D and / or MASP-3 to form additional sites where the alternative pathway C3 and C5 convertase complexes can form. The latter process is required for efficient cell lysis, and lectins are not required once the initial C3b deposition has occurred. Recent publications (Iwaki D. et al., J Immunol 187(7):3751-8 (2011)) and data obtained by the present inventors ( Figure 37 ) demonstrated that the alternative pathway C3 convertase zymogen complex, C3bB, is converted to its enzymatically active form by activation of MASP-3. The present inventors have now discovered that MASP-3-mediated cleavage of Factor B represents a newly described subcomponent of LEA-1 that promotes the lectin-dependent formation of the alternative pathway C3 convertase, C3bBb.
[0084] 2. Lectin pathway effector branch (LEA-2) The second effector branch of the lectin pathway, LEA-2, is formed by the lectin pathway-associated serine protease MASP-2. Upon binding of the recognition motif to its respective motif, MASP-2 becomes activated, and can also be activated by MASP-1, subsequently cleaving complement component C4 into C4a and C4b. When the cleavage product, C4b, binds to plasma C2, the C4b-bound C2 becomes the substrate for a second, MASP-2-mediated cleavage step, which converts the C4b-bound C2 into the enzymatically active complex C4bC2a and the small C2b cleavage fragment. C4b2a is the C3-converting C3 convertase of the lectin pathway, converting the abundant plasma component C3 into C3a and C3b. C3b binds to any nearby surface via a thioester bond. If several C3b fragments come into close proximity and bind to the C3 convertase complex, C4b2a, the convertase changes its specificity, converting C5 into C5b and C5a, forming the C5 convertase complex, C4b2a(C3b). Although this C5 convertase can initiate MAC formation, this process is not believed to be effective in promoting cell lysis on its own. Instead, the initial C3b opsonin generated by LEA-2 forms the nucleus for the formation of new alternative pathway C3 convertase and C5 convertase sites, which ultimately lead to extensive MAC formation and cell lysis. This latter event is mediated by factor D activation of factor B associated with LEA-2-formed C3b and is therefore dependent on LEA-1 due to its essential role in factor D maturation. There is also a MASP-2-dependent C4-alternative activation pathway that activates C3 in the absence of C4, which plays an important role in the pathophysiology of ischemia-reperfusion injury, as C4-deficient mice cannot protect themselves from ischemia-reperfusion injury, while MASP-2-deficient mice can (Schwaeble et al., PNAS, 2011 supra). LEA-2 is also involved in the coagulation pathway, including cleaving prothrombin to thrombin (common pathway) and also cleaving factor XII (contact factor) to convert it to its enzymatically active form, XIIa. Factor XIIa, in turn, cleaves factor XI to factor XIa (intrinsic pathway). Activation of the intrinsic pathway of the coagulation cascade leads to fibrin formation, which is crucial for thrombus formation.
[0085] Figure 1 Based on the results presented herein, a new understanding of the lectin pathway and the alternative pathway is demonstrated. Figure 1 A role for LEA-2 in both opsonization and cytolysis has been described. Although MASP-2 is an initiator of "downstream" C3b deposition (and resulting opsonization) in multiple lectin-dependent settings in physiological settings ( Figure 20A 、 20B , 20C), but it also plays a role in the lysis of serum-sensitive bacteria. Figure 1As shown, the proposed molecular mechanism responsible for the increased bactericidal activity of MASP-2-deficient or MASP-2-depleted serum / plasma for serum-sensitive pathogens such as Neisseria meningitidis is that for bacterial lysis, the lectin pathway recognition complex associated with MASP-1 and MASP-3 must be bound to the bacterial surface in close proximity to each other, thereby allowing MASP-1 to cleave MASP-3. In contrast to MASP-1 and MASP-2, MASP-3 is not a self-activating enzyme, but in many cases requires activation / cleavage by MASP-1 to be converted to its enzymatically active form.
[0086] Further Figure 1 As shown, activated MASP-3 can then cleave C3b-bound Factor B on the pathogen surface, initiating the alternative activation cascade by forming the enzymatically active alternative pathway C3 and C5 convertases C3bBb and C3bBb(C3b)n, respectively. Lectin-pathway activation complexes bearing MASP-2 do not participate in MASP-3 activation, and, in the absence or upon depletion of MASP-2, all lectin-pathway activation complexes will be loaded with either MASP-1 or MASP-3. Thus, in the absence of MASP-2, the probability that lectin-pathway activation complexes bearing MASP-1 and MASP-3 will be in close proximity to each other on the microbial surface is significantly increased, resulting in more MASP-3 being activated, and thus leading to a higher rate of MASP-3-mediated cleavage of C3b-bound Factor B, forming the alternative pathway C3 and C5 convertases C3bBb and C3bBb(C3b)n on the microbial surface. This leads to activation of the terminal activation cascade C5b-C9, forming the membrane attack complex, which consists of surface-bound C5b associated with C6, C5bC6 associated with C7, C5bC6C7 associated with C8, and C5bC6C7C8, resulting in polymerization of C9, which inserts into bacterial surface structures and forms small holes in the bacterial wall, which will lead to osmotic killing of complement-targeted bacteria.
[0087] Central to this new concept are the data presented here that clearly show that the lectin pathway activation complex drives two distinct activation pathways, e.g. Figure 1 As shown: i) LEA-1: A MASP-3-dependent activation pathway that initiates and drives complement activation through the initial cleavage and activation of factor B on the activator surface, generating the alternative pathway convertase C3bBb, which then catalyzes C3b deposition and the formation of the alternative pathway convertase C3bBb. The MASP-3-driven activation pathway plays an important role in opsonization and microbial cell lysis and drives the alternative pathway on the bacterial surface, resulting in an optimal activation rate and the generation of the membrane attack complex; and ii) LEA-2: A MASP-2-dependent activation pathway that leads to the formation of the lectin pathway C3 convertase C4b2a, and subsequent formation of the C5 convertase C4b2a(C3b)n following accumulation of the C3 cleavage product C3b. In the absence of complement C4, MASP-2 can form the alternative C3 convertase complex, which includes C2 and coagulation factor XI.
[0088] In addition to its role in cytolysis, the MASP-2-driven activation pathway also plays an important role in bacterial opsonization, resulting in the coating of microorganisms with covalently bound C3b and its cleavage products (i.e., iC3b and C3dg), which are then targeted for uptake and killing by C3 receptor-bearing phagocytes (e.g., granulocytes, macrophages, monocytes, microglia) and the reticuloendothelial system. This is the most effective pathway for the elimination of bacteria and microorganisms that resist complement cytolysis. These include most Gram-positive bacteria.
[0089] In addition to LEA-1 and LEA-2, the possibility exists for lectin-independent activation of factor D by MASP-3, MASP-1 and / or HTRA-1, and the possibility also exists for lectin-independent activation of factor B by MASP-3.
[0090] While not wishing to be bound by any particular theory, it is believed that lectin-independent activation of (i) LEA-1, (ii) LEA-2, and (iii) Factor B and / or Factor D each results in opsonization and / or MAC formation with resulting cytolysis.
[0091] ii. Background on MASP-1, MASP-2, and MASP-3 Three mannan-binding lectin-related serine proteases (MASP-1, MASP-2, and MASP-3) are currently known to be associated with human serum with mannan-binding lectin (MBL). Mannan-binding lectin is also referred to as "mannose-binding protein" or "mannose-binding lectin" in recent literature. The MBL-MASP complex plays an important role in innate immunity through the binding of MBL to carbohydrate structures present on various microorganisms. Interaction of MBL with a specific arrangement of carbohydrate structures leads to activation of the MASP proenzyme, which in turn activates complement by cleaving complement components C4 and C2 to form the C3 convertase C4b2b (Kawasaki et al., J. Biochem 106:483-489 (1989); Matsushita & Fujita, J. Exp Med. 176:1497-1502 (1992); Ji et al., J. Immunol 150:571-578 (1993)).
[0092] Until recently, the MBL-MASP proenzyme complex was thought to contain only one type of protease (MASP-1), but it is now clear that two other distinct proteases, MASP-2 and MASP-3, are associated with MBL (Thiel et al., Nature 386:506-510 (1997); Dahl et al., Immunity 15:127-135 (2001)), as well as an additional serum protein of 19 kDa, termed "MAp19" or "sMAP" (Stover et al., J. Immunol 162:3481-3490 (1999); Stover et al., J. Immunol 163:6848-6859 (1999); Takahashi et al., Int. Immunol 11:859-63 (1999)).
[0093] MAp19 is the alternatively spliced gene product of the structural gene for MASP-2 and lacks the four C-terminal domains of MASP-2, including the serine endopeptidase domain. Alternative splicing / polyadenylation events of the MASP-2 gene produce a truncated mRNA transcript encoding MAp19 that is expressed in large quantities. By a similar mechanism, the MASP-1 / 3 genes result in three major gene products: two serine proteases, MASP-1 and MASP-3, and a 44 kDa truncated gene product termed "MAp44" (Degn et al., J. Immunol 183(11):7371-8 (2009); Skjoedt et al., J Biol Chem 285:8234-43 (2010)).
[0094] MASP-1 was first described as the P-100 protease component of serum Ra-responsive factor, which is now considered to be a complex consisting of MBL plus MASP (Matsushita et al., Collectins and Innate Immunity, (1996); Ji et al., J Immunol 150:571-578 (1993). The ability of the MBL-associated endopeptidase within the MBL-MASP complex to act on complement components C4 and C2 in a manner remarkably similar to the C1s enzyme within the C1q-(Clr)2-(Cls)2 complex of the classical complement pathway suggests the existence of MBL-MASP complexes that function similarly to the C1q-(Clr)2-(Cls)2 complex. The C1q-(C1r)2-(C1s)2 complex is activated by the interaction of C1q with the Fc region of antibodies IgG or IgM present in the immune complex. This results in the self-activation of the C1r proenzyme, which in turn activates the C1s proenzyme, which then acts on complement components C4 and C2.
[0095] The stoichiometry of the MBL-MASP complex differs from that found in the C1q-(C1r)2-(C1s)2 complex in that different MBL oligomers appear to be associated with different ratios of MASP-1 / MApl9 or MASP-2 / MASP-3 (Dahl et al., Immunity 15:127-135 (2001). The majority of MASPs and MApl9 present in serum are not complexed with MBL (Thiel et al., J Immunol 165:878-887 (2000)) and may be partially associated with ficolins, a group of lectins currently described that have fibrinogen-like domains capable of binding to N-acetylglucosamine residues on the surface of microorganisms (Le et al., FEBS Lett. 425:367 (1998); Sugimoto et al., J. Biol Chem 273:207-21 (1998)). Among them, human L-ficolin, H-ficolin, and M-ficolin associate with MASPs and MAp19 and can activate the lectin pathway after binding to specific carbohydrate structures recognized by ficolin (Matsushita et al., J Immunol 164:2281-2284 (2000); Matsushita et al., J Immunol 168:3502-3506 (2002)). In addition to ficolin and MBL, the MBL-like lectin collectin (called CL-11) has been identified as a lectin pathway recognition molecule (Hansen et al., J Immunol 185:6096-6104 (2010); Schwaeble et al., PNAS 108:7523-7528 (2011). Given the strong evidence for the physiological importance of these alternative carbohydrate recognition molecules, it is important to understand that MBL is not the only recognition component of the lectin activation pathway and that MBL deficiency should not be mistaken for a lectin pathway deficiency. The potential existence of a set of alternative carbohydrate recognition complexes related to the MBL structure could broaden the spectrum of microbial structures that initiate a direct response of the innate immune system via complement activation.
[0096] All lectin pathway recognition molecules are characterized by a specific MASP-binding motif within their collagen-homologous stem region (Wallis et al., J. Biol Chem 279:14065-14073 (2004)). The MASP-binding sites in MBL, CL-11, and ficolin are characterized by a unique motif within this domain: Hyp-Gly-Lys-Xaa-Gly-Pro, where Hyp is hydroxyproline and Xaa is typically an aliphatic residue. Point mutations in this sequence abolish MASP binding.
[0097] 1. Their respective structures, sequences, chromosomal locations, and splice variants Figure 2 is a schematic diagram showing the domain structures of the MASP-2 polypeptide (SEQ ID NO: 5) and the MAp19 polypeptide (SEQ ID NO: 2) and the exons encoding them. Figure 3 FIG is a schematic diagram showing the domain structures of MASP-1 polypeptide (SEQ ID NO: 10), MASP-3 polypeptide (SEQ ID NO: 8), and MAp44 polypeptide (SEQ ID NO: 11) and the exons encoding them. Figure 2 and 3 As shown, the serine proteases MASP-1, MASP-2, and MASP-3 are composed of six unique domains arranged as seen in C1r and C1s; namely, (I) an N-terminal C1r / C1s / sea urchin VEGF / bone morphogenetic protein (or CUBI) domain; (II) an epidermal growth factor (EGF)-like domain; (III) a second CUB domain (CUBII); (IV and V) two complement control protein (CCP1 and CCP2) domains; and (VI) a serine protease (SP) domain.
[0098] cDNA-derived amino acid sequences of human and mouse MASP-1 (Sato et al., Int Immunol 6:665-669 (1994); Takada et al., Biochem Biophys Res Commun 196:1003-1009 (1993); Takayama et al., J. Immunol 152:2308-2316 (1994)); cDNA-derived amino acid sequences of human, mouse, and rat MASP-2 (Thiel et al., Nature 386:506-510 (1997); Endo et al., J Immunol 161:4924-30 (1998); Stover et al., J. Immunol 162:3481-3490 (1999); Stover et al., J. Immunol 163:6848-6859 (1999)); and the cDNA-derived amino acid sequence of human MASP-3 (Dahl et al., Immunity 15:127-135 (2001)) indicate that these proteases are serine peptidases with a characteristic triad of His, Asp, and Ser residues in their putative catalytic domains (Genbank accession numbers: human MASP-1: BAA04477.1; mouse MASP-1: BAA03944; rat MASP-1: AJ457084; human MASP-3: AAK84071; mouse MASP-3: AB049755, as accessed on 2 / 15 / 2012, each of which is incorporated herein by reference).
[0099] Further Figure 2 and 3 As shown, after the zymogen is converted to the active form, the heavy chain (α or A chain) and the light chain (β or B chain) are cleaved to yield a disulfide-linked A-chain and a smaller B-chain representing the serine protease domain. The single-chain proenzyme MASP-1 is activated by cleaving the Arg-Ile bond between the second CCP domain (domain V) and the serine protease domain (domain VI) (like proenzymes C1r and C1s). Proenzymes MASP-2 and MASP-3 are thought to be activated in a manner similar to MASP-1. Each MASP protein forms a homodimer and binds to Ca ++ -dependent manner with MBL and ficolins, respectively.
[0100] 2. MASP-1 / 3 The human MASP-1 polypeptide (SEQ ID NO: 10) and MASP-3 polypeptide (SEQ ID NO: 8) are derived from a structural gene (Dahl et al., Immunity 15: 127-135 (2001)), which has been mapped to the 3q27-28 region of the long arm of chromosome 3 (Takada et al., Genomics 25: 757-759 (1995)). MASP-3 and MASP-1 mRNA transcripts are generated from the primary transcript by an alternative splicing / polyadenylation process. The MASP-3 translation product is composed of an α chain (which is common to both MASP-1 and MASP-3) and a β chain (serine protease domain) (which is unique to MASP-3). Figure 3 As shown, the human MASP-1 gene includes 18 exons. The human MASP-1 cDNA (set forth in SEQ ID NO:9) is encoded by exons 2, 3, 4, 5, 6, 7, 8, 10, 11, 13, 14, 15, 16, 17, and 18. Figure 3 As shown, the human MASP 3 gene comprises 12 exons. The human MASP-3 cDNA (set forth in SEQ ID NO:7) is encoded by exons 2, 3, 4, 5, 6, 7, 8, 10, 11, and 12. Alternative splicing produces a protein termed MBL-associated protein 44 ("MAp44") (set forth in SEQ ID NO:11) from exons 2, 3, 4, 5, 6, 7, 8, and 9.
[0101] The human MASP-1 polypeptide (SEQ ID NO: 10 from Genbank BAA04477.1) has 699 amino acid residues, including a 19-residue leader peptide. When the leader peptide is omitted, the calculated molecular weight of MASP-1 is 76,976 Da. Figure 3 As shown in FIG, the amino acid sequence of MASP-1 contains four N-linked glycosylation sites. The human MASP-1 protein domain (see SEQ ID NO: 10) is shown in FIG. Figure 3 And includes an N-terminal C1r / C1s / sea urchin VEFG / bone morphogenetic protein (CUBI) domain (aa 25-137 of SEQ ID NO: 10), an epidermal growth factor-like domain (aa 139-181 of SEQ ID NO: 10), a second CUB domain (CUBII) (aa 185-296 of SEQ ID NO: 10), and tandem complement control protein (CCP1 aa 301-363 and CCP2 aa 367-432 of SEQ ID NO: 10) domains and a serine protease domain (aa 449-694 of SEQ ID NO: 10).
[0102] The human MASP-3 polypeptide (SEQ ID NO: 8, from Genbank AAK84071) has 728 amino acid residues, including a 19-residue leader peptide. When the leader peptide is omitted, the calculated molecular weight of MASP-3 is 81,873 Da. Figure 3 As shown in FIG, there are 7 N-linked glycosylation sites in MASP-3. The human MASP-3 protein domain (refer to SEQ ID NO: 8) is shown in FIG. Figure 3 and includes an N-terminal C1r / C1s / sea urchin VEGF / bone morphogenetic protein (CUBI) domain (aa 25-137 of SEQ ID NO: 8), an epidermal growth factor-like domain (aa 139-181 of SEQ ID NO: 8), a second CUB domain (CUBII) (aa 185-296 of SEQ ID NO: 8), and tandem complement control protein (CCP1 aa301-363 and CCP2 aa367-432 of SEQ ID NO: 8) domains and a serine protease domain (aa450-711 of SEQ ID NO: 8).
[0103] The MASP-3 translation product is composed of an alpha chain (heavy chain) (alpha chain: aa 1-448 of SEQ ID NO: 8) containing the CUB-1-EGF-CUB-2-CCP-1-CCP-2 domain, which is common to both MASP-1 and MASP-3, and a light chain (beta chain: aa 449-728 of SEQ ID NO: 8) containing a serine protease domain, which is unique to MASP-3 and MASP-1.
[0104] 3. MASP-2 The human MASP-2 gene is located on chromosome 1p36.3-2 (Stover et al., Cytogenet and Cell Genet 84:148-149 (1999) and comprises 12 exons, such as Figure 2MASP-2 (SEQ ID NO:5) and MAp19 (SEQ ID NO:2) are encoded by transcripts of a single structural gene generated by alternative splicing / polyadenylation (Stover et al., Genes and Immunity 2:119-127 (2001)). The human MASP-2 cDNA (SEQ ID NO:4) is encoded by exons 2, 3, 4, 6, 7, 8, 9, 10, 11, and 12. A 20 kDa protein, designated MBL-associated protein 19 ("MAp19," also known as "sMAP") (SEQ ID NO:2), is encoded by (SEQ ID NO:1) and is generated from exons 2, 3, 4, and 5. MAp19 is a nonenzymatic protein containing the N-terminal CUB1-EGF region of MASP-2 with four additional residues (EQSL) derived from exon 5, as shown. Figure 2 shown.
[0105] The MASP-2 polypeptide (SEQ ID NO: 5) has 686 amino acid residues, including a 15-residue leader peptide that is cleaved off after secretion to produce the mature form of human MASP-2 (SEQ ID NO: 6). Figure 2 As shown, the amino acid sequence of MASP-2 does not contain any N-linked glycosylation sites. The MASP-2 polypeptide has a molecular structure similar to that of MASP-1, MASP-3, and C1r and C1s (proteases of the C1 complement system). The human MASP-2 protein domains (numbered according to SEQ ID NO: 5) are shown in Figure 2 And includes an N-terminal C1r / C1s / sea urchin VEGF / bone morphogenetic protein (CUBI) domain (aa24-136 of SEQ ID NO:5), an epidermal growth factor-like domain (aa 138-180 of SEQ ID NO:5), a second CUB domain (CUBII) (aa184-295 of SEQ ID NO:5), and tandem complement control protein (CCP1 aa 300-359 and CCP2 aa 364-431 of SEQ ID NO:5) domains and a serine protease domain (aa 445-682 of SEQ ID NO:5).
[0106] like Figure 2As shown, the MASP-2 polypeptide has an α chain (heavy chain) containing the CUB-1-EGF-CUB-2-CCP-1-CCP-2 domain (α chain: aa 1-443 of SEQ ID NO:5) and a β chain (light chain) containing the serine protease domain (β chain: aa 444-686). The CUB-1, EGF, and CUB-2 domains are required for dimerization, and the CUB-1, EGF, CUB-2, and CCP-1 domains contain MBP binding sites. As described in Wallis et al., J. Biol Chem 279:14065-14073 (2004), each MASP-2 dimer binds to two MBL subunits.
[0107] 4. Comparison of the amino acid sequences of MASP-1, MASP-2, and MASP-3 Figure 4 The amino acid alignment of the protein sequences of MASP-1 (SEQ ID NO: 10), MASP-2 (SEQ ID NO: 6), and MASP-3 (SEQ ID NO: 8) shows the conserved catalytic triad residues (H, D, S) in the CUBI, EGF, CUBII, CCP1, CCP2 domains, and the serine protease (SP) domain. The symbol "." indicates identical amino acid sequences.
[0108] Figure 5 It is an amino acid alignment of the α chain sequences of MASP-1 (α chain: aa 1-447 of SEQ ID NO: 10), MASP-2 (α chain: aa 1-443 of SEQ ID NO: 5), and MASP-3 (α chain: aa 1-448 of SEQ ID NO: 8), including CUBI-EGF-CUBII-CCP1-CCP2. There are multiple patches of identity in the CUBI, EGF, and CUBII domains, such as Figure 5 The CCP1 and CCP2 domains are represented by the black shaded boxes. The overall % identity between the α chains of human MASP1 / 3 and human MASP-2 is provided in Table 1 below.
[0109] Figure 6 An amino acid alignment of the beta chain sequences (including the serine protease domain) of MASP-1 (beta chain: aa 448-699 of SEQ ID NO: 10), MASP-2 (beta chain: aa 444-686 of SEQ ID NO: 5), and MASP-3 (beta chain: aa 449-728 of SEQ ID NO: 8). Figure 7AShown is a pairwise amino acid alignment between the beta chain sequences of MASP-1 (beta chain: aa 448-699 of SEQ ID NO: 10) and MASP-2 (beta chain: aa 444-686 of SEQ ID NO: 5). Figure 7B Shown is a pairwise amino acid alignment between the beta chain sequences of MASP-1 (beta chain: aa 448-699 of SEQ ID NO: 10) and MASP-3 (beta chain: aa 449-728 of SEQ ID NO: 8). Figure 7C Shown is a pairwise amino acid alignment between the beta chain sequences of MASP-2 (beta chain: aa 444-686 of SEQ ID NO: 5) and MASP-3 (beta chain: aa 449-728 of SEQ ID NO: 8). Figure 5 Regions of identity in -7 are shown as dashed boxes surrounding identical amino acids (shown as "." symbols).
[0110] The percent identity between the α and β chains of human MASP-1, MASP-2, and MASP-3 proteins is provided in Table 1 below.
[0111] Table 1: Percent Identity Between Human MASP Proteins With respect to the α chain (heavy chain), as shown in Table 1 above, the α chains of MASP-1 and MASP-3 are identical (except for the 15 amino acid sequence at the 3' end). The overall % identity between the α chains of MASP-2 and MASP-3 is 45.4%, with multiple identical positions in the CUBI-EGF-CUBII domain, such as Figure 5 shown.
[0112] For the β chains (light chains), the overall percent identity between the three β chains is very low, ranging from 27% to 28%. However, despite the low overall identity between the three B-chains, there are multiple identity fills, such as Figure 6 As shown. Figure 7A As shown in Figure 3-C, identical complements of sequence are more widely distributed between MASP-2 and 3 than between 1 and 2 or between 1 and 3.
[0113] All cysteine residues present in MASP-2, MASP-3, C1r, and C1s are aligned with the equivalent residues in MASP-1; however, MASP-1 has two cysteine residues (at positions 465 and 481 in the L chain) that are absent from MASP-2, MASP-3, C1r, and C1s. These two cysteine residues in MASP-1 are in predicted positions for the formation of a "histidine-loop" disulfide bridge, as seen in trypsin and chymotrypsin. This suggests that MASP-2, MASP-3, C1r, and C1s may have evolved from MASP-1 through gene duplication and divergence (Nonaka & Miyazawa, Genome Biology 3 Reviews 1001.1-1001.5 (2001)).
[0114] 5. Respective biological functions / activities, including relevant human genetic data The role of the MBL / ficolin-MASP complex in innate immunity is mediated through calcium-dependent binding of the C-type lectin domain (present in the MBL molecule) to carbohydrate structures present on yeast, bacteria, viruses, and fungi, or through binding of the fibrinogen-like domain (present in the ficolin molecule) to carbohydrate structures present on yeast, bacteria, viruses, and fungi. This recognition stage leads to the activation of the proenzyme MASP-2, which then mimics the action of activated C1s within the C1q-(C1r)2-(C1s)2 complex to form the C3 convertase C4b2b by cleaving C4 and C2. This allows C4b and C3b to be deposited on the target pathogen and thus promote killing and clearance by phagocytosis.
[0115] Recent evidence in the literature indicates that the lectin pathway activation complex requires only MASP-2 activity to cleave C4 and C2: i) Reconstitution of a minimal lectin-pathway activation complex using recombinant MBL and recombinantly expressed MASP-2 appears sufficient to efficiently cleave both C4 and C2 in vitro (Vorup-Jensen et al., J. Immunol 165:2093-2100 (2000); Rossi et al., J. Biol Chem 276:40880-40887 (2001); Ambrus et al., J. Immunol 170:1374-1382 (2003); Gál et al., J. Biol Chem 280:33435-33444 (2005); and ii) serum from mice with a gene-targeted deficiency of MASP-2 lacks any lectin pathway functional activity (Schwaeble et al., PNAS 108:7523-7528 (2011)). A genetically defined deficiency of MASP-2 was recently described (Stengaard-Pedersen et al., New Eng. J. Med. 349:554-560, (2003)). A single nucleotide mutation results in an Asp-Gly exchange in the CUB1 domain and renders MASP-2 unable to bind to MBL.
[0116] In addition, functional characterization of sera from mice lacking both MASP-1 and MASP-3 showed that when wild-type and MASP-1 / MASP-3 knockout (MASP-1 / 3 - / -) mice, lectin pathway activity was slowed, but not abolished (Takahashi et al., J. Immunol 180:6132-6138 (2008); Schwaeble et al., PNAS (2011)). These studies indicate that, in contrast to the classical pathway effector endopeptidase C1s, activation of MASP-2 does not necessarily involve or require the activity of any other MBL-associated serine endopeptidase (i.e., MASP-1 or MASP-3) and that the proteolytic activity of MASP-2 is sufficient to convert binding of lectin pathway carbohydrate recognition molecules (i.e., MBL, ficolin, or CL-11) into complement activation. However, recent studies have demonstrated that, despite the ability of MASP-2 to self-activate, the catalytic rate of MASP-1 activation of the MASP-2 zymogen exceeds the rate of MASP-2 cleavage of its own zymogen form by approximately 85,000-fold (Héja et al., PNAS 106:10498-503 (2011); Megyeri et al., J. Biol. Chem. 288(13):8922-34 (2013)). Therefore, in physiological settings, it is likely that the primary activator of MASP-2 is MASP-1. Judging by the size of the C4 fragment produced and the functional C3 convertase activity produced, it seems likely that activated MASP-2 cleaves C4 and C2 in the same manner as activated C1s, i.e., at a single arginyl bond within the α-chain of C4 (Arg76 Ala77) and at a single arginyl bond within the proenzyme chain of C2 (Arg223 Lys224). It has also been reported that mouse MASP (in the form of the mouse MBL-MASP complex, termed Ra-responsive factor), unlike C1s, can cleave the α-chain of complement component C3 to yield the biologically active fragments C3a and C3b (Ogata et al., J. Immunol 154:2351-2357 (1995)). If this were to occur in the human system, it would require cleavage of a single arginyl bond (Arg77 Ser78) within the α-chain of C3. Activated MASP-2, like activated C1s, is unable to cleave complement component C5. The proteolytic activity of MASP-1 and MASP-2 is inhibited by C1-inhibitor (Matsushita et al., J Immunol 165:2637-2642 (2000), whereas C1-inhibitor does not react with MASP-3 (Dahl et al., Immunity 15:127-135 (2001); Zundel et al., J Immunol 172:4342-4350 (2004)).
[0117] The biological functions of MASP-1 and MASP-3 have been slowly being discovered. The substrate specificity and physiological role of MASP-1 have been the subject of debate since its discovery. A large number of potential substrates have been identified in recent years. It has been proposed that MASP-1 can slowly cleave native C3, and that this direct cleavage of C3 could initiate the complement cascade, perhaps via the alternative pathway (Matsushita et al., J Immunol 165:2637-2642 (2000)). Recombinant MASP-1 was subsequently shown to cleave an inactive (thioester-hydrolyzed) form of C3, which is futile for initiating the complement cascade (Ambrus et al., J Immunol 170:1374-1382 (2003)). The lack of lectin pathway activity in serum dilutions from MASP-2-deficient mice clearly demonstrated the absence of a MASP-1-driven C3-bypass mechanism (Schwaeble et al., PNAS 108:7523-7528 (2011)). Complement components that are cleaved with remarkable efficiency by MASP-1 are C2 (Rossi et al., J Biol Chem 276:40880-40887 (2001); Ambrus et al., J Immunol 170:1374-1382 (2003)) and the zymogen form of Factor D (Takahashi et al., J Exp Med 207:29-37 (2010)). As with the ability of MASP-1 to cleave C2, it seems possible that MASP-1 can also amplify the C3-convertase (C4b2a)-forming capacity of MASP-2 through C2 cleavage. This suggestion is supported by the observation that lectin pathway activity is reduced in MASP-1-depleted human serum and in MASP-1 / 3-deficient mouse serum (Takahashi et al., J Immunol 180:6132-6138 (2008)), which also suggests that MASP-1 plays a role in activating MASP-2. Furthermore, although each C4b deposited by the MBL-MASP complex can form a C4b2a convertase, only one of the four C4bs deposited by the classical pathway C1 complex can do so (Rawal et al., J Biol Chem 283(12):7853-63 (2008)).
[0118] MASP-1 also cleaves MASP-2 and MASP-3 (Megyeri M., et al., J Biol Chem. 2013 Mar 29; 288(13): 8922-34). Recent experiments have shown that, although MASP-2 can activate itself, MASP-1 is the primary activator of the zymogen MASP-2. MASP-2 activation is delayed in serum from MASP-1 knockout mice (Takahashi et al., J Immunol 180: 6132-6138 (2008)), and similar results were observed in normal human serum when MASP-1 activity was blocked by a specific inhibitor (Kocsis et al., J Immunol 185(7): 4169-78 (2010)). Furthermore, Degn et al. (J. Immunol. 189(8):3957-69 (2012)) found that MASP-1 is essential for MASP-2 activation and subsequent C4 cleavage in human serum. The catalytic rate of conversion of proenzyme MASP-2 to active MASP-2 is more than 85,000-fold greater than the rate at which MASP-2 can self-activate (Megyeri et al., J. Biol. Chem. 288:8922-8934 (2013); Héja et al., J. Biol. Chem. 287(24):20290-300 (2012); Héja et al., PNAS 109:10498-503 (2012)).
[0119] Recent studies have also linked MASP-1 to the alternative pathway. MASP-1 converts the proenzyme factor D into its enzymatically active form ( Figure 39 ; Takahashi et al., J Exp Med 207:29-37 (2010)). In addition, MASP-1 activates the proenzyme form of MASP-3 (Megyeri et al., J. Biol. Chem. 288:8922–8934 (2013); Degn et al., J. Immunol. 189(8):3957-69 (2012)), which itself can activate the proenzyme factor D ( Figure 39 ) and cleaves factor B, another essential component of the alternative pathway, into its active form (Iwaki et al., J. Immunol. 187:3751-58 (2011). However, the conversion of pro-factor D and pro-factor B may be independent of the activation state of LEA-2 and may occur via non-complex-bound MASP-1.
[0120] Several lines of evidence suggest that MASP-1 is a thrombin-like enzyme and is important in the activation of the coagulation pathway. MASP-1 can cleave several substrates of thrombin, including fibrinogen (Hajela K. et al., Immunobiology 205(4-5):467-75 (2002)), factor XIII (Krarup et al., Biochim Biophys Acta 1784(9):1294-1300 (2008)), and protease-activated receptor 4 (PAR4) (Megyeri et al., J Immunol 183(5):3409-16 (2009)). Furthermore, antithrombin in the presence of heparin is a more potent MASP-1 inhibitor than C1-inhibitor (Dobó et al., J Immunol 183:1207-1214 (2009)). The connection between the complement and coagulation pathways is also emphasized by the following observations: MASP-2 can activate prothrombin (Krarup A. et al., PLoS One 2(7):e623 (2007)). Limited coagulation represents an ancient form of innate immunity, where fibrin clots prevent the spread of invading pathogens. The released fibrinopeptide B has proinflammatory activity. MASP-1-mediated cleavage of PAR4 activates endothelial cells, initiating an inflammatory response (Megyeri et al., J Immunol 183(5):3409-16 (2009)).
[0121] MASP-3 has no proteolytic activity against C4, C2, or C3 substrates. Instead, MASP-3 has been reported to act as an inhibitor of the lectin pathway (Dahl et al., Immunity 15:127-135 (2001)). This conclusion may be due to the fact that, in contrast to MASP-1 and MASP-2, MASP-3 is not a self-activating enzyme (Zundel S. et al., J Immunol 172:4342-4350 (2004); Megyeri et al., J. Biol. Chem. 288:8922–8934 (2013).
[0122] Recently, evidence for possible physiological functions of MASP-1 and MASP-3 has been obtained from transgenic mouse studies using mouse strains deficient in both MASP-1 and MASP-3. Although MASP-1 / 3-knockout mice have a functional lectin pathway (Schwaeble et al., PNAS 108:7523-7528 (2011)), they appear to lack alternative pathway activity (Takahashi et al., JEM 207(1):29-37 (2010)). The lack of alternative pathway activity appears to be due to a defect in the processing of complement factor D, which is required for alternative pathway activity. In MASP-1 / 3 knockout mice, all factor D circulates in a proteolytically inactive pro-form, whereas in normal mouse serum, almost all factor D is in the active form. Biochemical analyses suggest that MASP-1 may be able to convert complement factor D from its zymogen form to its enzymatically active form ( Figure 39 ; Takahashi et al., JEM 207(1):29-37 (2010). MASP-3 also cleaves pro-factor D zymogen in vitro and produces active factor D ( Figure 39 ; Takahashi et al., JEM 207(1):29-37 (2010). Factor D is present in the circulation of normal individuals as an active enzyme, and MASP-1 and MASP-3, as well as HTRA-1, are likely responsible for this activation. Furthermore, mice with combined MBL and ficolin deficiencies still produce normal levels of factor D and have a fully functional alternative pathway. Thus, these physiological functions of MASP-1 and MASP-3 do not necessarily involve lectins and are therefore unrelated to the lectin pathway. Recombinant mouse and human MASP-3 also appear to cleave factor B in vitro and support C3 deposition on S. aureus ( Figure 36 ;Iwaki D. et al., JImmunol 187(7):3751-8(2011)).
[0123] An unexpected physiological role for MASP-3 has been discovered in recent studies of patients with 3MC syndrome (formerly known as Carnevale, Mingarelli, Malpuech, and Michels syndrome; OMIM #257920). These patients exhibit severe developmental abnormalities, including cleft palate, cleft lip, skull deformities, and mental retardation. Genetic analysis identified 3MC patients who were homozygous for a dysfunctional MASP-3 gene (Rooryck et al., Nat Genet. 43(3):197-203 (2011)). Another group of 3MC patients was found to be homozygous for a mutation in the MASP-1 gene that results in the absence of functional MASP-1 and MASP-3 proteins. Yet another group of 3MC patients lacked a functional CL-11 gene (Rooryck et al., Nat Genet. 43(3):197-203 (2011)). Thus, the CL-11 MASP-3 axis appears to function during embryonic development. The molecular mechanism of this developmental pathway remains unclear. However, this is unlikely to be mediated by a conventional complement-driven process, as individuals deficient in the common complement component C3 do not develop this syndrome. Thus, prior to the inventors' discoveries, as described herein, a functional role for MASP-3 in lectin-dependent complement activation had not previously been determined.
[0124] The structures of the catalytic fragments of MASP-1 and MASP-2 have been determined by X-ray crystallography. Structural comparisons of the MASP-1 protease domain with those of other complement proteases reveal the basis for its relaxed substrate specificity (Dobó et al., J. Immunol 183:1207-1214 (2009)). While accessibility to the substrate-binding groove of MASP-2 is restricted by surface loops (Harmat et al., J Mol Biol 342:1533-1546 (2004)), MASP-1 possesses an open substrate-binding pocket, similar to trypsin rather than other complement proteases. The thrombin-like nature of the MASP-1 structure is due to an unusually large 60-amino acid loop (loop B) that can interact with the substrate. Another intriguing property of the MASP-1 structure is the internal salt bridge between S1 Asp189 and Arg224. A similar salt bridge is found in the substrate-binding pocket of Factor D, which may modulate its protease activity. C1s and MASP-2 have nearly identical substrate specificities. Surprisingly, some of the eight surface loops of MASP-2 that determine substrate specificity have completely different conformations compared to those of C1s. This suggests that these two functionally related enzymes interact with the same substrate in different ways. The structure of proenzyme MASP-2 reveals an inactive protease domain with a disrupted oxyanion hole and substrate-binding pocket (Gál et al., J Biol Chem 280:33435-33444 (2005)). Surprisingly, proenzyme MASP-2 exhibits considerable activity on the large protein substrate C4. It is likely that the structure of proenzyme MASP-2 is quite flexible, enabling conversion between inactive and active forms. This flexibility, reflected in the structure, may play a role in the self-activation process.
[0125] Western blot analysis indicates that the liver is the primary source of MASP-1 and MASP-2 mRNA. Using a 5'-specific cDNA probe for MASP-1, a large MASP-1 transcript of 4.8 kb and a small one of approximately 3.4 kb were found in human and mouse liver (Stover et al., Genes Immunity 4:374-84 (2003)). MASP-2 mRNA (2.6 kb) and MApl9 mRNA (1.0 kb) are abundantly expressed in liver tissue. MASP-3 is expressed in the liver and also in many other tissues, including neural tissue (Lynch NJ et al., J Immunol 174:4998-5006 (2005)).
[0126] Patients with a history of infections and chronic inflammatory diseases were found to have a mutated form of MASP-2 that was unable to form an active MBL-MASP complex (Stengaard-Pedersen et al., NEngl J Med 349:554-560 (2003)). Some researchers have determined that MBL deficiency leads to a predisposition to frequent infections in children (Super et al., Lancet 2:1236-1239 (1989); Garred et al., Lancet 346:941-943 (1995)) and increased resistance to HIV infection (Nielsen et al., Clin Exp Immunol 100:219-222 (1995); Garred et al., Mol Immunol 33(Suppl 1):8 (1996)). However, other studies have not demonstrated a significant correlation between low MBL levels and increased infection (Egli et al., PLoS One. 8(1):e51983 (2013); Ruskamp et al., J Infect Dis. 198(11):1707-13 (2008); et al., Arch Dis Child Fetal Neonatal Ed. 95(6):F452-61 (2010). Although the literature is mixed, deficiency or ineffectiveness of MASPs may have adverse effects on an individual's ability to mount a direct, non-antibody-dependent defense against certain pathogens.
[0127] iii. Supporting data for the new understanding, emphasizing the lack of Ca ++ Traditional assay conditions and the use of Ca ++ The results were obtained under more physiological conditions.
[0128] Several independent lines of compelling experimental evidence are presented herein, pointing to the conclusion that the lectin pathway activation pathway of complement activates complement via two independent effector mechanisms: i) LEA-2: a MASP-2-driven pathway that mediates complement-driven opsonization, chemotaxis (Schwaeble et al., PNAS 108:7523-7528 (2011)), and cytolysis, and ii) LEA-1: a novel MASP-3-dependent activation pathway that initiates complement activation by cleavage and activation of factor B on the surface of the activator to generate the alternative pathway convertase C3bBb, which then catalyzes C3b deposition and formation of the alternative pathway convertase C3bBb, which can lead to cytolysis and microbial opsonization. In addition, as described herein, lectin-independent activation of factor B and / or factor D alone by MASP-1, MASP-3, or HTRA-1, or any combination of these three, can also lead to complement activation via the alternative pathway.
[0129] Lectin pathway-dependent MASP-3-driven activation of the alternative pathway appears to facilitate the well-established factor D-mediated cleavage of C3b-bound factor B to achieve optimal activation rates for complement-dependent cytolysis through the terminal activation cascade, lysing bacterial cells by forming the C5b-9 membrane attack complex (MAC) on the cell surface ( Figure 14-15 ). This rate-limiting event appears to require optimal coordination because it is defective in the absence of MASP-3 functional activity and in the absence of Factor D functional activity. As described in Examples 1-4 herein, the inventors discovered this MASP-3-dependent lectin pathway function while studying the phenotypes of MASP-2 deficiency and MASP-2 inhibition in an experimental mouse model of N. meningitidis infection. Gene-targeted MASP-2-deficient mice and wild-type mice treated with antibody-based MASP-2 inhibitors were highly resistant to experimental N. meningitidis infection (see Figures 8-12). When the infectious dose was adjusted to achieve approximately 60% mortality in wild-type littermates, all MASP-2-deficient or MASP-2-depleted mice cleared the infection and survived (see Figure 8 and Figure 12 This extremely high degree of resistance was reflected in the markedly increased bactericidal activity of serum in sera from MASP-2-deficient or MASP-2-depleted mice. Further experiments demonstrated that this bactericidal activity was dependent on alternative pathway-driven bacterial lysis. Sera from mice deficient in factor B, factor D, or factor C3 exhibited no bactericidal activity against N. meningitidis, indicating that the alternative pathway is necessary to drive the terminal activation cascade. Surprisingly, sera from mice deficient in MBL-A and MBL-C, both lectin-pathway recognition molecules that recognize N. meningitidis, as well as sera from mice deficient in the lectin pathway-associated serine proteases MASP-1 and MASP-3, lost all lytic activity against N. meningitidis. Figure 15 ). A recent paper (Takahashi M. et al., JEM 207:29-37 (2010)) and the work presented here ( Figure 39) demonstrated that MASP-1 can convert the proenzyme form of factor D into its enzymatically active form and may partially explain the loss of cytolytic activity due to the absence of enzymatically active factor D in these sera. This does not explain the lack of bactericidal activity in MBL-deficient mice, as these mice have normal enzymatically active factor D (Banda et al., Mol Imunol 49(1-2):281-9 (2011)). Notably, when human sera from patients with the rare autosomal recessive disorder 3MC, who have mutations that render the MASP-3 serine protease domain dysfunctional, were tested (Rooryck C, et al., Nat Genet. 43(3):197-203), no bactericidal activity against Neisseria meningitidis was detected (note: these sera have MASP-1 and factor D, but not MASP-3).
[0130] The hypothesis that human serum requires lectin pathway-mediated MASP-3-dependent activity to develop bactericidal activity is further supported by the observation that MBL-deficient human serum is also unable to lyse N. meningitidis ( Figure 13-14 MBL is the only human lectin-pathway recognition molecule bound to this pathogen. Because MASP-3 is not self-activating, the inventors hypothesized that the higher bacteriolytic activity in MASP-2-deficient serum could be explained by the favorable activation of MASP-3 by MASP-1, since in the absence of MASP-2, all lectin-pathway activation complexes bound to the bacterial surface would be loaded with either MASP-1 or MASP-3. Because activated MASP-3 simultaneously cleaves factor D ( Figure 39 ) and factor B, producing their respective enzymatically active forms ( Figure 37 and Iwaki D., et al., J. Immunol. 187(7):3751-3758 (2011)), so the most likely function of MASP-3 is to promote the formation of the alternative pathway C3 convertase (ie, C3bBb).
[0131] Although the data on lectin-dependent effects are intriguing, several experiments have shown that MASP-3 and MASP-1 are not necessarily functional in complex with lectin molecules. Figure 35B The experiments shown demonstrate the ability of MASP-3 to activate the alternative pathway (as demonstrated by C3b deposition in S. aureus) under conditions in which complexes with lectins are absent (ie, in the presence of EGTA). Figure 35A Deposition under these conditions was shown to be dependent on Factor B, Factor D, and Factor P, all of which are key components of the alternative pathway. In addition, Factor D activation by MASP-3 and MASP-1 ( Figure 39) and MASP-3-induced factor B activation ( Figure 37 ) can occur in vitro in the absence of lectins. Finally, hemolysis studies of mouse erythrocytes in the presence of human serum demonstrated clear contributions of both MBL and MASP-3 to cell lysis. However, deficiency in MBL did not fully recapitulate the severity of MASP-3 deficiency, contrary to what would be expected if all functional MASP-3 were complexed with MBL. Thus, the inventors do not wish to be limited by the notion that all effects of MASP-3 (and MASP-1) demonstrated herein can be attributed solely to lectin-related functions.
[0132] The identification of two effector branches of the lectin pathway and possible lectin-independent functions of MASP-1, MASP-3, and HTRA-1 presents new opportunities for therapeutic intervention to effectively treat selected human pathologies that result from excessive complement activation in the presence of microbial pathogens or altered host cells or metabolic deposits. As described herein, the inventors have now discovered that in the absence of MASP-3 and in the presence of MASP-1, the alternative pathway is not activated on surface structures (see Figure 17-18 , 35B, 41-42, 45-46). Because the alternative pathway is important in driving the rate-limiting events that lead to bacterial lysis as well as cell lysis (Mathieson PW, et al., J Exp Med 177(6):1827-3 (1993)), our results demonstrate that activated MASP-3 plays an important role in the cytolytic activity of complement. Figure 14-15 , 21-23, 43-44, and 46-47, the terminal activation cascade of complement cytolysis is defective in sera from 3MC patients who lack MASP-3 but not MASP-1. Figure 14 and 15 The data presented demonstrates loss of lytic activity in the absence of MASP-3 and / or MASP-1 / MASP-3 functional activity. Similarly, loss of hemolytic activity in MASP-3-deficient human serum ( Figure 21-23 , 43-44 and 46-47), and the ability to reconstitute hemolysis by adding recombinant MASP-3 ( Figures 46-47 ), strongly supports the conclusion that activation of the alternative pathway on the target surface, which is essential for driving complement-mediated cytolysis, is dependent on the presence of activated MASP-3. Based on the new understanding of the lectin pathway detailed above, alternative pathway activation on the target surface is therefore dependent on lectin-independent activation of LEA-1 and / or Factor B and / or Factor D, which are also mediated by MASP-3, and therefore, agents that block MASP-3-dependent complement activation will prevent alternative pathway activation on the target surface.
[0133] The disclosure of the essential role of MASP-3-dependent priming for alternative pathway activation suggests that the alternative pathway is not a separate, single pathway of complement activation, as is described in essentially all current medical textbooks and recent review articles on complement. The current and widely held scientific concept is that the alternative pathway is activated on the surface of certain specific targets (microorganisms, zymosan, and rabbit erythrocytes) through amplification of spontaneous "tick-over" C3 activation. However, the absence of any alternative pathway activation on zymosan-coated plates and on two different bacteria (Neisseria meningitidis and Staphylococcus aureus) in serum from mice doubly deficient in MASP-1 and MASP-3 and in serum from human 3MC patients, and the reduction in erythrocyte hemolysis in MASP-3-deficient sera from humans and mice, all indicate that the initiation of alternative pathway activation on these surfaces requires functional MASP-3. The desired action of MASP-3 can be either lectin-dependent or lectin-independent and leads to the formation of the alternative pathway C3 convertase and C5 convertase complexes, C3bBb and C3bBb(C3b)n, respectively. Thus, the inventors herein disclose the existence of a previously elusive priming pathway for the alternative pathway. This priming pathway is dependent on (i) LEA-1, a newly discovered activation branch of the lectin pathway, and / or (ii) the lectin-independent actions of the proteins MASP-3, MASP-1, and HTRA-1.
[0134] III. The role of MASP-2 and MASP-3 in paroxysmal nocturnal hemoglobinuria and treatment approaches using MASP-2 and MASP-3 inhibitors Overview of i.PNH Paroxysmal nocturnal hemoglobinuria (PNH), sometimes also called Marchiafava-Micheli syndrome, is an acquired, potentially life-threatening blood disorder. PNH can occur spontaneously, called "primary PNH," or in the setting of other bone marrow disorders, such as aplastic anemia, called "secondary PNH." The majority of cases are primary PNH. PNH is characterized by complement-induced red blood cell destruction (hemolysis), low red blood cell counts (anemia), thrombosis, and bone marrow failure. Laboratory findings in PNH show changes consistent with intravascular hemolytic anemia: low hemoglobin, elevated lactate dehydrogenase, elevated reticulocyte counts (immature red blood cells released by the bone marrow to replace destroyed cells), elevated bilirubin (a degradation product of hemoglobin), in the absence of autoreactive RBC-binding antibodies as a possible causative agent.
[0135] The hallmark of PNH is chronic complement-mediated hemolysis caused by the activation of unregulated terminal complement components on the surface of circulating RBCs, including the membrane attack complex. PNH RBCs experience uncontrolled complement activation and hemolysis due to the absence of complement regulators CD55 and CD59 on their surfaces (Lindorfer, MA, et al., Blood 115 (11): 2283-91 (2010), Risitano, et al., Mini-Reviews in Medicinal Chemistry, 11: 528-535 (2011)). CD55 and CD59 are expressed in large quantities on normal RBCs and control complement activation. CD55 acts as a negative regulator of the alternative pathway, inhibiting the assembly of the alternative pathway C3 convertase (C3bBb) complex and accelerating the decay of the preformed convertase, thereby blocking the formation of the membrane attack complex (MAC). CD59 directly inhibits the complement membrane attack complex by binding to the C5b678 complex and preventing the binding and polymerization of C9.
[0136] Although hemolysis and anemia are the main clinical characteristics of PNH, the disease is a complex hematological disorder that further includes thrombosis and bone marrow failure as part of clinical findings (Risitano et al., MiniReviews in MedChem 11:528-535 (2011)). At the molecular level, PNH is caused by abnormal clonal expansion of hematopoietic stem cells lacking a functional PIG A gene. PIG A is an X-linked gene encoding glycosylation-phosphatidylinositol transferase, which is required for the stable surface expression of GPI-anchored class A glycoproteins (including CD55 and CD59). For reasons currently under investigation, hematopoietic stem cells with dysfunctional PIG A genes as a result of spontaneous somatic mutations can be cloned and expanded to the point where their offspring constitute a significant portion of the peripheral hematopoietic cell pool. Although the offspring of erythrocytes and lymphocytes of mutant stem cell clones lack CD55 and CD59, only RBCs experience significant hemolysis after they enter the circulation.
[0137] Current treatments for PNH include blood transfusions for anemia, anticoagulation for thrombosis, and the monoclonal antibody eculizumab. It protects blood cells from immune destruction due to inhibition of the complement system (Hillmen P. et al., N. Engl. J. Med. 350(6):552-559 (2004)). It is a humanized monoclonal antibody that targets complement component C5, blocking its cleavage by the C5 convertase, thereby preventing the generation of C5a and the assembly of MAC. Treatment of PNH patients with eculizumab results in a reduction in intravascular hemolysis (as measured by lactate dehydrogenase (LDH)) in approximately half of the patients, leading to hemoglobin stabilization and transfusion independence (Risitano et al., Mini-Reviews in Medicinal Chemistry, 11(6)(2011)). Although almost all patients treated with eculizumab achieve normal or nearly normal LDH levels (because of controlled intravascular hemolysis), only about one-third of patients achieve hemoglobin values of approximately 11 gr / dL, and the remaining patients receiving eculizumab continue to exhibit moderate to severe (i.e., transfusion-dependent) anemia in approximately the same proportion (Risitano AM et al., Blood 113:4094-100(2009)). As described by Risitano et al., Mini-Reviews in Medicinal Chemistry 11:528-535 (2011), it has been shown that PNH patients receiving eculizumab contain large amounts of C3 fragments associated with their PNH red blood cells (while untreated patients do not). This finding led to the realization that in PNH patients treated with Soliris, PNH RBCs that are no longer hemolyzed due to C5 blockade can now accumulate large amounts of membrane-bound C3 fragments, which act as opsonins, causing them to be recruited into reticuloendothelial cells via specific C3 receptors and subsequently leading to extravascular hemolysis. Therefore, although intravascular hemolysis and the resulting results are prevented, eculizumab treatment merely shifts the disposal of these RBCs from intravascular to extravascular hemolysis, resulting in a large amount of residual untreated anemia in many patients (Risitano AM et al., Blood 113:4094-100 (2009)). Therefore, for patients who develop C3-fragment-mediated extravascular hemolysis, treatment strategies other than eculizumab are needed because they continue to require red blood cell transfusions. Such C3 fragment-targeted approaches have demonstrated utility in experimental systems (Lindorfer et al., Blood 115:2283-91, 2010).
[0138] ii. Complement-activating mechanisms in PNH The causal relationship between the defective surface expression of the negative complement regulators CD55 and CD59 in PNH, and the effectiveness of eculizumab in preventing intravascular hemolysis, clearly defines PNH as a condition mediated by the complement system. Although this paradigm is widely accepted, the nature of the events that initiate complement activation and the complement activation pathways involved remain unresolved. Because CD55 and CD59 negatively regulate the terminal amplification step in the complement cascade common to all complement initiation pathways, defects in these molecules will lead to excessive formation and membrane integration of the membrane attack complex, regardless of whether complement activation is initiated by the lectin pathway, the classical pathway, or spontaneous renewal of the alternative pathway. Therefore, in PNH patients, any complement activation event that leads to C3b deposition on the RBC surface can trigger subsequent amplification and pathological hemolysis (intravascular and / or extravascular) and precipitate hemolytic crisis. A clear mechanistic understanding of the molecular events that trigger hemolytic crisis in PNH subjects remains elusive. Because no complement-initiating events are evident in PNH patients experiencing hemolytic crisis, the prevailing view is that complement activation in PNH may occur spontaneously due to low-level "tick-over" activation of the alternative pathway, which is subsequently amplified by inappropriate control of terminal complement activation due to the absence of CD55 and CD59.
[0139] However, it is important to note that in its natural history, PNH typically develops or worsens following certain events, such as infection or injury (Risitano, Biologics 2:205-222 (2008)), which have been shown to trigger complement activation. Such complement activation reactions are independent of the host's prior immunity to the inciting pathogen and, therefore, may not involve the classical pathway. Rather, it appears that such complement activation reactions are initiated by lectin binding to exogenous or "auto-altered" carbohydrate patterns expressed on the surface of microbial substrates or damaged host tissues. Therefore, the events that precipitate hemolytic crises in PNH are closely related to complement activation initiated via lectins. This makes it possible that the lectin activation pathway provides the trigger for initiation, which ultimately leads to hemolysis in PNH patients.
[0140] Using well-defined pathogens that activate complement via lectins as experimental models to analyze the activation cascade at the molecular level, we demonstrated that complement activation can be initiated by either LEA-2 or LEA-1, leading to opsonization and / or cytolysis, depending on the stimulating microorganism. The same principles underlying the dual response of lectin-initiated events (i.e., opsonization and / or cytolysis) may also apply to other types of infectious agents, or to lectin-induced complement activation following host tissue damage, or to other lectin-driven complement activation events that may contribute to PNH. Based on this duality in the lectin pathway, we hypothesize that in PNH patients, LEA-2- and / or LEA-1-initiated complement activation promotes opsonization and / or lysis of RBCs by C3b and subsequent extravascular and intravascular hemolysis. Therefore, in the setting of PNH, simultaneous inhibition of LEA-1 and LEA-2 is expected to address both intravascular and extravascular hemolysis, providing a clear advantage over the C5 inhibitor eculizumab.
[0141] It has been determined that exposure to S. pneumoniae preferentially triggers lectin-dependent activation of LEA-2, which leads to opsonization of the microorganism by C3b. Because S. pneumoniae is resistant to MAC-mediated cytolysis, its clearance from the circulation occurs through opsonization by C3b. This opsonization and subsequent clearance from the circulation is LEA-2-dependent, as shown by bacterial controls exposed in MASP-2-deficient mice and in mice treated with a MASP-2 monoclonal antibody (PLOS Pathog., 8:e1002793. (2012)).
[0142] In studying the role of LEA-2 in the innate host response to microbial agents, we tested additional pathogens. Very different results were observed when studying Neisseria meningitidis as a model organism. Neisseria meningitidis also activates complement via lectins, and complement activation is essential for N. meningitidis infection in naive hosts. However, LEA-2 does not play a host protective role in this response: as shown in Figures 8 and 9, LEA-2 blockade by genetic ablation of MASP-2 did not reduce survival after N. meningitidis infection. In contrast, in these studies, LEA-2 blockade by MASP-2 ablation significantly improved survival (Figures 8 and 9) and disease scores (Figures 9 and 10). Figure 11 The same results were obtained by blocking LEA-2 with MASP-2 antibodies ( Figure 12 ), eliminating secondary or compensatory effects as possible causes in knockout mouse strains. These favorable results in LEA-2-ablated animals were associated with more rapid clearance of N. meningitidis from the blood ( Figure 10 ). In addition, as described herein, incubation of N. meningitidis with normal human serum kills N. meningitidis ( Figure 13 The killing response was enhanced by the addition of a functional monoclonal antibody specific for human MASP-2 that blocks LEA-2, but not by the administration of an isotype control monoclonal antibody. However, this process depends on lectins and at least a partially functional complement system, as MBL-deficient human serum or heat-inactivated human serum failed to kill N. meningitidis ( Figure 13 Taken together, these novel findings indicate that N. meningitidis infection is controlled by a lectin-dependent, but LEA-2-independent, pathway of complement activation in the presence of a functional complement system.
[0143] The hypothesis that LEA-1 may be responsible for the complement pathway's lectin-dependent killing of N. meningitidis was tested using serum specimens from a patient with 3MC. This patient was homozygous for a nonsense mutation in exon 12 of the MASP-1 / 3 gene. Consequently, the patient lacked functional MASP-3 protein but otherwise had sufficient complement (exon 12 is specific for MASP-3 transcripts; the mutation had no effect on MASP-1 function or expression levels) (see Nat Genet 43(3):197-203 (2011)). Normal human serum effectively killed N. meningitidis, but heat-inactivated serum lacking MBL (a recognition molecule of the lectin pathway) and MASP-3-deficient serum failed to kill N. meningitidis. Figure 14 Thus, LEA-1 appears to mediate killing of N. meningitidis. This finding was confirmed using serum samples from knockout mouse strains. Although normal mouse serum containing complement readily kills N. meningitidis, serum from MBL-deficient or MASP-1 / 3-deficient mice is as ineffective as heat-inactivated serum lacking functional complement ( Figure 15 In contrast, MASP-2-deficient serum exhibited effective killing of N. meningitidis.
[0144] These findings provide evidence of a hitherto unknown duality in the lectin pathway by revealing the existence of separate LEA-2 and LEA-1 pathways for lectin-dependent complement activation. In the examples detailed above, LEA-2 and LEA-1 are non-redundant and mediate different functional outcomes. The data suggest that certain types of lectin pathway activators (including but not limited to Streptococcus pneumoniae) preferentially initiate complement activation via LEA-2, leading to opsonization, while others (taking Neisseria meningitidis as an example) preferentially initiate complement activation via LEA-1 and promote the cytolysis process. However, the data do not necessarily limit LEA-2 to opsonization and LEA-1 to the cytolysis process, because in other cases the two pathways can mediate opsonization and / or cytolysis.
[0145] In the case of lectin-dependent complement activation by N. meningitidis, the LEA-2 and LEA-1 branches appear to compete with each other, as blockade of LEA-2 enhances LEA-1-dependent cytolytic destruction of the organism in vitro ( Figure 15 As detailed above, this finding can be explained as follows: in the absence of MASP-2, the likelihood of the lectin-MASP-1 complex being retained in proximity to the lectin-MASP-3 complex is increased, which would enhance LEA-1 activation and thus promote more efficient lysis of N. meningitidis. Because lysis of N. meningitidis is a primary protective mechanism in naive hosts, blockade of LEA-2 increases clearance of N. meningitidis in vivo and leads to increased killing.
[0146] While the above examples illustrate opposing effects of LEA-2 and LEA-1 on outcomes following infection with Neisseria meningitidis, there may be other situations in which LEA-2 and LEA-1 may work together to produce a certain outcome. As described in detail below, in other situations of pathological complement activation via lectins (such as those present in PNH), LEA-2- and LEA-1-driven complement activation may work together in a synergistic manner to contribute to the overall pathology of PNH. In addition, as described herein, MASP-3 also promotes the lectin-independent conversion of Factor B and Factor D, which may be activated in the presence of Ca. ++ In its absence, it typically results in conversion of C3bB to C3bBb and profactor D to factor D, which can further contribute to PNH pathology.
[0147] iii. Biology and expected functional activity in PNH This section describes the inhibitory effects of LEA-2 and LEA-1 blockade on hemolysis in an in vitro model of PNH. The findings support the use of LEA-2 blockers (including, but not limited to, antibodies that bind to MASP-2 and block its function) and LEA-1 blockers (including, but not limited to, antibodies that bind to MASP-3 and block MASP-1-mediated activation of MASP-3, block MASP-3 function, or both) to treat subjects with one or more aspects of PNH, and also the use of inhibitors of LEA-2 and / or LEA-1, and / or inhibitors of MASP-3-dependent, lectin-independent complement activation (including MASP-2 inhibitors, MASP-3 inhibitors, and dual- or bispecific MASP-2 / MASP-3 or MASP-1 / MASP-2 inhibitors, and pan-specific MASP-1 / MASP-2 / MASP-3 inhibitors) to ameliorate the effects of C3-fragment-mediated extravascular hemolysis in PNH patients undergoing treatment with C5 inhibitors, such as eculizumab.
[0148] iv. MASP-2 inhibitors block opsonization and extravascular hemolysis of PNH RBCs by the reticuloendothelial system As detailed above, PNH patients are anemic due to two different mechanisms of RBC clearance from the circulation: intravascular hemolysis via activation of the membrane attack complex (MAC), and extravascular hemolysis following opsonization of C3b and subsequent clearance by complement receptor binding and uptake by the reticuloendothelial system. When patients are treated with eculizumab, intravascular hemolysis is greatly prevented. Because eculizumab blocks the terminal lytic effector mechanism (which occurs downstream of the complement-initiated activation event and subsequent opsonization), eculizumab does not block extravascular hemolysis (Risitano AM et al., Blood 113:4094-100 (2009)). Instead, RBCs that would undergo hemolysis in untreated PNH subjects can now accumulate activated C3b protein on their surface, which increases uptake by the reticuloendothelial system and increases their extravascular hemolysis. Thus, eculizumab treatment effectively shifts the disposition of RBCs from intravascular hemolysis to possible extravascular hemolysis. As a result, some eculizumab-treated PNH patients remain anemic. Therefore, agents that block complement activation upstream and prevent opsonization of PNH RBCs may be particularly suitable for blocking the extravascular hemolysis occasionally seen with eculizumab.
[0149] The microbial data presented here indicate that LEA-2 is generally the primary pathway for lectin-dependent opsonization. Furthermore, when activated on three prototypical lectin surfaces (mannan, Figure 19A ; Zymosan, Figure 19B , and Streptococcus pneumoniae; Figure 19C When lectin-dependent opsonization (measured as C3b deposition) was assessed on 1000 bp LEA-2 appeared to be activated under physiological conditions (i.e., in the presence of Ca ++ LEA-1 is the primary pathway for lectin-dependent opsonization when all complement pathways are active. Under these experimental conditions, MASP-2-deficient serum (which lacks LEA-2) was substantially less effective at opsonizing the test surface than WT serum. MASP-1 / 3-deficient serum (which lacks LEA-1) was also deficient, although the effect was much less pronounced than that of serum lacking LEA-2. The relative contributions of LEA-2 and LEA-1 to lectin-driven opsonization are shown in Table 1. Figure 20A –20C. Although the alternative pathway of complement has been reported to support opsonization of lectin-activated surfaces in the absence of either the lectin or classical pathways (Selander et al., J Clin Invest 116(5):1425-1434 (2006)), in isolation (in the absence of Ca ++ The alternative pathway (determined under the assay conditions described herein) appears to be substantially less efficient than the LEA-2- and LEA-1-initiated processes described herein. By extrapolation, these data suggest that opsonization of PNH RBCs may also be initiated preferentially by LEA-2, and to a lesser extent by LEA-1 (possibly amplified by the alternative pathway amplification loop), rather than as a result of lectin-independent alternative pathway activation. Therefore, LEA-2 inhibitors would be expected to be most effective in limiting opsonization and preventing extravascular hemolysis in PNH. However, the recognition that lectins, rather than MBL (e.g., ficolins), bind to non-carbohydrate structures (e.g., acetylated proteins) and that MASP-3 preferentially associates with H-ficolin (Skjoedt et al., Immunobiol. 215:921-931, 2010), also leaves open the possibility of an important role for LEA-1 in PNH-associated RBC opsonization. Therefore, LEA-1 inhibitors are expected to have additional anti-opsonization effects, and combinations of LEA-1 and LEA-2 inhibitors are expected to be optimal and mediate the most potent therapeutic benefit in limiting opsonization and extravascular hemolysis in PNH patients. This concept is further supported by Figure 28This is supported by the opsonization data shown in : Factor D-deficient mouse serum (which lacks the ability to activate the alternative pathway in fluid phase, but has functional classical pathways as well as functional LEA-1 and LEA-2 pathways) showed no defect in opsonization compared to WT serum. Factor B-deficient serum (which lacks LEA-1) showed reduced opsonization, while factor D-deficient serum treated with a MASP-2 monoclonal antibody to block LEA-2-mediated complement activation resulted in a more potent inhibition of opsonization ( Figure 28 Importantly, the addition of a MASP-2 monoclonal antibody to factor B-deficient serum inhibited opsonization more effectively than either MASP-2 blockade or factor D blockade alone. Thus, LEA-2 and LEA-1 act additively or synergistically to promote opsonization, and cross-reactive or bispecific LEA-1 / LEA-2 inhibitors are expected to be most effective in blocking opsonization and extravascular hemolysis in PNH.
[0150] v. Role of MASP-3 inhibitors in PNH Using an in vitro model of PNH, we demonstrated that complement activation and the resulting hemolysis in PNH is indeed initiated by LEA-2 and / or LEA-1 activation and is not an alternative pathway-independent function. These studies used mannan-sensitized RBCs from different mouse strains, including RBCs from Crry-deficient mice (an important negative regulator of the terminal complement pathway in mice), and RBCs from CD55 / CD59-deficient mice (which lack the complement regulators that are absent in PNH patients). When mannan-sensitized Crry-deficient RBCs were exposed to complement-sufficient human serum, the RBCs efficiently hemolyzed at a serum concentration of 3% ( Figure 21 and 22 ), whereas complement-deficient serum (HI: heat-inactivated) was non-hemolytic. Notably, complement-sufficient serum (in which LEA-2 was blocked by the addition of MASP-2 antibodies) had reduced hemolytic activity, and for effective hemolysis, 6% serum was required. Similar observations were made when CD55 / CD59-deficient RBCs were tested ( Figure 24 Complement-sufficient human serum supplemented with MASP-2 monoclonal antibodies (i.e., serum in which LEA-2 is inhibited) was approximately 2-fold less effective than untreated serum in supporting hemolysis. Furthermore, higher concentrations of LEA-2-blocked serum (i.e., treated with anti-MASP-2 monoclonal antibodies) were required to promote efficient hemolysis of untreated WT RBCs compared to untreated serum. Figure 23 ).
[0151] Even more surprising was that serum from a 3MC patient homozygous for a dysfunctional MASP-3 protein (and therefore lacking LEA-1) was completely unable to hemolyze mannan-sensitized Crry-deficient RBCs ( Figure 22 and Figure 23 ). Similar results were observed when unsensitized normal RBCs were used: Figure 23 As shown, LEA-1-deficient serum isolated from 3MC patients was completely ineffective in mediating hemolysis. Taken together, these data indicate that while LEA-2 significantly promotes intravascular hemolytic reactions, LEA-1 is the primary complement-initiating pathway leading to hemolysis. Therefore, while LEA-2 blockade is expected to significantly reduce intravascular hemolysis of RBCs in PNH patients, LEA-1 blockade is expected to have a more profound effect and substantially eliminate complement-driven hemolysis.
[0152] It should be noted that the serum from the LEA-1-deficient 3MC patients used in this study has a reduced but functional alternative pathway ( Figure 17 This finding suggests that LEA-1 contributes significantly to hemolysis compared to alternative pathway activity, as conventionally defined in this experimental setting of PNH. Extrapolated, this suggests that LEA-1 blockade is at least as effective as blockade of other aspects of the alternative pathway in preventing or treating intravascular hemolysis in patients with PNH.
[0153] vi. Role of MASP-2 inhibitors in PNH The data presented herein suggest the following pathogenesis of anemia in PNH: intravascular hemolysis due to RBC hemolysis caused by unregulated activation of terminal complement components and MAC formation, which is primarily (but not exclusively) initiated by LEA-1; and extravascular hemolysis due to opsonization of RBCs by C3b, which appears to be primarily initiated by LEA-2. Although a recognizable role for LEA-2 in initiating complement activation and promoting MAC formation and hemolysis is evident, this process appears to be significantly less effective than LEA-1-initiated complement activation leading to hemolysis. Therefore, LEA-2 blockade is expected to significantly reduce intravascular hemolysis in PNH patients, although this therapeutic activity is expected to be only partial. By comparison, intravascular hemolysis in PNH patients is expected to be more significantly reduced for LEA-1 blockade.
[0154] Extravascular hemolysis, a less significant but still equally important mechanism of RBC destruction leading to anemia in PNH, is primarily the result of opsonization by C3b, which appears to be primarily mediated by LEA-2. Therefore, LEA-2 blockers are expected to preferentially block RBC opsonization and subsequent extravascular hemolysis in PNH. This unique therapeutic activity of LEA-2 blockers is expected to provide important therapeutic benefits to all PNH patients, as there are currently no treatments for PNH patients experiencing this pathological process.
[0155] vii. LEA-2 Inhibitors as Adjunct Therapy to LEA-1 Inhibitors or Terminal Complement Blockade The data presented here detail two pathogenic mechanisms of RBC clearance and anemia in PNH that can be targeted separately or in combination by different types of therapeutic agents: intravascular hemolysis, which is primarily (but not exclusively) initiated by LEA-1 and is therefore expected to be effectively prevented by LEA-1 blockade; and extravascular hemolysis, which is primarily caused by C3b opsonization driven by LEA-2 and is therefore effectively prevented by LEA-2 blockade.
[0156] It is well documented that both intravascular and extravascular hemolytic mechanisms contribute to anemia in PNH patients (Risitano et al., Blood 113:4094-4100 (2009)). Therefore, the combination of a LEA-1 blocker, which prevents intravascular hemolysis, and a LEA-2 blocker, which primarily prevents extravascular hemolysis, is expected to be more effective in preventing anemia in PNH patients than either agent alone. In fact, the combination of LEA-1 and LEA-2 blockers is expected to prevent all relevant mechanisms of complement initiation in PNH and thus block all anemic symptoms in PNH.
[0157] It is also known that C5-blockers (e.g., eculizumab) effectively block intravascular hemolysis but do not interfere with opsonization. This leaves some PNH patients treated with anti-C5-therapy with substantial residual anemia due to untreated extravascular hemolysis mediated by LEA-2. Therefore, the combination of a C5-blocker (e.g., eculizumab) to prevent intravascular hemolysis and a LEA-2 blocker to reduce extravascular hemolysis is expected to be more effective in preventing anemia in PNH patients than either agent alone.
[0158] Other agents that block the terminal amplification loop of the complement system, leading to C5 activation and MAC deposition (including but not limited to agents that block properdin, factor B or factor D or enhance the inhibitory activity of factor I, factor H or other complement inhibitory factors) are also expected to inhibit intravascular hemolysis. However, these agents are not expected to interfere with LEA-2-mediated opsonization in PNH patients. This leaves some PNH patients treated with such agents with a large amount of residual anemia due to LEA-2-mediated extravascular hemolysis that remains untreated. Therefore, it is expected that treatment with such agents that prevent intravascular hemolysis, combined with LEA-2 blockers that minimize extravascular hemolysis, will be more effective in preventing anemia that occurs in PNH patients than with either agent alone. In fact, the combination of such agents and LEA-2 blockers is expected to prevent all relevant mechanisms of RBC destruction in PNH and thus block all anemic symptoms in PNH.
[0159] viii. Using Bispecific or Panspecific Antibodies Against LEA-1 and LEA-2 to Treat PNH As detailed above, the combined use of pharmaceutical agents that block LEA-1 and LEA-2 separately and thus jointly block all complement activation events that mediate intravascular and extravascular hemolysis is expected to provide the best clinical outcomes for patients with PNH. This outcome can be achieved, for example, by co-administering an antibody with LEA-1 blocking activity and an antibody with LEA-2 blocking activity. In certain embodiments, LEA-1 and LEA-2 blocking activities are combined into a single molecular entity, and such entities with combined LEA-1 and LEA-2 blocking activities will effectively block intravascular and extravascular hemolysis and prevent anemia in PNH. Such entities may comprise or consist of bispecific antibodies in which one antigen-binding site specifically recognizes MASP-1 and blocks LEA-1 and reduces LEA-2, while a second antigen-binding site specifically recognizes MASP-2 and further blocks LEA-2. Alternatively, such entities may consist of bispecific monoclonal antibodies in which one antigen-binding site specifically recognizes MASP-3 and thereby blocks LEA-1, and a second antigen-binding site specifically recognizes MASP-2 and thereby blocks LEA-2. Such entities may preferably consist of bispecific monoclonal antibodies in which one antigen-binding site specifically recognizes both MASP-1 and MASP-3 and thereby blocks LEA-1 and reduces LEA-2, while the second antigen-binding site specifically recognizes MASP-2 and thereby further blocks LEA-2. Based on the similarities in overall protein sequence and structure, it is also anticipated that conventional antibodies with two identical binding sites could be developed that specifically bind to MASP-1, MASP-2, and MASP-3 in a functional manner, thereby achieving functional blockade of LEA-1 and LEA-2. Such antibodies with pan-MASP inhibitory activity are expected to simultaneously block both intravascular and extravascular hemolysis and thus effectively treat anemia in PNH patients.
[0160] IV. The Role of MASP-2 and MASP-3 in Age-Related Macular Degeneration and Treatment Methods Using MASP-2 and MASP-3 Inhibitors Age-related macular degeneration (AMD) is the leading cause of visual impairment and blindness in the elderly, accounting for up to 50% of blindness cases in developed countries. The prevalence of AMD in adults is approximately 3% and increases with age, with nearly two-thirds of the population over 80 years old having some symptoms. It is estimated that more than 1.75 million individuals in the United States have late-stage AMD, and the prevalence is increasing as the population ages, with a projected figure of nearly 3 million by 2020 (Friedman, DS et al., Arch. Ophthalmol. 122:564-572, 2004). AMD is an abnormality of the retinal pigment epithelium (RPE) that leads to degeneration of the overlying central retinal photoreceptors, or macula, and loss of central vision. Early and intermediate forms of AMD are characterized by progressive deposition of drusen in the subretinal space adjacent to the RPE, accompanied by pigment irregularities in the retina. Drusen is a yellowish substance containing lipids, proteins, lipoproteins and cell debris. Late AMD consists of two clinical subtypes: non-neovascular geographic atrophy ("dry") AMD and neovascular exudative ("wet") AMD. Although dry AMD accounts for 80-90% of late AMD, most sudden and severe vision loss occurs in wet AMD patients. It is also unknown whether these two types of AMD represent different phenotypes arising from similar pathology or two different conditions. For the treatment of dry AMD, the U.S. Food and Drug Administration (FDA) has not yet approved therapy. FDA-approved treatment options for wet AMD include intravitreal injections of anti-angiogenic drugs (ranibizumab, pegaptanib sodium, aflibercept), laser therapy, photodynamic laser therapy and implantable telescopes.
[0161] The cause of disease and pathophysiology of AMD are complex and not fully understood. Several pieces of evidence support the role of the imbalance of complement system in the pathogenesis of AMD. Gene association studies have determined the multiple gene loci relevant to AMD, including genes encoding a series of complement proteins, factors and regulators. The strongest association is the polymorphism of complement factor H (CFH) gene, wherein the risk of AMD occurring in Y402H variant homozygotes compared with non-risk genotypes increases by about 6 times, and Y402H variant heterozygotes increase by about 2.5 times (Khandhadia, S. et al., Immunobiol. 217: 127-146, 2012). Mutations in other complement pathway encoding genes have also been associated with increased or reduced risk of AMD, including complement factor B (CFB), C2, C3, factor I and CFH-related proteins 1 and 3 (Khandhadia et al.). Immunohistochemical and proteomic studies in donor eyes of AMD patients have shown that proteins of the complement cascade are increased and localized to drusen (Issa, PC et al., Graefes. Arch. Clin. Exp. Ophthalmol. 249: 163-174, 2011). In addition, AMD patients have increased systemic complement activation, as measured in peripheral blood (Issa et al., 2011, supra).
[0162] In the pathogenesis of AMD, the alternative complement pathway appears to be more relevant than the classical pathway. By immunohistochemical analysis, C1q, which is an essential recognition component for activating the classical pathway, was not detected in drusen (Mullins et al., FASEB J. 14: 835-846, 2000; Johnson et al., Exp. Eye Res. 70: 441-449, 2000). Genetic association studies have implicated the CFH and CFB genes. These proteins participate in the alternative pathway amplification loop, in which CFH is a fluid phase inhibitor and CFB is an activated protease component of the alternative pathway. The Y402H variant of CFH affects the interaction with ligand binding, including binding to C-reactive protein, heparin, M protein and glycosaminoglycans. This change in ligand binding can reduce binding to the cell surface, which in turn may lead to reduced degradation of the C3b activation fragment mediated by factor I and impaired regulation of the alternative C3 convertase, which leads to overactivation of the alternative pathway (Khandhadia et al., 2012, supra). CFB gene mutations are associated with protection against the development of AMD. The functional variant fB32Q binds to C3b with one-fourth the affinity of the risk variant fB32R, resulting in reduced C3 convertase formation (Montes, T. et al., Proc. Natl. Acad. Sci. USA 106:4366-4371, 2009).
[0163] Complement activation mechanisms in AMD The human genetic linkage study discussed above shows the important role of the complement system in AMD pathogenesis. In addition, complement activation products are present in a large number of drusen (Issa, PC etc., Graefes.Arch.Clin.Exp.Ophthalmol.249:163-174,2011), which are the hallmark pathological damages of wet and dry AMD. However, the nature of the event that starts complement activation and the involved complement activation pathways are still not fully understood.
[0164] It is important to note that drusen deposits are composed of cell debris and oxidative waste products (which accumulate under RPE as eye ages) derived from retina. In addition, oxidative stress seems to play an important role (Cai et al.; Front Biosci., 17: 1976-95, 2012), and has been shown to cause RPE complement activation (J Biol Chem., 284 (25): 16939-47, 2009). It is widely believed that oxidative stress and cell or tissue damage activate the lectin of the complement system. For example, Collard et al. have shown that endothelial cells exposed to oxidative stress trigger a large amount of complement deposition mediated by lectins (Collard CD et al., Mol Immunol., 36 (13-14): 941-8, 1999; Collard CD et al., Am J Pathol., 156 (5): 1549-56, 2000), and that lectin binding and blocking of lectin-dependent complement activation improve the results in experimental models of oxidative stress injury (Collard CD et al., Am J Pathol., 156 (5): 1549-56, 2000). Therefore, it seems possible that the oxidative waste products present in drusen also activate complement via lectins. It is inferred that lectin-dependent complement activation may play a key role in the pathogenesis of AMD.
[0165] The role of the complement system has been evaluated in mouse models of AMD. In the light damage mouse model (an experimental model of oxidative stress-mediated photoreceptor degeneration), knockout mice with ablation of the classical pathway (C1qα in a C57BL / 6 background) - / - ) have the same sensitivity to light damage as wild-type littermates, while ablation of the alternative pathway complement factor D (CFD - / - ) leads to protection from light damage (Rohrer, B. et al., Invest. Ophthalmol. Vis. Sci. 48:5282-5289, 2007). In a mouse model of choroidal neovascularization (CNV) induced by laser photocoagulation of Bruch's membrane, knockout mice without complement factor B (CFB) showed a significantly higher expression of CFB than wild-type mice. - / -) were protected from CNV (Rohrer, B. et al., Invest. Ophthalmol. Vis. Sci. 50:3056-3064, 2009). In the same model, intravenous administration of a recombinant form of complement factor H (CR2-fH), which targets complement activation sites, reduced the extent of CNV. This protective effect was observed regardless of whether CR2-fH was administered at the time of laser injury or therapeutically (after laser injury). A human therapeutic form of CR2-fH (TT30) was also effective in a murine CNV model (Rohrer, B. et al., J. Ocul. Pharmacol. Ther., 28:402-409, 2012). Because fB is activated by LEA-1, and because MASP-1 and MASP-3 contribute to the maturation of factor D, these findings suggest that LEA-1 inhibitors may have therapeutic benefits in patients with AMD.
[0166] Initial experimental studies using MBL-deficient mice in rodent models of AMD did not support a key role for the lectin pathway in pathogenic complement activation (Rohrer et al., Mol Immunol. 48:e1-8, 2011). However, MBL is only one of several lectins, and lectins other than MBL may trigger complement activation in AMD. In fact, our previous work has shown that MASP-2, a rate-limiting serine protease that is essential for lectin pathway function, plays a key role in AMD. As described in U.S. Patent 7,919,094 (assigned to Omeros Corporation), incorporated herein by reference, and in Examples 20 and 21 herein, MASP-2-deficient mice and mice treated with MASP-2 antibodies were protected in a laser-induced CNV mouse model (a validated preclinical model of wet AMD) (Ryan et al., Tr Am Opth Soc LXXVII:707-745, 1979). Therefore, inhibitors of LEA-2 are expected to be effective in preventing CNV and improving outcomes in AMD patients.
[0167] Therefore, in light of the foregoing, LEA-1 and LEA-2 inhibitors are expected to have independent therapeutic benefits in AMD. Furthermore, the use of LEA-1 and LEA-2 inhibitors together may achieve additional therapeutic benefit compared to either agent alone, or may provide effective treatment for a wider range of patient subpopulations. Combined LEA-1 and LEA-2 inhibition can be achieved by co-administering a LEA-1 blocker and a LEA-2 blocker. Optimally, the inhibitory functions of LEA-1 and LEA-2 can be contained in a single molecular entity, such as a bispecific antibody containing specific binding sites for both MASP-1 / 3 and MASP-2, or a bispecific antibody in which each binding site can bind to and block either MASP-1 / 3 or MASP-2.
[0168] In accordance with the foregoing, one aspect of the present invention provides methods for inhibiting LEA-1-dependent complement activation to treat age-related macular degeneration (wet and dry forms) by administering to a subject suffering from the condition a composition comprising a therapeutically effective amount of a MASP-1 inhibitory agent, a MASP-3 inhibitory agent, or a combination of MASP-1 / 3 inhibitory agents in a pharmaceutical carrier. The MASP-1, MASP-3, or MASP-1 / 3 inhibitory composition can be administered topically to the eye, for example, by irrigation, intravitreal administration, or application of the composition in the form of a gel, ointment, or drops. Alternatively, the MASP-1, MASP-3, or MASP-1 / 3 inhibitory agent can be administered systemically to the subject, for example, by intraarterial, intravenous, intramuscular, inhalation, nasal, subcutaneous, or other parenteral administration, or possibly by oral administration of a non-peptidergic agent. Administration can be repeated, as determined by a physician, until the condition is resolved or controlled.
[0169] In one embodiment, the method according to this aspect of the invention further comprises inhibiting LEA-2-dependent complement activation in a subject suffering from age-related macular degeneration, comprising administering to the subject in need thereof a therapeutically effective amount of a MASP-2 inhibitory agent and a MASP-1, MASP-3, or MASP 1 / 3 inhibitory agent. As detailed above, in patients with AMD, the use of a combination of pharmacological agents that each block LEA-1 and LEA-2 is expected to provide improved therapeutic outcomes compared to inhibition of LEA-1 alone. This outcome can be achieved, for example, by co-administering an antibody having LEA-1 blocking activity in conjunction with an antibody having LEA-2 blocking activity. In some embodiments, the LEA-1 and LEA-2 blocking activities are combined into a single molecular entity, and the entity possesses combined LEA-1 and LEA-2 blocking activities. Such an entity may comprise or consist of a bispecific antibody in which one antigen-binding site specifically recognizes MASP-1 and blocks LEA-1, while a second antigen-binding site specifically recognizes MASP-2 and blocks LEA-2. Alternatively, such an entity may consist of a bispecific monoclonal antibody in which one antigen-binding site specifically recognizes MASP-3, thereby blocking LEA-1, while a second antigen-binding site specifically recognizes MASP-2, thereby blocking LEA-2. Optimally, such an entity may consist of a bispecific monoclonal antibody in which one antigen-binding site specifically recognizes both MASP-1 and MASP-3, thereby blocking LEA-1, while a second antigen-binding site specifically recognizes MASP-2, thereby blocking LEA-2.
[0170] The MASP-2 inhibitory composition can be administered topically to the eye, for example, by irrigation, intravitreal injection, or topical application of the composition in the form of a gel, ointment, or drops. Alternatively, the MASP-2 inhibitory agent can be administered systemically to the subject, for example, by intraarterial, intravenous, intramuscular, inhalation, nasal, subcutaneous, or other parenteral administration, or possibly by oral administration of a non-peptidergic agent. Administration can be repeated as determined by the physician until the condition is resolved or controlled.
[0171] Administration of the MASP-3 inhibitory compositions and, optionally, MASP-2 inhibitory compositions of the invention can be performed by a single administration of the composition (e.g., a single composition containing both a MASP-2 and a MASP-3 inhibitory agent or a bispecific or dual inhibitory agent, or co-administration of separate compositions), or by limited sequential administration for the treatment of AMD. Alternatively, the compositions can be administered at periodic intervals, such as daily, biweekly, weekly, every other week, monthly, or bimonthly, over an extended period of time to treat AMD.
[0172] V. The Role of MASP-2 and MASP-3 in Ischemia-Reperfusion Injury and Therapeutic Methods Using MASP-2 and MASP-3 Inhibitors Tissue ischemia underlies a wide range of clinical conditions. While prompt restoration of blood flow is essential for protecting ischemic tissue, it has long been recognized that reperfusion, which can occur spontaneously or through therapeutic intervention, can cause additional tissue damage, a phenomenon known as ischemia-reperfusion (I / R) injury (Eltzschig, HK and Tobias, E., Nat. Med. 17:1391-1401, 2011). I / R injury can affect individual organs, such as the heart (acute coronary syndrome), kidney (acute kidney injury), intestine (intestinal I / R), and brain (stroke). I / R injury can also affect multiple organs, such as in the following major trauma and resuscitation (multiple organ failure), circulatory arrest (anoxic brain injury, acute kidney injury), peripheral vascular disease, and sickle cell disease (acute chest syndrome, acute kidney injury). Major surgery can be associated with I / R injury, including cardiac surgery (acute heart failure after cardiopulmonary bypass), thoracic surgery (acute lung injury), peripheral vascular surgery (compartment syndrome), vascular surgery (acute kidney injury), and solid organ transplantation (acute graft failure). Currently, there is no specific therapy for I / R injury, and effective treatments are needed to maximize tissue salvage of the ischemic zone and improve functional outcomes in these common conditions.
[0173] The pathophysiology of I / R injury is complex and is characterized by a robust inflammatory response after reperfusion. Activation of the complement system has been implicated as an important component of I / R injury, and inhibition of complement activity is effective in a variety of animal models (Diepenhorst, GMP et al., Ann.Surg.249:889-899, 2009). The relative importance of classical, lectin, and alternative pathways in I / R injury is largely unstable and may be different depending on the organ affected. Recently, knockout mice with defects in specific complement proteins and pathway-specific inhibitors have been available, which have produced data related to lectin and alternative pathways in I / R injury.
[0174] The role of the alternative pathway in gastrointestinal I / R injury was studied using factor D-deficient (- / -) mice and heterozygous (+ / -) mice (Stahl, GL et al. Am. J. Pathol. 162: 449-455, 2003). Compared with heterozygous mice, in mice deficient in factor D, intestinal and lung injury was reduced but not prevented after transient gastrointestinal ischemia, and the addition of human factor D to - / - mice restored I / R injury. The same model was evaluated in mice deficient in C1q and deficient in MBL-A / C, and the results showed that gastrointestinal I / R injury was independent of C1q and classical pathway activation, but MBL and lectin pathway activation were required for intestinal injury (Hart, ML et al. J. Immunol. 174: 6373-6380, 2005). In contrast, the C1q recognition molecule of the classical pathway is responsible for lung injury after intestinal I / R (Hart, ML et al. J. Immunol. 174: 6373-6380, 2005). One hypothesis is that during I / R injury, complement activation occurs through the binding of natural IgM to autoantigens (e.g., non-muscle myosin heavy chain type II) presented on the surface of ischemic (but not normal) tissue. In a mouse model of gastrointestinal I / R injury, the presence of initiating factors in immune complexes from intestinal tissue was evaluated in the classical (C1q), lectin (MBL), or alternative (factor B) pathways (Lee, H. et al., Mol. Immunol. 47: 972-981, 2010). The results showed that C1q and MBL were detected in these immune complexes, but factor B was not detected, indicating the involvement of the classical and lectin pathways, but not the alternative pathway. In the same model, factor B-deficient mice were not protected from local tissue damage, providing additional support for the lack of involvement of the alternative pathway. The role of the lectin pathway in gastrointestinal I / R injury was directly evaluated in MASP-2-deficient mice, and the results showed that gastrointestinal damage was reduced in these mice compared to wild-type controls; treatment with a MASP-2 monoclonal antibody was also protective (Schwaeble, WJ et al., Proc. Natl. Acad. Sci. 108:7523-7528, 2011), see also Example 23 herein. Taken together, these results provide support for the involvement of the lectin pathway in gastrointestinal I / R injury, despite conflicting data regarding the involvement of alternative pathways.
[0175] In a mouse model of myocardial I / R injury, a pathogenic role for the lectin pathway was demonstrated, as MBL-deficient mice were protected from myocardial injury, whereas C1q-deficient and C2 / fB-deficient mice were not (Walsh, MC et al., J. Immunol. 175:541-546, 2005). Protection from myocardial I / R injury was also observed in MASP-2-deficient mice (Schwaeble, WJ et al., Proc. Natl. Acad. Sci. 108:7523-7528, 2011); see also Examples 22 and 23 herein. Treatment of rats with a monoclonal antibody directed against rat MBL in a myocardial I / R model resulted in reduced post-ischemia reperfusion injury (Jordan, JE et al., Circulation 104:1413-18, 2001). In a study of myocardial infarction patients treated with angioplasty, MBL deficiency was associated with reduced 90-day mortality compared to MBL-sufficient counterparts (M. Trendelenburg et al., Eur Heart J. 31: 1181, 2010). Furthermore, myocardial infarction patients who developed cardiac dysfunction after angioplasty had approximately three times the MBL levels of patients with functional recovery (Haahr-Pedersen S. et al., J Inv Cardiology, 21: 13, 2009). MBL antibodies also reduced complement deposition on endothelial cells in vitro after oxidative stress, indicating a role for the lectin pathway in myocardial I / R injury (Collard, CD et al., Am. J. Pathol. 156: 1549-56, 2000). In a mouse heterotopic syngeneic heart transplant model of I / R injury, the role of the alternative pathway was studied using the pathway-specific fusion protein CR2-fH (Atkinson, C. et al., J. Immunol. 185: 7007-7013, 2010). Systemic administration of CR2-fH immediately after transplantation resulted in a reduction in myocardial I / R injury comparable to treatment with CR2-Crry, which inhibits all complement pathways, indicating that the alternative pathway is crucial in this model.
[0176] In a mouse model of renal I / R injury, the alternative pathway has been implicated, as mice deficient in factor B are protected from decreased renal function and tubular damage compared to wild-type mice (Thurman, JM et al., J. Immunol. 170:1517-1523, 2003). Treatment with an inhibitory monoclonal antibody against factor B prevents complement activation and reduces renal I / R injury in mice (Thurman, JM et al., J. Am. Soc. Nephrol. 17:707-715, 2006). In a bilateral renal I / R injury model, MBL-A / C-deficient mice are protected from renal injury compared to wild-type mice, and recombinant human MBL reverses the protective effect of MBL-A / C-deficient mice, suggesting a role for MBL in this model (Moller-Kristensen, M. et al., Scand. J. Immunol. 61:426-434, 2005). In a rat model of unilateral renal I / R injury, inhibition of MBL with a monoclonal antibody against MBL-A preserved renal function after I / R (van der Pol, P. et al., Am. J. Transplant. 12:877-887, 2010). Interestingly, the effects of MBL in this model did not involve activation of terminal complement components, as treatment with the C5 antibody was ineffective in preventing renal injury. Instead, MBL appears to have a direct toxic effect on renal tubular cells, as human proximal tubular cells incubated with MBL internalized MBL in vitro and subsequently underwent apoptosis. In a porcine model of renal I / R, Castellano G. et al. (Am J Pathol, 176(4):1648-59, 2010) tested C1 inhibitor, which irreversibly inactivates C1r and C1s proteases in the classical pathway and MASP-1 and MASP-2 proteases in the MBL complex of the lectin pathway, and found that C1 inhibitor reduced complement deposition in peritubular capillaries and glomeruli and reduced tubular damage.
[0177] The alternative pathway appears to be involved in experimental traumatic brain injury, as mice deficient in factor B have reduced systemic complement activation (as measured by serum C5a levels) and reduced post-traumatic neuronal cell death compared to wild-type mice (Leinhase, I. et al., BMC Neurosci. 7:55-67, 2006). In human stroke, activation of the classical pathway has been suggested by immunohistochemical staining of complement components C1q, C3c, and C4d in ischemic lesions (Pedersen, ED et al., Scand. J. Immunol. 69:555-562, 2009). Targeting the classical pathway in animal models of cerebral ischemia has yielded mixed results, with some studies demonstrating protection and others showing no benefit (Arumugam, TV et al., Neuroscience 158:1074-1089, 2009). Experimental and clinical studies provide strong evidence for the involvement of the lectin pathway. In experimental stroke models, the lack of MBL or MASP-2 results in reduced infarct size compared to wild-type mice (Cervera A et al., PLoS One 3; 5(2): e8433, 2010; Osthoff M. et al., PLoS One, 6(6): e21338, 2011 and Example 26 herein). In addition, stroke patients with low levels of MBL have a better prognosis than their MBL-sufficient counterparts (Osthoff M. et al., PLoS One, 6(6): e21338, 2011).
[0178] In a baboon model of cardiopulmonary bypass, treatment with a factor D monoclonal antibody suppressed systemic inflammation (as measured by plasma levels of C3a, SC5b-9, and IL-6) and reduced myocardial tissue injury, suggesting involvement of the alternative pathway in this model (Undar, A. et al., Ann. Thorac. Surg. 74:355-362, 2002).
[0179] Therefore, depending on the organ affected by I / R, all three pathways of complement can contribute to morbidity and adverse outcomes. Based on the experimental and clinical findings detailed above, LEA-2 inhibitors are expected to be protective in most I / R situations. At least in some cases, lectin-dependent activation of LEA-1 can lead to complement activation via the alternative pathway. In addition, LEA-2-initiated complement activation can be further amplified by the alternative pathway amplification loop, thereby exacerbating I / R-related tissue damage. Therefore, LEA-1 inhibitors are expected to provide additional or supplemental therapeutic benefits in patients with ischemia-related conditions.
[0180] In view of the above, LEA-1 and LEA-2 inhibitors are expected to have independent therapeutic benefits in treating, preventing, or reducing the severity of ischemia-reperfusion-related conditions. In addition, LEA-1 and LEA-2 inhibitors used together may achieve additional therapeutic benefits compared to either agent alone. Therefore, the optimal effective treatment for I / R-related conditions includes active pharmaceutical ingredients that block both LEA-1 and LEA-2, either alone or in combination. Combined LEA-1 and LEA-2 inhibition can be achieved by co-administering a LEA-1 blocker and a LEA-2 blocker. Preferably, the inhibitory functions of LEA-1 and LEA-2 can be contained in a single molecular entity, such as a bispecific antibody comprising specific binding sites for MASP-1 / 3 and MASP-2, or a bispecific antibody in which each binding site can bind to and block either MASP-1 / 3 or MASP-2.
[0181] In accordance with the foregoing, one aspect of the present invention provides a method for inhibiting LEA-1-dependent complement activation to treat, prevent, or reduce the severity of ischemia-reperfusion injury by administering to a subject experiencing ischemia-reperfusion a composition comprising a therapeutically effective amount of a LEA-1 inhibitory agent, including a MASP-1 inhibitory agent, a MASP-3 inhibitory agent, or a combination of MASP-1 / 3 inhibitory agents, in a pharmaceutical carrier. The MASP-1, MASP-3, or MASP-1 / 3 inhibitory composition can be administered to the subject via intra-arterial, intravenous, intracranial, intramuscular, subcutaneous, or other parenteral administration, and potentially oral administration for non-peptidergic inhibitors, and is most preferably administered via intra-arterial or intravenous administration. Administration of the LEA-1 inhibitory composition of the present invention is preferably initiated immediately or as soon as possible after the ischemia-reperfusion event. In cases where reperfusion occurs in a controlled environment (e.g., after aortic aneurysm repair, organ transplantation, or repositioning of a severed or traumatized limb or digit), the LEA-1 inhibitor may be administered prior to and / or during and / or after reperfusion. Administration may be repeated periodically as determined by the physician to achieve optimal therapeutic effect.
[0182] In some embodiments, the method is used to treat or prevent ischemia-reperfusion injury associated with at least one of: aortic aneurysm repair, cardiopulmonary bypass, revascularization associated with organ transplantation and / or limb / finger / toe replantation, stroke, myocardial infarction, and hemodynamic resuscitation following shock and / or surgery.
[0183] In some embodiments, the method is used to treat or prevent ischemia-reperfusion injury in a subject who is about to undergo, is undergoing, or has undergone an organ transplant. In some embodiments, the method is used to treat or prevent ischemia-reperfusion injury in a subject who is about to undergo, is undergoing, or has undergone an organ transplant, provided that the organ transplant is not a kidney transplant.
[0184] In one embodiment, the method according to this aspect of the invention further comprises inhibiting LEA-2-dependent complement activation in a subject experiencing ischemia-reperfusion, comprising administering to the subject a therapeutically effective amount of a MASP-2 inhibitory agent and a MASP-1, MASP-3, or MASP-1 / 3 inhibitory agent. As detailed above, in treating, preventing, or reducing the severity of ischemia-reperfusion injury, the use of a combination of pharmacological agents that each block LEA-1 and LEA-2 is expected to provide improved therapeutic outcomes compared to inhibition of LEA-1 alone. This outcome can be achieved, for example, by co-administering an antibody having LEA-1 blocking activity in conjunction with an antibody having LEA-2 blocking activity. In some embodiments, the LEA-1 and LEA-2 blocking activities are combined into a single molecular entity, and the entity possesses combined LEA-1 and LEA-2 blocking activities. Such an entity may comprise or consist of a bispecific antibody in which one antigen-binding site specifically recognizes MASP-1 and blocks LEA-1, while a second antigen-binding site specifically recognizes MASP-2 and blocks LEA-2. Alternatively, such an entity may consist of a bispecific monoclonal antibody in which one antigen-binding site specifically recognizes MASP-3, thereby blocking LEA-1, while a second antigen-binding site specifically recognizes MASP-2, thereby blocking LEA-2. Optimally, such an entity may consist of a bispecific monoclonal antibody in which one antigen-binding site specifically recognizes both MASP-1 and MASP-3, thereby blocking LEA-1, while a second antigen-binding site specifically recognizes MASP-2, thereby blocking LEA-2.
[0185] The MASP-2 inhibitory compositions can be administered to a subject in need thereof by intraarterial, intravenous, intracranial, intramuscular, subcutaneous, or other parenteral administration, and potentially, for non-peptidergic inhibitors, oral administration, and most preferably by intraarterial or intravenous administration. Administration of the MASP-2 inhibitory compositions of the present invention is preferably initiated immediately or as soon as possible after the ischemia-reperfusion event. In cases where reperfusion occurs in a controlled environment (e.g., following aortic aneurysm repair, organ transplantation, or repositioning of an amputated or traumatized limb or digit), the MASP-2 inhibitory agent can be administered prior to and / or during and / or after reperfusion. Administration can be repeated periodically as determined by the physician to achieve optimal therapeutic effect.
[0186] Administration of the MASP-3 inhibitory compositions and, optionally, MASP-2 inhibitory compositions of the invention can be performed by a single administration of the composition (e.g., a single composition containing both a MASP-2 and a MASP-3 inhibitory agent or a bispecific or dual inhibitory agent, or co-administration of separate compositions), or by limited sequential administration for the treatment or prevention of ischemia-reperfusion injury. Alternatively, the compositions can be administered at periodic intervals, e.g., daily, biweekly, weekly, every other week, monthly, or bimonthly, over an extended period of time to treat a subject experiencing ischemia-reperfusion injury.
[0187] VI. Role of MASP-2 and MASP-3 in Inflammatory and Non-Inflammatory Arthritis and Therapeutic Approaches Using MASP-2 and MASP-3 Inhibitors. Rheumatoid arthritis (RA) is a chronic inflammatory disease of the synovial joints that can also have systemic manifestations. RA affects approximately 1% of the world's population, with women being two to three times more likely to develop the disease. Joint inflammation manifests as redness, swelling, pain, and stiffness. As the disease progresses, joint erosion and destruction may occur, leading to impaired range of motion and deformity. The goals of RA treatment include preventing or controlling joint damage, preventing loss of joint function and disease progression, alleviating symptoms and improving quality of life, and achieving drug-free remission. Pharmacological treatments for RA include disease-modifying antirheumatic drugs (DMARDs), analgesics, and anti-inflammatory drugs (glucocorticoids and nonsteroidal anti-inflammatory drugs). DMARDs are the most important treatments because they can induce durable remission and delay or prevent the progression of irreversible joint destruction. Traditional DMARDs include small molecules such as methotrexate, sulfasalazine, hydroxychloroquine, gold salts, leflunomide, D-penicillamine, cyclosporine, and azathioprine. If traditional DMARDs are insufficient to control the disease, several biologic agents targeting inflammatory cells or mediators are available treatment options, such as tumor necrosis factor inhibitors (etanercept, infliximab, adalimumab, certolizumab pegol, and golimumab), cytokine antagonists (anakinra and tocilizumab), rituximab, and abatacept.
[0188] While adaptive immunity is clearly important for the pathogenesis of RA (as demonstrated by genetic associations with T cell activation genes and the presence of autoantibodies), innate immune mechanisms have also been implicated (McInnes, IB and Schett, G. New Engl. J. Med. 365: 2205-2219, 2011). In human RA, synovial fluid levels of the alternative pathway cleavage fragment Bb are several times higher than those in samples from patients with crystal-induced arthritis or degenerative joint disease, suggesting that the alternative pathway is preferentially activated in RA patients (Brodeur, JP et al., Arthritis Rheum. 34: 1531-1537, 1991). In an experimental anti-type II collagen antibody passive transfer model of arthritis, factor B-deficient mice had reduced inflammation and joint destruction compared to wild-type mice, while C4-deficient mice had similar disease activity to wild-type mice, indicating that the alternative pathway, rather than the classical pathway, is required in this model (Banda, NK et al., J. Immunol. 177: 1904-1912, 2006). In the same experimental model of collagen antibody-induced arthritis (CAIA), mice with only the classical pathway active or only the lectin pathway active were unable to develop arthritis (Banda, NK et al., Clin. Exp. Immunol. 159: 100-108, 2010). The data from this study indicate that both the classical and lectin pathways are capable of activating low levels of C3 in vitro. However, in the absence of an alternative pathway amplification loop, the level of C3 deposition in the joints is insufficient to produce clinical disease. A key step in the activation of the alternative pathway is the conversion of factor D (pro-factor D) zymogen to mature factor D, which is mediated by MASP-1 and / or MASP-3 (Takahashi, M. et al., J. Exp. Med. 207:29-37, 2010) and / or HTRA1 (Stanton et al., Evidence That the HTRA1 Interactome Influences Susceptibility to Age-Related Macular Degeneration, presented at the 2011 meeting of The Association for Research in Vision and Ophthalmology on March 4, 2011). The role of MASP-1 / 3 was evaluated in murine CAIA, and the results showed that MASP-1 / 3-deficient mice were protected from arthritis compared with wild-type mice (Banda, NK et al., J. Immunol. 185:5598-5606, 2010).In MASP-1 / 3-deficient mice, primary factor D, but not mature factor D, was detected in the serum during the development of CAIA, and using serum from these mice, the addition of human factor D in vitro reconstituted C3 activation and C5a production. In contrast, in a murine model of the effector phase of arthritis, C3-deficient mice developed very mild arthritis compared to WT mice, while factor B-deficient mice still developed arthritis, indicating independent contributions of both the classical / lectin and alternative pathways (Hietala, MA et al., Eur. J. Immunol. 34:1208-1216, 2004). In a K / BxN T cell receptor transgenic mouse model of inflammatory arthritis, mice lacking C4 or C1q developed arthritis similar to wild-type mice, while mice lacking factor B did not develop arthritis or had mild arthritis, indicating that the alternative pathway, rather than the classical pathway, is required in this model (Ji H. et al., Immunity 16:157-168, 2002). In the K / BxN model, mice lacking MBL-A were not protected from serum-induced arthritis, but since the role of MBL-C was not studied, a potential role for the lectin pathway cannot be excluded (Ji et al., 2002, supra).
[0189] Two research groups have independently proposed that lectin-dependent complement activation promotes inflammation in RA patients through the interaction of MBL with specific IgG glycoforms (Malhotra et al., Nat. Med. 1:237-243, 1995; Cuchacovich et al., J. Rheumatol. 23:44-51, 1996). It should be noted that rheumatoid conditions are associated with a significant increase in IgG glycoforms that lack galactose in the Fc region of the molecule, known as IgG0 glycoforms (Rudd et al., Trends Biotechnology 22:524-30, 2004). The percentage of IgG0 glycoforms increases with disease progression in rheumatoid conditions and returns to normal when patients are in remission. In vivo, IgG0 is deposited in synovial tissue, and MBL is present at increased levels in the synovial fluid of individuals with RA. RA-associated aggregated galactose-free IgG (IgG0) can bind to MBL, thereby initiating lectin-dependent complement activation through LEA-1 and / or LEA-2. Furthermore, clinical studies examining MBL allelic variants in RA patients have shown that MBL may have an inflammatory-enhancing role in the disease (Garred et al., J. Rheumatol. 27:26-34, 2000). Therefore, lectin-dependent complement activation through LEA-1 and / or LEA-2 may play an important role in the pathogenesis of RA.
[0190] Complement activation also plays an important role in juvenile rheumatoid arthritis (Mollnes, TE et al., Arthritis Rheum. 29: 1359-64, 1986). Similar to adult RA, in juvenile rheumatoid arthritis, serum and synovial fluid levels of the alternative pathway complement activation product Bb are elevated compared to C4d (a marker of classical or LEA-2 activation), indicating that complement activation is primarily mediated by LEA-1 (El-Ghobarey, AF et al., J. Rheumatology 7: 453-460, 1980; Agarwal, A. et al., Rheumatology 39: 189-192, 2000).
[0191] Similarly, complement activation plays an important role in psoriatic arthritis. Patients with this condition have increased complement activation products in their circulation, and their red blood cells appear to have lower levels of the complement regulator CD59 (Triolo,. Clin Exp Rheumatol., 21 (2): 225-8, 2003). Complement levels are associated with disease activity and have a high predictive value to determine the efficacy of treatment (Chimenti et al., Clin Exp Rheumatol., 30 (1): 23-30, 2012). In fact, recent studies have shown that the effect of anti-TNF therapy for this condition can be attributed to complement regulation (Ballanti et al., Autoimmun Rev., 10 (10): 617-23, 2011). Although the precise role of complement in psoriatic arthritis has not been determined, the presence of C4d and Bb complement activation products in the circulation of these patients suggests that they play an important role in the pathogenesis. Based on the observed products, it is believed that LEA-1, and possibly LEA-2, is responsible for the pathological complement activation in these patients.
[0192] Osteoarthritis (OA) is the most common form of arthritis, affecting more than 25 million people in the United States. OA is characterized by the breakdown and eventual loss of articular cartilage, accompanied by new bone formation and synovial hyperplasia, leading to pain, stiffness, loss of joint function, and disability. The joints most commonly affected by OA are the hands, neck, lower back, knees, and hips. The disease is progressive and current treatments are symptomatic and do not alter the natural history of the disease. The pathogenesis of OA is unclear, but a role for complement has been implicated. In proteomic and transcriptomic analyses of synovial fluid from OA patients, several components of complement were abnormally expressed compared to samples from healthy individuals, including the classical (C1s and C4A) and alternative (factor B) pathways, and also C3, C5, C7, and C9 (Wang, Q. et al., Nat. Med. 17:1674-1679, 2011). Furthermore, in a medial meniscectomy-induced OA mouse model, C5-deficient mice had less cartilage loss, osteophyte formation, and synovitis than C5-positive mice, and treatment of wild-type mice with CR2-fH, a fusion protein that inhibits the alternative pathway, attenuated the development of OA (Wang et al., 2011 supra).
[0193] Ross River virus (RRV) and Chikungunya virus (CHIKV) belong to a group of mosquito-borne viruses that can cause acute and persistent arthritis and myositis in humans. In addition to causing endemic diseases, these viruses can cause epidemics involving millions of infected individuals. Arthritis is thought to be initiated by viral replication in the joints and the induction of a host inflammatory response, and the complement system has been called into action as a key component in this process. Synovial fluid from humans with RRV-induced polyarthritis contains higher levels of C3a than synovial fluid from humans with OA (Morrison, TE et al., J. Virol. 81:5132-5143, 2007). In a mouse model of RRV infection, C3-deficient mice developed less severe arthritis than wild-type mice, suggesting a role for complement (Morrison et al., 2007, supra). The specific complement pathways involved were studied, and mice with an inactivated lectin pathway (MBL-A - / - and MBL-C - / - ) had attenuated arthritis compared to wild-type mice. In contrast, mice with inactivated classical pathway (C1q - / - ) or alternative pathway (factor B - / -Mice with MASP-2KO (KO) mice develop severe arthritis, indicating that the lectin pathway, initiated by MBL, plays an important role in this model (Gunn, BM et al., PLoS Pathog. 8:e1002586, 2012). Since arthritis involves joint damage, initial joint damage caused by various etiologies can trigger a second wave of complement activation through LEA-2. In support of this concept, our previous work has demonstrated that MASP-2KO mice have reduced joint damage compared to WT mice in a collagen-induced RA model, as described in Example 27 herein.
[0194] In view of the overwhelming evidence detailed above, inhibitors of LEA-1 and LEA-2, alone or in combination, are expected to be therapeutically useful for treating arthritis. Thus, the most effective treatment for arthritis may comprise active pharmaceutical ingredients that, alone or in combination, block both LEA-1 and LEA-2. Combined LEA-1 and LEA-2 inhibition can be achieved by co-administering a LEA-1 blocker and a LEA2 blocker. Preferably, the inhibitory functions of LEA-1 and LEA-2 can be contained in a single molecular entity, such as a bispecific antibody comprising specific binding sites for both MASP-1 / 3 and MASP-2, or a bispecific antibody in which each binding site can bind to and block either MASP-1 / 3 or MASP-2. In accordance with the foregoing, one aspect of the present invention provides a method for inhibiting LEA-1-dependent complement activation to treat, prevent, or reduce the severity of inflammatory or non-inflammatory arthritis, including osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, and psoriatic arthritis, by administering to a subject suffering from, or at risk of developing, inflammatory or non-inflammatory arthritis, a composition comprising a therapeutically effective amount of a LEA-1 inhibitory agent comprising a MASP-1 inhibitory agent, a MASP-3 inhibitory agent, or a combination of MASP-1 / 3 inhibitory agents in a pharmaceutical carrier. The MASP-1, MASP-3, or MASP-1 / 3 inhibitory composition can be administered systemically to the subject, for example, by intra-arterial, intravenous, intramuscular, subcutaneous, or other parenteral administration, or by oral administration. Alternatively, administration can be by local delivery, for example, by intra-articular injection. The LEA-1 inhibitors may be administered periodically over an extended period of time to treat or manage chronic conditions, or may be administered in single or repeated doses before, during, and / or after acute trauma or injury, including surgery to a joint.
[0195] In one embodiment, the methods according to this aspect of the invention further comprise inhibiting LEA-2-dependent complement activation in a subject suffering from or at risk for developing inflammatory or non-inflammatory arthritis, including osteoarthritis, rheumatoid arthritis, juvenile rheumatoid arthritis, and psoriatic arthritis, by administering to the subject a therapeutically effective amount of a MASP-2 inhibitory agent and a MASP-1, MASP-3, or MASP-1 / 3 inhibitory agent. As detailed above, the use of a combination of pharmacological agents that each block LEA-1 and LEA-2 is expected to provide improved therapeutic outcomes for treating or preventing arthritis compared to inhibiting LEA-1 alone. This outcome can be achieved, for example, by co-administering an antibody having LEA-1 blocking activity in conjunction with an antibody having LEA-2 blocking activity. In some embodiments, the LEA-1 and LEA-2 blocking activities are combined into a single molecular entity, and said entity possesses the combined LEA-1 and LEA-2 blocking activities. Such an entity may comprise or consist of a bispecific antibody in which one antigen-binding site specifically recognizes MASP-1 and blocks LEA-1, while a second antigen-binding site specifically recognizes MASP-2 and blocks LEA-2. Alternatively, such an entity may consist of a bispecific monoclonal antibody in which one antigen-binding site specifically recognizes MASP-3, thereby blocking LEA-1, while a second antigen-binding site specifically recognizes MASP-2 and blocks LEA-2. Optimally, such an entity may consist of a bispecific monoclonal antibody in which one antigen-binding site specifically recognizes both MASP-1 and MASP-3, thereby blocking LEA-1, while a second antigen-binding site specifically recognizes MASP-2 and blocks LEA-2.
[0196] The MASP-2 inhibitory composition can be administered systemically to a subject in need thereof, for example, by intra-arterial, intravenous, intramuscular, subcutaneous or other parenteral administration, or potentially for non-peptidergic inhibitors, by oral administration. Alternatively, administration can be by local delivery, for example, by intra-articular injection. The MASP-2 inhibitory agent can be administered periodically over an extended period of time to treat or control chronic conditions, or can be administered by single or repeated administration before, during, and / or after acute trauma or injury, including surgery to a joint.
[0197] Administration of the MASP-3 inhibitory compositions and, optionally, MASP-2 inhibitory compositions of the invention can be performed by a single administration of the composition (e.g., a single composition containing both a MASP-2 and a MASP-3 inhibitory agent or a bispecific or dual inhibitory agent, or co-administration of separate compositions), or by limited sequential administration, for treating, preventing, or reducing the severity of inflammatory or non-inflammatory arthritis. Alternatively, the compositions can be administered at periodic intervals, e.g., daily, biweekly, weekly, every other week, monthly, or bimonthly, over an extended period of time to treat a subject suffering from inflammatory or non-inflammatory arthritis.
[0198] VII. The Role of MASP-2 and MASP-3 in Disseminated Intravascular Coagulation (DIC) and Therapeutic Methods Using MASP-2 and MASP-3 Inhibitory Agents Disseminated intravascular coagulation (DIC) is a syndrome of pathological overstimulation of the coagulation system that can manifest clinically as bleeding and / or thrombosis. DIC does not present as a primary condition but is associated with a variety of disease processes, including tissue injury (trauma, burns, heat stroke, transfusion reactions, acute transplant rejection), neoplasia, infection, obstetric conditions (placenta previa, amniotic fluid embolism, pregnancy toxemia), and other conditions such as cardiogenic shock, near drowning, fat embolism, and aortic aneurysm. Thrombocytopenia is a common abnormality in patients in intensive care units, with an incidence of 35%-44%, and DIC is the cause in about 25% of these cases, i.e., DIC occurs in about 10% of critically ill patients (Levi, M. and Opal, SM Crit. Care 10:222-231, 2006). The pathophysiology of DIC is that the underlying disease process initiates a physiological coagulation reaction. However, prothrombotic substances suppress normal checks and balances, causing inappropriate deposition of fibrin and platelets in the microcirculation, leading to organ ischemia, hypofibrinogenemia, and thrombocytopenia. The diagnosis of DIC is based on clinical manifestations in the appropriate underlying disease or process, as well as abnormal laboratory parameters (prothrombin time, partial thromboplastin time, fibrin degradation products, D-dimers, or platelet counts). The primary treatment for DIC is to address the underlying condition that is the trigger responsible. Blood product support in the form of red blood cells, platelets, fresh frozen plasma, and cryoprecipitate may be necessary to treat or prevent clinical complications.
[0199] The role of the complement pathway in DIC has been investigated in several studies. Complement activation was evaluated in pediatric patients with meningococcal infection, and clinical course was compared relative to MBL genotype (Sprong, T. et al., Clin. Infect. Dis. 49:1380-1386, 2009). On admission, patients with MBL deficiency had lower circulating levels of C3bc, terminal complement complex, C4bc, and C3bBbP than patients with MBL-sufficient complement, indicating lower levels of common complement, terminal complement, and alternative pathway activation. In addition, the extent of systemic complement activation correlated with the severity and parameters of DIC disease, with patients with MBL deficiency having a milder clinical course than those with MBL-sufficient complement. Thus, while MBL deficiency is a risk factor for susceptibility to infection, MBL deficiency during septic shock may be associated with lower disease severity.
[0200] As shown in Examples 1-4 herein, experimental studies have highlighted the important contributions of MBL and MASP-1 / 3 in the innate immune response to Neisseria meningitidis, the causative agent of meningococcal infection. Mouse or human MBL-deficient sera, MASP-3-deficient human sera, or MASP-1 / 3 knockout mice are less effective than wild-type sera at activating complement and lysing meningococci in vitro. Similarly, naive MASP-1 / 3 knockout mice are more susceptible to Neisserial infection than their wild-type counterparts. Thus, in the absence of adaptive immunity, the LEA-1 pathway contributes to innate host resistance to Neisserial infection. Conversely, LEA-1 enhances pathological complement activation, triggering deleterious host responses, including DIC.
[0201] In a murine model of arterial thrombosis, MBL-deficient and MASP-1 / -3 knockout mice exhibited reduced FeCl3-induced thrombosis compared to wild-type or C2 / factor B-free mice, and this defect was reconstituted by recombinant human MBL (La Bonte, LR et al., J. Immunol. 188:885-891, 2012). In vitro, serum from MBL-deficient or MASP-1 / -3 knockout mice exhibited reduced thrombin substrate cleavage compared to serum from wild-type or C2 / factor B-free mice; addition of recombinant human MASP-1 restored thrombin substrate cleavage in serum from MASP-1 / -3 knockout mice (La Bonte et al., 2012, supra). These results suggest that the MBL / MASP complex, and in particular MASP-1, plays a key role in thrombosis. Therefore, LEA-1 may play an important role in pathological thrombosis, including DIC.
[0202] Experimental studies have established a similarly important role for LEA-2 in pathological thrombosis. As described herein in Example 30, in a mouse model of localized DIC, we have shown that MASP-2 knockout mice are less susceptible to LPS-induced microvascular coagulation than wild-type mice. In vitro studies have also shown that LEA-2 provides a molecular link between the complement and coagulation systems. As described in Examples 29 and 31, MASP-2 has factor Xa-like activity and activates prothrombin by cleavage to form thrombin, which subsequently clears fibrinogen and promotes fibrin clot formation (see also Krarup et al., PLoS One, 18:2(7):e623, 2007).
[0203] Independent studies have shown that lectin-MASP complexes can promote clot formation, fibrin deposition, and fibrinopeptide release in a MASP-2-dependent process (Gulla et al., Immunology, 129(4):482-95, 2010). Thus, LEA-2 promotes simultaneous lectin-dependent activation of the complement and coagulation systems.
[0204] In vitro studies have also shown that MASP-1 has thrombin-like activity (Presanis JS, et al., Mol Immunol, 40(13):921-9, 2004) and cleaves fibrinogen and factor XIII (Gulla KC et al., Immunology, 129(4):482-95, 2010), suggesting that LEA-1 can activate the coagulation pathway independently or in combination with LEA-2.
[0205] The data detailed above indicate that LEA-1 and LEA-2 provide an independent link between lectin-dependent complement activation and coagulation. Therefore, in view of the above, LEA-1 and LEA-2 inhibitors are expected to have independent therapeutic benefits in treating subjects with disseminated intravascular coagulation. In some embodiments, the subject suffers from disseminated intravascular coagulation secondary to: sepsis, trauma, infection (bacterial infection, viral infection, fungal infection, parasitic infection), malignancy, transplant rejection, transfusion reaction, obstetric complications, vascular aneurysm, liver failure, heat stroke, burns, radiation exposure, shock or severe toxic reaction (such as snake bite, insect bite, transfusion reaction). In some embodiments, the trauma is neurotrauma. In some embodiments, the infection is a bacterial infection, such as Neisseria meningitidis infection.
[0206] In addition, LEA-1 and LEA-2 inhibitors used together may achieve additional therapeutic benefits compared to either agent alone. Since both LEA-1 and LEA-2 are known to be activated by conditions that lead to DIC (e.g., infection or trauma), LEA-1- and LEA-2 blockers, alone or in combination, are expected to have therapeutic utility in the treatment of DIC. LEA-1 and LEA-2 blockers can prevent different cross-talk mechanisms between complement and coagulation. LEA-1 and LEA-2 blockers may therefore have complementary, additive, or synergistic effects in preventing DIC and other thrombotic conditions.
[0207] Furthermore, the use of LEA-1 and LEA-2 inhibitors together may achieve additional therapeutic benefits compared to either agent alone, or may provide effective treatment for a wider range of patient subpopulations. Combined LEA-1 and LEA-2 inhibition can be achieved by co-administering a LEA-1 blocker and a LEA-2 blocker. Optimally, the inhibitory functions of LEA-1 and LEA-2 can be contained in a single molecular entity, such as a bispecific antibody containing specific binding sites for both MASP-1 / 3 and MASP-2, or a bispecific antibody in which each binding site can bind to and block either MASP-1 / 3 or MASP-2.
[0208] In accordance with the foregoing, one aspect of the present invention provides a method for inhibiting LEA-1-dependent complement activation to treat, prevent, or reduce the severity of disseminated intravascular coagulation in a subject in need thereof, the method comprising administering to a subject suffering from or at risk of developing disseminated intravascular coagulation a composition comprising a therapeutically effective amount of a LEA-1 inhibitory agent comprising a MASP-1 inhibitory agent, a MASP-3 inhibitory agent, or a combination of MASP-1 / 3 inhibitory agents in a pharmaceutical carrier. The MASP-1, MASP-3, or MASP-1 / 3 inhibitory composition can be administered to the subject systemically, for example, by intraarterial, intravenous, intramuscular, inhalation, nasal, subcutaneous, or other parenteral administration, or possibly by oral administration of a non-peptidergic agent. Administration can be repeated as determined by a physician until the condition is resolved or controlled. For the treatment or prevention of DIC secondary to trauma or other acute events, the LEA-1 inhibitory composition can be administered immediately after the traumatic injury, or prophylactically administered before, during, or immediately after a trauma-induced injury or condition (e.g., surgery in a patient deemed at risk for DIC), or within 1 to 7 days or longer, e.g., 24 to 72 hours. In some embodiments, the LEA-1 inhibitory composition can be administered in a fast-acting dosage form, such as by intravenous or intra-arterial delivery of a bolus solution containing the LEA-1 inhibitor composition.
[0209] In one embodiment, the methods according to this aspect of the invention further comprise inhibiting LEA-2-dependent complement activation in a subject in need thereof to treat, prevent, or reduce the severity of disseminated intravascular coagulation, comprising administering to the subject a therapeutically effective amount of a MASP-2 inhibitory agent and a MASP-1, MASP-3, or MASP-1 / 3 inhibitory agent. As detailed above, the use of a combination of pharmacological agents that each block LEA-1 and LEA-2 is expected to provide improved therapeutic outcomes in treating or preventing disseminated intravascular coagulation compared to inhibiting LEA-1 alone. This outcome can be achieved, for example, by co-administering an antibody having LEA-1 blocking activity in conjunction with an antibody having LEA-2 blocking activity. In some embodiments, the LEA-1 and LEA-2 blocking activities are combined into a single molecular entity, and the entity possesses combined LEA-1 and LEA-2 blocking activities. Such an entity may comprise or consist of a bispecific antibody in which one antigen-binding site specifically recognizes MASP-1 and blocks LEA-1, while a second antigen-binding site specifically recognizes MASP-2 and blocks LEA-2. Alternatively, such an entity may consist of a bispecific monoclonal antibody in which one antigen-binding site specifically recognizes MASP-3, thereby blocking LEA-1, while a second antigen-binding site specifically recognizes MASP-2, thereby blocking LEA-2. Optimally, such an entity may consist of a bispecific monoclonal antibody in which one antigen-binding site specifically recognizes both MASP-1 and MASP-3, thereby blocking LEA-1, while a second antigen-binding site specifically recognizes MASP-2, thereby blocking LEA-2.
[0210] The MASP-2 inhibitory agent can be administered systemically to a subject in need thereof, for example, by intra-arterial, intravenous, intramuscular, inhaled, nasal, subcutaneous, or other parenteral administration, and potentially oral administration for non-peptidergic agents. Administration can be repeated as determined by the physician until the condition is resolved or controlled. For DIC secondary to trauma or other acute events, the MASP-2 inhibitory composition can be administered immediately after the traumatic injury, or prophylactically before, during, or immediately after a trauma-induced injury or condition (e.g., surgery in patients deemed at risk for DIC), or within 1 to 7 days or longer, for example, 24 to 72 hours. In some embodiments, the MASP-2 inhibitory composition can be administered, as appropriate, in a fast-acting dosage form, for example, by intravenous or intra-arterial delivery of a bolus solution containing the MASP-2 inhibitory composition.
[0211] Administration of the MASP-3 inhibitory compositions and, optionally, MASP-2 inhibitory compositions of the invention can be performed by a single administration of the composition (e.g., a single composition containing both a MASP-2 and a MASP-3 inhibitory agent or a bispecific or dual inhibitory agent, or co-administration of separate compositions), or by limited sequential administration, to treat, prevent, or reduce the severity of disseminated intravascular coagulation in a subject in need thereof. Alternatively, the compositions can be administered at periodic intervals, e.g., daily, biweekly, weekly, every other week, monthly, or bimonthly, over an extended period of time to treat a subject suffering from or at risk of developing disseminated intravascular coagulation.
[0212] VIII. The Role of MASP-2 and MASP-3 in Thrombotic Microangiopathy (TMA), Including Hemolytic Uremic Syndrome (HUS), Atypical Hemolytic Uremic Syndrome (AHUS), and Thrombotic Thrombocytopenic Purpura (TTP), and Treatment Methods Using MASP-2 and MASP-3 Inhibitors. Thrombotic microangiopathy (TMA) refers to a group of conditions characterized by thrombocytopenia, microangiopathic hemolytic anemia, and multi-organ ischemia. The characteristic pathological features of TMA are platelet activation and the formation of microthrombi in arterioles and venules. The classic TMAs are hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP). HUS is distinguished from TTP by the presence of acute renal failure. HUS occurs in two forms: diarrhea-associated (D+) or classic HUS and diarrhea-free (D-) or atypical HUS (aHUS).
[0213] HUS D+HUS is associated with a prodromal diarrheal illness, usually caused by E. coli O157 or another Shiga toxin-producing bacterial strain, and accounts for over 90% of childhood HUS cases and is the most common cause of acute renal failure in children. Although human infection with E. coli O157 is relatively frequent, the percentage of bloody diarrhea that progresses to D+HUS ranges from 3% to 7% in sporadic cases and 20% to 30% in some outbreaks (Zheng, XL and Sadler, JE, Annu. Rev. Pathol. 3:249-277, 2008). HUS typically develops 4 to 6 days after the onset of diarrhea, and approximately two-thirds of children require dialysis during the acute phase of the disease. Treatment of D+HUS is supportive, as no specific treatment has been proven effective. The prognosis for D+HUS is good, and most patients recover renal function.
[0214] The pathogenesis of D+HUS involves bacterially produced Shiga toxins that bind to the membranes of microvascular endothelial cells, monocytes, and platelets. Renal microvessels are most commonly affected. Following binding, the toxins are internalized, leading to the release of inflammatory mediators and ultimately cell death. Endothelial cell damage is thought to trigger renal microvascular thrombosis by promoting activation of the coagulation cascade. There is evidence of complement system activation in D+HUS. Compared with normal controls, plasma levels of Bb and SC5b-9 are increased in children with D+HUS at hospitalization, and by day 28 after discharge, plasma levels have normalized (Thurman, JM et al., Clin. J. Am. Soc. Nephrol. 4:1920-1924, 2009). Shiga toxin 2 (Stx2) was found to activate human complement in vitro primarily through the alternative pathway in the fluid phase, as activation occurs in the presence of ethylene glycol tetraacetic acid, which blocks the classical pathway (Orth, D. et al., J. Immunol. 182: 6394-6400, 2009). Furthermore, Stx2 binds to factor H, but not factor I, and delays the cofactor activity of factor H on the cell surface (Orth et al., 2009, supra). These results suggest that Shiga toxin may cause renal damage through multiple potential mechanisms, including direct toxic effects and indirectly through complement activation or inhibition of complement regulators. Toxic effects on the vascular endothelium are expected to activate complement through LEA-2, as demonstrated by the effectiveness of MASP-2 blockade in preventing complement-mediated reperfusion injury in various vascular beds, as shown in Examples 21-23 herein, see also Schwaeble, WJ et al., Proc. Natl. Acad. Sci. 108: 7523-7528, 2011.
[0215] In a murine HUS model induced by co-injection of Shiga toxin and lipopolysaccharide, factor B-deficient mice had less thrombocytopenia and were protected from renal damage compared to wild-type mice, suggesting LEA-1-dependent activation of the alternative pathway in microvascular thrombosis (Morigi, M. et al., J. Immunol. 187: 172-180, 2011). As described in Example 33 herein, in the same model, administration of MASP-2 antibodies was also effective and increased survival after STX challenge, suggesting a LEA-2-dependent complement pathway in microvascular thrombosis.
[0216] In view of the above, LEA-1 and LEA-2 inhibitors are expected to have independent therapeutic benefits in the treatment or prevention of HUS. In addition, LEA-1 and LEA-2 inhibitors used together may achieve additional therapeutic benefits compared to either agent alone, or may provide effective treatment for a wider range of patient subpopulations. Combined LEA-1 and LEA-2 inhibition can be achieved by co-administering a LEA-1 blocker and a LEA-2 blocker. Optimally, the inhibitory functions of LEA-1 and LEA-2 can be contained in a single molecular entity, such as a bispecific antibody containing specific binding sites for MASP-1 / 3 and MASP-2, or a bispecific antibody in which each binding site can bind to and block either MASP-1 / 3 or MASP-2.
[0217] aHUS Atypical HUS is a rare disease with an estimated incidence of 2 in 1 million patients in the United States (Loirat, C. and Fremeaux-Bacchi, V. Orphanet J. Rare Dis. 6:60-90, 2011). Atypical HUS can develop at any age, but most patients present during childhood. Atypical HUS is heterogeneous: some cases are familial, some are recurrent, and some are triggered by infectious illnesses, typically upper respiratory tract or gastroenteritis. The onset of aHUS is typically sudden, and most patients require dialysis upon admission. Additional renal manifestations are present in approximately 20% of patients and may involve the central nervous system, myocardial infarction, distal ischemic gangrene, or multiorgan failure. Treatment of aHUS includes supportive care for organ dysfunction, plasma transfusions or plasma exchange, and eculizumab, a humanized monoclonal antibody against C5 recently approved for use in the United States and the European Union. The prognosis of aHUS is not as good as that of D+HUS, with a mortality rate of approximately 25% in the acute phase, and most survivors develop end-stage renal disease.
[0218] Atypical HUS is characterized by complement dysregulation, with approximately 50% of patients harboring mutations in genes encoding complement regulatory proteins (Zheng and Sadler, 2008, supra). Most mutations are found in factor H (FH); others include membrane cofactor protein (MCP), factor I (FI), factor B, and C3. Functional studies have shown that FH, MCP, and FI mutations result in loss of function, leading to increased complement activation, while factor B mutations are gain-of-function. The effects of these mutations primarily affect the alternative pathway. These genetic abnormalities are risk factors, not the sole cause of the disease, as approximately 50% of family members carrying the mutation do not develop the disease by age 45 (Loirat and Fremeaux-Bacchi, 2011, supra).
[0219] Factor H is a complement regulatory protein that protects host tissues from alternative pathway complement attack. FH regulates the alternative pathway amplification loop in three ways: it is a cofactor for FI, which cleaves C3b; it inhibits the formation of the alternative pathway C3 convertase, C3bBb; and it binds to polyanions on the cell surface and tissue matrix and blocks C3b deposition (Atkinson, JP and Goodship, THJ, J. Exp. Med. 6:1245-1248, 2007). Most FH mutations in patients with aHUS occur in the protein's C-terminal short consensus repeat domain, which results in defective FH binding to heparin, C3b, and endothelium, but does not alter plasma C3 regulation residing in the N-terminal domain (Pickering, MC et al., J. Exp. Med. 204:1249-1256, 2007). FH-deficient mice have uncontrolled plasma C3 activation and spontaneously develop membranoproliferative glomerulonephritis type II, but not aHUS. However, FH-deficient mice transgenically expressing a mouse FH protein functionally equivalent to the aHUS-associated human FH mutant spontaneously develop HUS but not membranoproliferative glomerulonephritis type II, providing in vivo evidence that defective control of alternative pathway activation in the renal endothelium is a key event in the pathogenesis of FH-associated aHUS (Pickering et al., 2007, supra). Another form of FH-associated aHUS occurs in patients with anti-FH autoantibodies that result in loss of FH functional activity; most of these patients have deletions in genes encoding five FH-associated proteins (Loirat and Fremeaux-Bacchi, 2011, supra).
[0220] Similar to FH, MCP inhibits complement activation by regulating C3b deposition on target cells. MCP mutations produce proteins with low C3b binding and cofactor activity, thus allowing dysregulated alternative pathway activation. FI is a serine protease that cleaves C3b and C4b in the presence of cofactors such as FH and MCP, thereby preventing the formation of C3 and C5 convertases and inhibiting both the alternative and classical complement pathways. Most FI-associated aHUS mutations result in reduced FI activity against C3b and C4b degradation (Zheng and Stadler, 2008, supra). FB is a zymogen that carries the catalytic site of the alternative pathway convertase C3bBb. Functional analysis has shown that aHUS-associated FB mutations result in increased alternative pathway activation (Loirat and Fremeaux-Bacchi, 2011, supra). Heterozygous mutations in C3 are associated with aHUS. Most C3 mutations cause defects in C3 binding to MCP, resulting in increased FB binding to C3b and increased formation of the C3 convertase (Loirat and Fremeaux-Bacchi, 2011, supra). Therefore, aHUS is a disease closely related to complement gene mutations that result in inadequate control of the alternative pathway amplification loop. Because the alternative pathway amplification loop is dependent on factor B proteolytic activity, and because LEA-1 is required for factor B activation (either through MASP-3-dependent cleavage or through factor D-type mediated cleavage, in which MASP-1 contributes to the maturation of factor D), LEA-1 blockade is expected to prevent uncontrolled complement activation in susceptible individuals. Therefore, LEA-1 blockade is expected to be effective in treating aHUS.
[0221] While the central role of the dysregulated alternative pathway amplification loop in aHUS is widely accepted, the triggers that initiate complement activation and the molecular pathways involved remain unresolved. Not all individuals carrying the aforementioned mutations develop aHUS. In fact, familial studies suggest that the penetrance of aHUS is only approximately 50% (Sullivan M. et al., Ann Hum Genet 74:17-26 2010). The natural history of the disease suggests that aHUS most commonly develops following an initiating event, such as an infectious episode or injury. It is well known that infectious agents activate the complement system. In the absence of pre-existing adaptive immunity, complement activation by infectious agents may be primarily initiated through LEA-1 or LEA-2. Therefore, in aHUS-susceptible individuals, lectin-dependent complement activation triggered by infection may represent the initiating trigger for the subsequent pathological amplification of complement activation, which may ultimately lead to disease progression. Therefore, another aspect of the present invention encompasses treating patients with aHUS secondary to infection by administering an effective amount of a LEA-1 or LEA-2 inhibitor.
[0222] Other forms of host tissue damage will activate complement via LEA-2, particularly vascular endothelial injury. Human vascular endothelial cells undergo oxidative stress and respond, for example, by expressing surface moieties that bind lectins and activate the LEA-2 complement pathway (Collard et al., Am J. Pathol 156(5):1549-56, 2000). Vascular injury following ischemia / reperfusion also activates complement via LEA-2 in vivo (Moller-Kristensen et al., Scand J Immunol 61(5):426-34, 2005). Activation of the lectin pathway in this setting has pathological consequences for the host, and as shown in Examples 22 and 23, inhibition of LEA-2 by blocking MASP-2 prevents further host tissue damage and adverse outcomes (see also Schwaeble PNAS, 2011, supra).
[0223] Thus, other pathways known to contribute to aHUS are activation of LEA-1 or LEA-2. It is therefore possible that in individuals genetically predisposed to aHUS, the LEA-1 and / or LEA-2 pathways may represent initial complement activation mechanisms that are inappropriately amplified in a dysregulated manner, thereby initiating the pathogenesis of aHUS. It follows that, in individuals susceptible to aHUS, agents that block complement activation through LEA-1 and / or LEA-2 are expected to prevent disease progression or reduce exacerbations.
[0224] Further supporting this concept, recent studies have identified Streptococcus pneumoniae as an important etiology in pediatric cases of aHUS (Lee, CS et al., Nephrology, 17(1):48-52 (2012); Banerjee R. et al., Pediatr Infect Dis J., 30(9):736-9 (2011)). This particular etiology appears to have a poor prognosis, with significant mortality and long-term morbidity. Notably, these cases involved non-intestinal infections that resulted in the manifestation of microangiopathy, uremia, and hemolysis without evidence of concurrent mutations in complement genes known to predispose to aHUS. It is important to note that Streptococcus pneumoniae is particularly effective at activating complement and does so primarily through LEA-2. Therefore, in the case of non-intestinal HUS associated with pneumococcal infection, the manifestations of microangiopathy, uremia, and hemolysis are expected to be driven primarily by LEA-2 activation, and agents that block LEA-2, including MASP-2 antibodies, are expected to prevent the progression of aHUS or reduce the severity of the disease in these patients. Thus, another aspect of the invention includes treating a patient suffering from non-intestinal aHUS associated with S. pneumoniae infection by administering an effective amount of a MASP-2 inhibitory agent.
[0225] TTP Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disorder of the blood coagulation system caused by autoimmune or inherited dysfunction of the activated coagulation cascade or complement system (George, JN, NEngl J Med; 354: 1927-35, 2006). This results in a large number of microscopic clots or thrombi in small blood vessels throughout the body, which is a unique feature of TMA. Red blood cells are subjected to shear stress, which damages their membranes, leading to intravascular hemolysis. The resulting reduced blood flow and endothelial damage lead to organ damage, including brain, heart and kidneys. The clinical features of TTP are thrombocytopenia, microangiopathic hemolytic anemia, neurological changes, renal failure and fever. In the era before plasma exchange, the mortality rate during acute attacks was 90%. Even with plasma exchange, the six-month survival rate is about 80%.
[0226] TTP can result from inherited or acquired inhibition of the enzyme ADAMTS-13, a metalloproteinase responsible for cleaving large multimers of von Willebrand factor (vWF) into smaller units. ADAMTS-13 inhibition or deficiency ultimately leads to increased coagulation (Tsai, H. J Am Soc Nephrol 14:1072–1081, 2003). ADAMTS-13 regulates vWF activity; in the absence of ADAMTS-13, vWF forms large multimers that are more likely to bind platelets and predispose patients to platelet aggregation and microvascular thrombosis.
[0227] Numerous ADAMTS13 mutations have been identified in individuals with TTP. The disease can also develop due to autoantibodies against ADAMTS-13. In addition, TTP can develop during breast, gastrointestinal, or prostate cancer (George JN., Oncology (Williston Park). 25: 908-14, 2011), pregnancy (mid-pregnancy or postpartum) (George JN., Curr Opin Hematol 10: 339-344, 2003), or is associated with diseases such as HIV or autoimmune diseases such as systemic lupus erythematosus (Hamasaki K et al., Clin Rheumatol. 22: 355-8, 2003). TTP can also be caused by certain drug therapies, including heparin, quinine, immune-mediated components, cancer chemotherapy agents (bleomycin, cisplatin, cytarabine, daunorubicin, gemcitabine, mitomycin C and tamoxifen), cyclosporine A, oral contraceptives, penicillin, rifampicin and antiplatelet drugs including ticlopidine and clopidogrel (Azarm, T. et al., J Res Med Sci., 16:353–357, 2011). Other factors or conditions associated with TTP are toxins such as bee venom, sepsis, splenic sequestration, transplantation, vasculitis, vascular surgery and infections such as Streptococcus pneumoniae and cytomegalovirus infection (Moake JL., N Engl J Med., 347:589–600, 2002). TTP due to transient functional ADAMTS-13 deficiency can occur due to endothelial cell damage associated with S. pneumoniae infection (Pediatr Nephrol, 26:631-5, 2011).
[0228] Plasma exchange is the standard treatment for TTP (Rock GA et al., N Engl J Med 325:393-397, 1991). Plasma exchange supplements ADAMTS-13 activity in patients with genetic defects and removes ADAMTS-13 autoantibodies in those with acquired autoimmune TTP (Tsai, HM, Hematol Oncol Clin North Am., 21(4):609–v, 2007). Additional agents such as immunosuppressive drugs are routinely added to the therapy (George, JN, N Engl J Med, 354:1927-35, 2006). However, plasma exchange is unsuccessful in approximately 20% of patients, relapse occurs in more than one-third of patients, and plasma exchange is expensive and technically demanding. In addition, many patients cannot tolerate plasma exchange. Therefore, there is still a pressing need for additional and better treatments for TTP.
[0229] Because TTP is a disease of the blood coagulation cascade, treatment with antagonists of the complement system can help stabilize and correct the disease. Although pathological activation of the alternative complement pathway is associated with aHUS, the role of complement activation in TTP is less clear. The functional deficiency of ADAMTS13 is important for TTP susceptibility, but it is not enough to cause acute attacks. Environmental factors and / or other genetic variations can contribute to the manifestation of TTP. For example, genes encoding proteins involved in the regulation of the coagulation cascade, vWF, platelet function, components of the endothelial vascular surface, or the complement system may be involved in the development of acute thrombotic microangiopathy (Galbusera, M. et al., Haematologica, 94: 166–170, 2009). Specifically, complement activation has been shown to play a key role; serum from thrombotic microangiopathy associated with ADAMTS-13 deficiency has been shown to cause C3 and MAC deposition and subsequent neutrophil activation, which may be eliminated by complement inactivation (Ruiz-Torres MP et al., Thromb Haemost, 93:443-52, 2005). In addition, it has recently been shown that during acute attacks of TTP, the levels of C4d, C3bBbP or C3a increase (M. Réti et al., J Thromb Haemost. 10 (5): 791-798, 2012), which is consistent with the activation of the classical, lectin and alternative pathways. This increased amount of complement activation in acute attacks can initiate terminal pathway activation and is responsible for the further deterioration of TTP.
[0230] The role of ADAMTS-13 and vWF in TTP is clearly responsible for platelet activation and aggregation, and its subsequent role in shear stress and deposition in microangiopathy. Activated platelets interact with and trigger both the classical and alternative complement pathways. Platelet-mediated complement activation increases the inflammatory mediators C3a and C5a (Peerschke E. et al., Mol Immunol, 47:2170-5 (2010)). Platelets can therefore serve as targets for classical complement activation in hereditary or autoimmune TTP.
[0231] As described above, lectin-dependent complement activation, by virtue of the thrombin-like activity of MASP-1 and LEA-2-mediated prothrombin activation, is the primary molecular pathway linking endothelial injury to the coagulation and microvascular thrombosis that occurs in HUS. Similarly, activation of LEA-1 and LEA-2 can directly drive the coagulation system in TTP. Activation of the LEA-1 and LEA-2 pathways can be initiated in response to the initial endothelial injury caused by ADAMTS-13 deficiency in TTP. Therefore, it is expected that LEA-1 and LEA-2 inhibitors, including but not limited to antibodies that block MASP-2 function, MASP-1 function, MASP-3 function, or both MASP-1 and MASP-3 function, will alleviate microangiopathy associated with intravascular coagulation, thrombosis, and hemolysis in patients with TTP.
[0232] Patients with TTP are often in the emergency room and have one or more of the following: purpura, renal failure, low platelets, anemia and / or thrombosis, including stroke. The current standard of care for TTP includes intraductal delivery (e.g., intravenous or other form of catheter) plasma exchange for two weeks or longer, generally three times a week, but up to daily. If the subject tests positive for the presence of an ADAMTS13 inhibitor (i.e., endogenous antibodies to ADAMTS13), plasma exchange can be performed in combination with immunosuppressive therapy (e.g., corticosteroids, rituximab (rituxan) or cyclosporine). Subjects with refractory TTP (approximately 20% of TTP patients) do not respond to at least two weeks of plasma exchange therapy.
[0233] In accordance with the foregoing, in one embodiment, in the setting of a preliminary diagnosis of TTP, or in a subject who exhibits one or more symptoms consistent with a diagnosis of TTP (e.g., central nervous system involvement, severe thrombocytopenia (platelet count less than or equal to 5000 / μL without aspirin, less than or equal to 20,000 / μL with aspirin), severe cardiac involvement, severe pulmonary involvement, gastrointestinal infarction, or gangrene), methods are provided for treating a subject with an effective amount of a LEA-2 inhibitor (e.g., a MASP-2 antibody) or a LEA-1 inhibitor (e.g., a MASP-1 or MASP-3 antibody) as a first-line therapy (in the absence of, or in combination with, plasma exchange). As a first-line therapy, the LEA-1 and / or LEA-2 inhibitor can be administered systemically to the subject, e.g., by intra-arterial, intravenous, intramuscular, inhalation, nasal, subcutaneous, or other parenteral administration. In some embodiments, LEA-1 and / or LEA-2 inhibitors are administered to subjects as first-line therapy in the absence of plasma exchange to avoid potential complications of plasma exchange, such as bleeding, infection, and exposure to conditions and / or allergic reactions inherent to plasma donors, or in subjects who are otherwise averse to plasma exchange, or in situations where plasma exchange is not available. In some embodiments, LEA-1 and / or LEA-2 inhibitors are administered to subjects with TTP in combination (including co-administration) with immunosuppressants (e.g., corticosteroids, rituximab, or cyclosporine) and / or in combination with concentrated ADAMTS-13.
[0234] In some embodiments, the method comprises administering a LEA-1 and / or LEA-2 inhibitor to a subject with TTP via a catheter (e.g., intravenously) for a first time period (e.g., an acute phase lasting at least one day to one or two weeks), and then administering the LEA-1 and / or LEA-2 inhibitor subcutaneously to the subject for a second time period (e.g., a chronic phase of at least two weeks or longer). In some embodiments, the administration in the first and / or second time periods is performed without plasma exchange. In some embodiments, the method is used to maintain the subject to prevent the subject from suffering from one or more symptoms associated with TTP.
[0235] In another embodiment, a method is provided for treating a subject with refractory TTP (i.e., a subject who has not responded to at least two weeks of plasma exchange therapy) by administering a LEA-1 and / or LEA-2 inhibitor in an amount effective to reduce one or more symptoms of TTP. In one embodiment, the LEA-1 and / or LEA-2 inhibitor is administered to a subject with chronic refractory TTP by subcutaneous or other parenteral administration for a period of at least two weeks or longer. Administration may be repeated as determined by a physician until the condition is resolved or controlled.
[0236] In some embodiments, the method further comprises determining the level of at least one complement factor (e.g., C3, C5) in the subject prior to and optionally during treatment, wherein determination of a decreased level of the at least one complement factor compared to a standard value or a healthy control subject indicates a need for continued treatment with the LEA-1 and / or LEA-2 inhibitor.
[0237] In some embodiments, the method comprises administering a LEA-1 and / or LEA-2 inhibitor subcutaneously or intravenously to a subject having or at risk of developing TTP. Treatment is preferably performed daily, but can be performed less frequently, such as monthly. Treatment is continued until the subject's platelet count is greater than 150,000 / ml for at least two consecutive days.
[0238] In summary, LEA-1 and LEA-2 inhibitors are expected to provide independent therapeutic benefits in the treatment of TMA, including HUS, aHUS, and TTP. Furthermore, the use of LEA-1 and LEA-2 inhibitors together is expected to achieve additional therapeutic benefits compared to either agent alone, or may provide effective treatment for a wider range of patient subpopulations suffering from variant forms of TMA. Combined LEA-1 and LEA-2 inhibition can be achieved by co-administration of a LEA-1 blocker and a LEA2 blocker. Optimally, the inhibitory functions of LEA-1 and LEA-2 can be contained in a single molecular entity, such as a bispecific antibody comprising specific binding sites for MASP-1 / 3 and MASP-2, or a bispecific antibody in which each binding site can bind to and block either MASP-1 / 3 or MASP-2.
[0239] In accordance with the foregoing, one aspect of the present invention provides a method for inhibiting LEA-1-dependent complement activation to treat, prevent, or reduce the severity of a thrombotic microangiopathy, such as hemolytic uremic syndrome (HUS), atypical hemolytic uremic syndrome (aHUS), or thrombotic thrombocytopenic purpura (TTP), comprising administering to a subject suffering from or at risk of developing a thrombotic microangiopathy a composition comprising a therapeutically effective amount of a LEA-1 inhibitory agent comprising a MASP-1 inhibitory agent, a MASP-3 inhibitory agent, or a combination of MASP-1 / 3 inhibitory agents in a pharmaceutical carrier. The MASP-1, MASP-3, or MASP-1 / 3 inhibitory composition can be administered to the subject systemically, for example, by intra-arterial, intravenous, intramuscular, inhalation, nasal, subcutaneous, or other parenteral administration, or, for non-peptidergic agents, by oral administration. Administration can be repeated as determined by a physician until the condition is resolved or controlled.
[0240] In one embodiment, the method according to this aspect of the invention further comprises inhibiting LEA-2-dependent complement activation to treat, prevent, or reduce the severity of a thrombotic microangiopathy, such as hemolytic uremic syndrome (HUS), atypical hemolytic uremic syndrome (aHUS), or thrombotic thrombocytopenic purpura (TTP), comprising administering to a subject having, or at risk for developing, a thrombotic microangiopathy, a therapeutically effective amount of a MASP-2 inhibitory agent and a MASP-1, MASP-3, or MASP-1 / 3 inhibitory agent. As detailed above, in treating, preventing, or reducing the severity of thrombotic microangiopathy, the use of a combination of pharmacological agents that each block LEA-1 and LEA-2 is expected to provide improved therapeutic results compared to inhibition of LEA-1 alone. This result can be achieved, for example, by administering an antibody having LEA-1 blocking activity in combination with an antibody having LEA-2 blocking activity. In some embodiments, LEA-1- and LEA-2-blocking activities are combined into a single molecular entity, and the entity possesses combined LEA-1- and LEA-2-blocking activities. Such an entity may comprise or consist of a bispecific antibody in which one antigen-binding site specifically recognizes MASP-1 and blocks LEA-1, while a second antigen-binding site specifically recognizes MASP-2 and blocks LEA-2. Alternatively, such an entity may consist of a bispecific monoclonal antibody in which one antigen-binding site specifically recognizes MASP-3, thereby blocking LEA-1, while a second antigen-binding site specifically recognizes MASP-2 and blocks LEA-2. Optimally, such an entity may consist of a bispecific monoclonal antibody in which one antigen-binding site specifically recognizes both MASP-1 and MASP-3, thereby blocking LEA-1, while a second antigen-binding site specifically recognizes MASP-2 and blocks LEA-2.
[0241] The MASP-2 inhibitory agent can be administered to the subject systemically, for example, by intra-arterial, intravenous, intramuscular, inhalation, nasal, subcutaneous or other parenteral administration, or, for non-peptidergic agents, possibly oral administration. Administration can be repeated as determined by the physician until the condition is resolved or controlled.
[0242] Administration of the MASP-3 inhibitory compositions and, optionally, MASP-2 inhibitory compositions of the invention can be performed by a single administration of the composition (e.g., a single composition containing both a MASP-2 and a MASP-3 inhibitory agent or a bispecific or dual inhibitory agent, or co-administration of separate compositions), or by limited sequential administration, for treating, preventing, or reducing the severity of thrombotic microangiopathy in a subject having or at risk of developing thrombotic microangiopathy. Alternatively, the compositions can be administered at periodic intervals, e.g., daily, biweekly, weekly, every other week, monthly, or bimonthly, over an extended period of time to treat a subject in need thereof.
[0243] IX. The Role of MASP-2 and MASP-3 in Asthma and Therapeutic Approaches Using MASP-2 and MASP-3 Inhibitors. Asthma is a common chronic inflammatory disease of the respiratory tract. Approximately 25 million people in the United States have asthma, including 7 million children under the age of 18. More than half of these individuals experience at least one asthma attack annually, resulting in over 1.7 million emergency room visits and 450,000 hospitalizations annually (worldwide-web at gov / health / prof / lung / asthma / naci / asthma-info / index.htm, accessed May 4, 2012). The disease is heterogeneous, with multiple clinical phenotypes. The most common phenotype is allergic asthma. Other phenotypes include non-allergic asthma, aspirin-exacerbated respiratory disease, post-infectious asthma, occupational asthma, airborne irritant-induced asthma, and exercise-induced asthma. The main features of allergic asthma include: airway hyperresponsiveness (AHR) to a variety of specific and nonspecific stimuli, excessive airway mucus production, pulmonary eosinophilia and elevated serum IgE concentrations. Symptoms of asthma include cough, wheezing, chest tightness and shortness of breath. The goal of asthma treatment is to control the disease and minimize exacerbations, daily symptoms, and allow patients to engage in physical activity. Current treatment guidelines recommend step-by-step treatment until asthma control is achieved. The first treatment step is a fast-acting inhaled beta-2 agonist as needed, followed by the addition of controller medications such as inhaled corticosteroids, long-acting inhaled beta-2 agonists, leukotriene modifier drugs, theophylline, oral glucocorticoids and anti-IgE monoclonal antibodies.
[0244] Although asthma is multifactorial in origin, it is generally believed to arise from an inappropriate immune response to common environmental antigens in genetically susceptible individuals. Asthma is associated with complement activation, and the anaphylatoxins (AT) C3a and C5a have proinflammatory and immunomodulatory properties that are relevant to the development and regulation of allergic reactions (Zhang, X. and Kohl, J. Expert. Rev. Clin. Immunol., 6:269-277, 2010). However, the relative involvement of the classical, alternative, and lectin complement pathways in asthma is not well understood. The alternative pathway can be activated on the surface of allergens, while the lectin pathway can be activated by recognizing allergen polysaccharide structures, and both processes lead to the production of AT. Depending on the causative allergen involved, complement can be activated through different pathways. For example, highly allergenic grass pollen from the Parietaria family very effectively promotes MBL-dependent activation of C4, which involves LEA-2. In contrast, house dust mite allergens do not require MBL for complement activation (Varga et al. Mol Immunol., 39(14):839-46, 2003).
[0245] Environmental triggers of asthma can activate complement via the alternative pathway. For example, exposing human serum to cigarette smoke or diesel exhaust particles in vitro resulted in complement activation, an effect that was unaffected by the presence of EDTA, suggesting that activation occurs via the alternative pathway, rather than the classical pathway (Robbins, RA et al., Am. J. Physiol. 260: L254-L259, 1991; Kanemitsu, H. et al., Biol. Pharm. Bull. 21: 129-132, 1998). The role of the complement pathway in allergic airway inflammation was assessed in a mouse ovalbumin sensitization and challenge model. Wild-type mice developed AHR and airway inflammation in response to aeroallergen challenge. In the mouse ovalbumin model of allergic lung inflammation, a Crry-Ig fusion protein that inhibits all pathways of complement activation effectively prevented AHR and lung inflammation when administered systemically or locally by inhalation (Taube et al., Am J Respir Crit Care Med., 168(11):1333-41, 2003).
[0246] Compared to wild-type mice, mice deficient in factor B showed less AHR and airway inflammation, while mice deficient in C4 had similar effects to wild-type mice (Taube, C. et al., Proc. Natl. Acad. Sci. USA 103:8084-8089, 2006). These results support the role of the alternative pathway, rather than the classical pathway, in the murine aeroallergen challenge model. In a model using the same mice, studies of factor H (FH) provided further evidence of the importance of the alternative pathway (Takeda, K. et al., J. Immunol. 188:661-667, 2012). FH is a negative regulator of the alternative pathway, whose function is to prevent autologous damage to one's own tissues. Endogenous FH was found in the airways during allergen challenge, and inhibition of FH with a recombinant competitive antagonist increased the extent of AHR and airway inflammation (Takeda et al., 2012, supra). Therapeutic delivery of CR2-fH (a chimeric protein linking the iC3b / C3d binding region of CR2 with the complement regulatory region of FH, which targets the complement regulatory activity of fH to existing complement activation sites) protects against the development of AHR and eosinophil infiltration into the respiratory tract after allergen challenge (Takeda et al., 2012, supra). This protective effect was demonstrated with ovalbumin as well as ragweed allergen, a human-related allergen.
[0247] The role of lectin-dependent complement activation in asthma was evaluated in a mouse model of fungal asthma (Hogaboam et al., J. Leukocyte Biol. 75:805-814, 2004). These studies used mice genetically deficient in mannan-binding lectin A (MBL-A), a carbohydrate-binding protein that serves as a recognition component of the activated lectin complement pathway. MBL-A (+ / +) and MBL-A (- / -) Aspergillus fumigatus-sensitized mice were examined 4 and 28 days after it challenge with Aspergillus fumigatus conidia. Compared to the sensitized MBL-A (+ / +) group, the AHR of sensitized MBL-A (- / -) mice was significantly attenuated at both time points after conidia challenge. Compared to the wild-type group, lung TH2 cytokine levels (IL-4, IL-5, and IL13) were significantly lower in MBL-A (- / -) mice sensitized with Aspergillus fumigatus on day 4 after conidia. These results suggest that MBL-A and the lectin pathway play a major role in the development and maintenance of AHR during chronic fungal asthma.
[0248] The findings detailed above suggest the involvement of lectin-dependent complement activation in the pathogenesis of asthma. Experimental data suggest that factor B activation plays a key role. Given the fundamental role of LEA-1 in lectin-dependent activation of factor B and subsequent activation of the alternative pathway, it is expected that LEA-1 blockers will be beneficial in treating certain forms of asthma mediated by the alternative pathway. Therefore, such treatments may be particularly useful for asthma caused by house dust mites or environmental triggers such as cigarette smoke or diesel exhaust. On the other hand, asthmatic reactions triggered by grass pollen may cause LEA-2-dependent complement activation. Therefore, LEA-2 blockers are expected to be particularly useful in treating asthmatic conditions in this patient subset.
[0249] In view of the data detailed above, the present inventors believe that LEA-1 and LEA-2 mediate pathological complement activation in asthma. Depending on the triggering allergy, LEA-1 or LEA-2 may be preferentially involved. Therefore, LEA-1 blockers combined with LEA-2 blockers may have therapeutic utility in various forms of asthma, regardless of the underlying etiology. LEA-1 and LEA-2 blockers may have complementary, additive, or synergistic effects in preventing, treating, or reversing lung inflammation and asthma symptoms.
[0250] Combined LEA-1 and LEA-2 inhibition can be achieved by co-administration of a LEA-1 blocker and a LEA2 blocker. Optimally, the LEA-1 and LEA-2 inhibitory functions can be contained in a single molecular entity, such as a bispecific antibody containing specific binding sites for both MASP-1 / 3 and MASP-2, or a bispecific antibody in which each binding site can bind to and block either MASP-1 / 3 or MASP-2.
[0251] In accordance with the foregoing, one aspect of the present invention provides a method for inhibiting LEA-1-dependent complement activation to treat, prevent, or reduce the severity of asthma, the method comprising administering to a subject suffering from or at risk of developing asthma a composition comprising a therapeutically effective amount of a LEA-1 inhibitory agent comprising a MASP-1 inhibitory agent, a MASP-3 inhibitory agent, or a combination of MASP-1 / 3 inhibitory agents in a pharmaceutical carrier. The MASP-1, MASP-3, or MASP-1 / 3 inhibitory composition can be administered to the subject systemically, for example, by intra-arterial, intravenous, intramuscular, inhalation, nasal, subcutaneous, or other parenteral administration, or, for non-peptidergic agents, by oral administration. Administration can be repeated as determined by a physician until the condition is resolved or controlled.
[0252] In one embodiment, the method according to this aspect of the invention further comprises inhibiting LEA-2-dependent complement activation to treat, prevent, or reduce the severity of asthma, comprising administering to a subject having asthma or at risk of developing asthma a therapeutically effective amount of a MASP-2 inhibitory agent and a MASP-1, MASP-3, or MASP-1 / 3 inhibitory agent. As detailed above, in treating, preventing, or reducing the severity of asthma, the use of a combination of pharmacological agents that each block LEA-1 and LEA-2 is expected to provide improved therapeutic outcomes compared to inhibition of LEA-1 alone. This outcome can be achieved, for example, by co-administering an antibody having LEA-1 blocking activity in conjunction with an antibody having LEA-2 blocking activity. In some embodiments, the LEA-1 and LEA-2 blocking activities are combined into a single molecular entity, and the entity possesses combined LEA-1 and LEA-2 blocking activities. Such an entity may comprise or consist of a bispecific antibody in which one antigen-binding site specifically recognizes MASP-1 and blocks LEA-1, while a second antigen-binding site specifically recognizes MASP-2 and blocks LEA-2. Alternatively, such an entity may consist of a bispecific monoclonal antibody in which one antigen-binding site specifically recognizes MASP-3, thereby blocking LEA-1, while a second antigen-binding site specifically recognizes MASP-2, thereby blocking LEA-2. Optimally, such an entity may consist of a bispecific monoclonal antibody in which one antigen-binding site specifically recognizes both MASP-1 and MASP-3, thereby blocking LEA-1, while a second antigen-binding site specifically recognizes MASP-2, thereby blocking LEA-2.
[0253] The MASP-2 inhibitory agent can be administered to the subject systemically, for example, by intra-arterial, intravenous, intramuscular, inhalation, nasal, subcutaneous or other parenteral administration, or, for non-peptidergic agents, possibly oral administration. Administration can be repeated as determined by the physician until the condition is resolved or controlled.
[0254] Administration of the MASP-3 inhibitory compositions and, optionally, MASP-2 inhibitory compositions of the invention can be performed by a single administration of the composition (e.g., a single composition containing both a MASP-2 and a MASP-3 inhibitory agent or a bispecific or dual inhibitory agent, or co-administration of separate compositions), or by limited sequential administration, for treating, preventing, or reducing the severity of asthma in a subject having asthma or at risk of developing asthma. Alternatively, the compositions can be administered at periodic intervals, e.g., daily, biweekly, weekly, every other week, monthly, or bimonthly, over an extended period of time to treat a subject in need thereof.
[0255] X. The Role of MASP-2 and MASP-3 in Dense Deposit Disease and Treatment Methods Using MASP-2 and MASP-3 Inhibitors Membranoproliferative glomerulonephritis (MPGN) is a renal disorder characterized morphologically by proliferation of mesangial cells and thickening of the glomerular capillary walls due to subendothelial extension of the glomerular mesangium. MPGN is classified as primary (also called idiopathic) or secondary, with underlying diseases such as infectious diseases, systemic immune complex diseases, tumors, chronic liver disease, etc. Idiopathic MPGN includes three morphological types. Type I, or classic MPGN, is characterized by subendothelial deposition of immune complexes and activation of the classical complement pathway. Type II, or dense deposit disease (DDD), is characterized by additional intramembranous dense deposits. Type III is characterized by additional subepithelial deposits. Idiopathic MPGN is rare, accounting for approximately 4% to 7% of primary renal causes of nephrotic syndrome (Alchi, B. and Jayne, D. Pediatr. Nephrol. 25:1409-1418, 2010). MPGN primarily affects children and adolescents and may present with nephrotic syndrome, acute nephritic syndrome, asymptomatic proteinuria and hematuria, or recurrent gross hematuria. Renal dysfunction develops in most patients, and the disease has a slowly progressive course, with approximately 40% of patients developing end-stage renal disease within 10 years of diagnosis (Alchi and Jayne, 2010, supra). Current treatment options include glucocorticoids, immunosuppressants, antiplatelet therapy, and plasma exchange.
[0256] By immunofluorescence staining of renal biopsy, DDD is diagnosed by lack of immunoglobulin and presence of C3, and electron microscopy shows characteristic dense osmium deposits along the glomerular basement membrane.DDD is caused by the imbalance of the complement alternative pathway (Sethi et al., Clin J Am Soc Nephrol. 6 (5): 1009-17, 2011), which may be due to many different mechanisms. The most common abnormality of the complement system in DDD is the presence of C3 nephritic factor, which is an autoantibody for the alternative pathway C3 convertase (C3bBb), which increases its half-life and therefore the activation of the pathway (Smith, RJH et al., Mol. Immunol. 48: 1604-1610, 2011). Other alternative pathway abnormalities include factor H autoantibodies, gain-of-function C3 mutations, and factor H genetic defects (Smith et al., 2011, ibid.) that block factor H function. Recent case reports have shown that eclizumab (anti-C5 monoclonal antibody) treatment was associated with improved renal function in two patients with DDD (Daina, E. et al., New Engl. J. Med. 366:1161-1163, 2012; Vivarelli, M. et al., New Engl. J. Med. 366:1163-1165, 2012), suggesting a pathogenic role for complement activation in the renal consequences.
[0257] Given the aforementioned genetic, functional, immunohistochemical, and anecdotal clinical data, the critical role of complement in the pathogenesis of DDD is well established. Therefore, interventions that block the pathogenic mechanisms of complement activation or subsequent complement activation products are expected to be therapeutically useful in treating this condition.
[0258] Although human genetic data suggest that inappropriate control or overactivation of the alternative pathway amplification loop plays a key role, the events that initiate complement have not been determined. Immunohistochemical studies of renal biopsies have shown evidence of MBL deposition in diseased tissue, indicating that the lectin pathway is involved in initiating pathological complement activation in DDD (Lhotta et al., Nephrol Dial Transplant., 14(4):881-6, 1999). The importance of the alternative pathway has been further confirmed in experimental models. Factor H-deficient mice develop progressive proteinuria and renal pathological lesions characteristic of the human condition (Pickering et al., Nat Genet., 31(4):424, 2002). Pickering et al. further demonstrated that ablation of factor B, which mediates LEA-1-dependent activation of the alternative pathway, fully protected factor H-deficient mice from DDD (Pickering et al., Nat Genet., 31(4):424, 2002).
[0259] Therefore, it is expected that agents that block LEA-1 will effectively block lectin-dependent activation of the alternative pathway and, therefore, will provide an effective treatment for DDD. Given that the alternative pathway amplification loop is dysregulated in patients with DDD, it is further expected that agents that block the amplification loop will be effective. Because LEA-1 targeting agents that block MASP-1 or MASP-1 and MASP-3 inhibit the maturation of Factor D, such agents are predicted to effectively block the alternative pathway amplification loop.
[0260] As detailed above, significant MBL deposition is found in diseased kidney specimens, highlighting the potential involvement of lectin-driven activation events in the pathogenesis of DDD. Once initial tissue damage to the glomerular capillaries is established, additional MBL is likely to bind to the damaged glomerular endothelium and underlying mesangial structures. This tissue damage is known to lead to LEA-2 activation, which can cause further complement activation. Therefore, LEA-2 blockade is also expected to have utility in preventing further complement activation in damaged glomerular structures, thereby preventing further disease progression to end-stage renal failure.
[0261] The data detailed above indicate that LEA-1 and LEA-2 contribute to separate pathological complement activation processes in DDD. Therefore, LEA-1 and LEA-2 blockers, alone or in combination, are expected to be useful in the treatment of DDD.
[0262] When used in combination, LEA-1 and LEA-2 blockers are expected to be more effective than either agent alone, or to be used to treat different stages of the disease. LEA-1 and LEA-2 blockers may therefore have complementary, additive, or synergistic effects in preventing, treating, or reversing DDD-associated renal dysfunction.
[0263] Combined LEA-1 and LEA-2 inhibition can be achieved by co-administering a LEA-1 blocker and a LEA-2 blocker. Optimally, the inhibitory LEA-1 and LEA-2 blockers can be contained within a single molecular entity, such as a bispecific antibody containing specific binding sites for both MASP-1 / 3 and MASP-2, or a bispecific antibody in which each binding site can bind to and block either MASP-1 / 3 or MASP-2.
[0264] In accordance with the foregoing, one aspect of the present invention provides a method for inhibiting LEA-1-dependent complement activation to treat, prevent, or reduce the severity of dense deposit disease, comprising administering to a subject having, or at risk for developing, dense deposit disease, a composition comprising a therapeutically effective amount of a LEA-1 inhibitory agent comprising a MASP-1 inhibitory agent, a MASP-3 inhibitory agent, or a combination of MASP-1 / 3 inhibitory agents in a pharmaceutical carrier. The MASP-1, MASP-3, or MASP-1 / 3 inhibitory composition can be administered to the subject systemically, for example, by intra-arterial, intravenous, intramuscular, inhalation, nasal, subcutaneous, or other parenteral administration, or, for non-peptidergic agents, by oral administration. Administration can be repeated as determined by a physician until the condition is resolved or controlled.
[0265] In another aspect, methods are provided for inhibiting LEA-2-dependent complement activation to treat, prevent, or reduce the severity of dense deposit disease, comprising administering to a subject having, or at risk for developing, dense deposit disease, a therapeutically effective amount of a MASP-2 inhibitory agent. In another aspect, methods are provided comprising inhibiting both LEA-1 and LEA-2-dependent complement activation to treat, prevent, or reduce the severity of dense deposit disease, comprising administering to a subject having, or at risk for developing, dense deposit disease, a therapeutically effective amount of a MASP-2 inhibitory agent and a MASP-1, MASP-3, or MASP-1 / 3 inhibitory agent.
[0266] In some embodiments, the methods involve inhibiting both LEA-1-dependent complement activation and LEA-2-dependent complement activation. As detailed above, in treating, preventing, or reducing the severity of dense deposit disease, the use of a combination of pharmacological agents that each block LEA-1 and LEA-2 is expected to provide improved therapeutic outcomes compared to inhibiting LEA-1 alone. This outcome can be achieved, for example, by co-administering an antibody with LEA-1 blocking activity in conjunction with an antibody with LEA-2 blocking activity. In some embodiments, the LEA-1- and LEA-2-blocking activities are combined into a single molecular entity, and the entity possesses combined LEA-1- and LEA-2-blocking activities. Such an entity may comprise or consist of a bispecific antibody in which one antigen-binding site specifically recognizes MASP-1 and blocks LEA-1, while a second antigen-binding site specifically recognizes MASP-2 and blocks LEA-2. Alternatively, such an entity may consist of a bispecific monoclonal antibody in which one antigen-binding site specifically recognizes MASP-3, thereby blocking LEA-1, while a second antigen-binding site specifically recognizes MASP-2, thereby blocking LEA-2. Optimally, such an entity may consist of a bispecific monoclonal antibody in which one antigen-binding site specifically recognizes both MASP-1 and MASP-3, thereby blocking LEA-1, while a second antigen-binding site specifically recognizes MASP-2, thereby blocking LEA-2.
[0267] The LEA-1 and / or LEA-2 inhibitor can be administered to the subject systemically, for example, by intra-arterial, intravenous, intramuscular, inhalation, nasal, subcutaneous or other parenteral administration, or, for non-peptidergic agents, possibly by oral administration. Administration can be repeated as determined by the physician until the condition is resolved or controlled.
[0268] Administration of the MASP-3 inhibitory compositions and / or MASP-2 inhibitory compositions of the invention can be performed by a single administration of the composition (e.g., a single composition containing a MASP-2 and / or MASP-3 inhibitory agent or a bispecific or dual inhibitory agent, or co-administration of separate compositions), or by limited sequential administration, to treat, prevent, or reduce the severity of dense deposit disease in a subject in need thereof. Alternatively, the compositions can be administered at periodic intervals, e.g., daily, biweekly, weekly, every other week, monthly, or bimonthly, over an extended period of time to treat a subject in need thereof.
[0269] XI. Role of MASP-2 and MASP-3 in Micro-Immune Necrotizing Crescentic Glomerulonephritis and Therapeutic Approaches Using MASP-2 and MASP-3 Inhibitory Agents Micro-Immune Necrotizing Crescentic Glomerulonephritis (NCGN) is a rapidly progressive form of glomerulonephritis in which the glomerular capillary walls show signs of inflammation but also have minimal detectable immune complex deposits or anti-glomerular basement membrane antibodies. This condition is associated with a rapid decline in renal function. Most patients with NCGN are found to have anti-neutrophil cytoplasmic autoantibodies (ANCAs) and therefore belong to a group of diseases known as ANCA-associated vasculitis. Vasculitis is a vascular disorder characterized by inflammation and fibrinoid necrosis of the vessel wall. Systemic vasculitis is classified according to vessel size: large, medium, and small. Several forms of small vessel vasculitis are associated with the presence of ANCAs, namely Wegener's granulomatosis, microscopic polyangiitis, Churg-Strauss syndrome, and renal-limited vasculitis (NCGN). They can also be manifestations of underlying conditions such as systemic lupus erythematosus. ANCA target antigens include proteinase-3 (PR3) and myeloperoxidase (MPO). Micro-immune NCGN is rare, with a reported incidence of approximately 4 per million in Wessex, UK (Hedger, N. et al., Nephrol. Dial. Transplant. 15: 1593-1599, 2000). In a Wessex series of 128 patients with micro-immune NCGN, 73% were ANCA positive, 59% required initial dialysis, and 36% required long-term dialysis. Treatment of micro-immune NCGN includes corticosteroids and immunosuppressants such as cyclophosphamide and azathioprine. Other treatment options for ANCA-associated vasculitis include rituximab and plasma exchange (Chen, M. and Kallenberg, CGM Nat. Rev. Rheumatol. 6: 653-664, 2010).
[0270] Although NCGN is characterized by trace complement deposition, the alternative complement pathway has been implicated in its pathogenesis. Renal biopsy evaluation of 7 patients with MPO-ANCA-associated microimmune NCGN detected the presence of membrane attack complex, C3d, factor B, and factor P (which were not detected in biopsies of normal controls or patients with minimal change disease), while C4d and mannose-binding lectin were not detected, indicating selective activation of the alternative pathway (Xing, GQ et al. J. Clin. Immunol. 29: 282-291, 2009). Experimental NCGN can be induced by transferring anti-MPO IgG to wild-type mice or transferring anti-MPO splenocytes to immunodeficient mice (Xiao, H. et al. J. Clin. Invest. 110: 955-963, 2002). In this mouse model of NCGN, gene knockout mice were used to study the role of specific complement activation pathways. After injection of anti-MPO IgG, C4d was activated. - / - Mice developed nephropathy comparable to wild-type mice, whereas C5 - / - and factor B - / - The mice did not develop renal disease, indicating that the alternative pathway is involved in this model, while the classical and lectin pathways are not (Xiao, H. et al. Am. J. Pathol. 170: 52-64, 2007). Furthermore, incubation of patients' MPO-ANCA or PR3-ANCA IgG with TNF-α-primed human neutrophils resulted in the release of factors that lead to complement activation in normal human serum, as detected by C3a production; this effect was not observed for IgG from healthy subjects, suggesting a potential pathogenic role for ANCA in neutrophil and complement activation (Xiao et al., 2007, supra).
[0271] Based on the above outlined role of the alternative pathway in this condition, it is expected that blocking activation of the alternative pathway will have utility in the treatment of ANCA-positive NCGN. Given that fB activation is required for pathogenesis, it is expected that inhibitors of LEA-1 will be particularly useful in treating this condition and preventing further decline in renal function in these patients.
[0272] However, another subset of patients develops progressive renal vasculitis with crescent formation, accompanied by a rapid decline in renal function in the absence of ANCA. This form of the condition is called ANCA-negative NCGN and constitutes approximately one-third of all patients with minimally immune NCGN (Chen et al., JASN 18(2):599-605, 2007). These patients tend to be younger, and the renal consequences are often particularly severe (Chen et al., Nat Rev Nephrol., 5(6):313-8, 2009). The distinguishing pathological feature of these patients is the deposition of MBL and C4d in renal lesions (Xing et al., J Clin Immunol. 30(1):144-56, 2010). The staining intensity of MBL and C4d in renal biopsies is negatively correlated with renal function (Xing et al., 2010, supra). These results suggest that lectin-dependent complement activation plays an important role in the pathogenesis. The fact that C4d, but not factor B, is commonly present in diseased tissue specimens suggests the involvement of LEA-2.
[0273] Based on the aforementioned role of lectin-dependent complement activation in ANCA-negative NCGN, it is expected that blocking activation of the LEA-2 pathway will have utility in the treatment of ANCA-negative NCGN.
[0274] The data detailed above indicate that LEA-1 and LEA-2 mediate pathological complement activation in ANCA-positive and ANCA-negative NCGN, respectively. Therefore, LEA-1 blockade combined with LEA-2 blockade is expected to have therapeutic utility in all forms of microimmune NCGN, regardless of underlying etiology. LEA-1 and LEA-2 blockade may therefore have complementary, additive, or synergistic effects in preventing, treating, or reversing NCGN-associated renal dysfunction.
[0275] LEA-1 and LEA-2 inhibitors used together may achieve additional therapeutic benefit compared to either agent alone, or may provide effective treatment for a wider range of patient subpopulations. Combined LEA-1 and LEA-2 inhibition can be achieved by co-administering a LEA-1 blocker and a LEA2 blocker. Optimally, LEA-1 and LEA-2 inhibitory functions can be contained in a single molecular entity, such as a bispecific antibody containing specific binding sites for both MASP-1 / 3 and MASP-2, or a bispecific antibody in which each binding site can bind to and block either MASP-1 / 3 or MASP-2.
[0276] In accordance with the foregoing, one aspect of the present invention provides a method for inhibiting LEA-1-dependent complement activation to treat, prevent, or reduce the severity of micro-immunonecrotizing crescentic glomerulonephritis, the method comprising administering to a subject suffering from or at risk for developing micro-immunonecrotizing crescentic glomerulonephritis a composition comprising a therapeutically effective amount of a LEA-1 inhibitory agent comprising a MASP-1 inhibitory agent, a MASP-3 inhibitory agent, or a combination of MASP-1 / 3 inhibitory agents in a pharmaceutical carrier. The MASP-1, MASP-3, or MASP-1 / 3 inhibitory composition can be administered to the subject systemically, for example, by intra-arterial, intravenous, intramuscular, inhalation, nasal, subcutaneous, or other parenteral administration, or, for non-peptidergic agents, by oral administration. Administration can be repeated as determined by a physician until the condition is resolved or controlled.
[0277] In another aspect, methods are provided for inhibiting LEA-2-dependent complement activation to treat, prevent, or reduce the severity of micro-immunonecrotizing crescentic glomerulonephritis, comprising administering to a subject having or at risk for developing micro-immunonecrotizing crescentic glomerulonephritis a therapeutically effective amount of a MASP-2 inhibitory agent. In another aspect, methods are provided comprising inhibiting both LEA-1 and LEA-2-dependent complement activation to treat, prevent, or reduce the severity of micro-immunonecrotizing crescentic glomerulonephritis, comprising administering to a subject in need thereof a therapeutically effective amount of a MASP-2 inhibitory agent and a MASP-1, MASP-3, or MASP-1 / 3 inhibitory agent.
[0278] In some embodiments, the methods involve inhibiting both LEA-1-dependent complement activation and LEA-2-dependent complement activation. As detailed above, in treating, preventing, or reducing the severity of microimmunonecrotizing crescentic glomerulonephritis, the use of a combination of pharmacological agents that each block LEA-1 and LEA-2 is expected to provide improved therapeutic outcomes compared to inhibiting LEA-1 alone. This outcome can be achieved, for example, by co-administering an antibody with LEA-1 blocking activity in conjunction with an antibody with LEA-2 blocking activity. In some embodiments, the LEA-1- and LEA-2-blocking activities are combined into a single molecular entity, and the entity possesses combined LEA-1- and LEA-2-blocking activities. Such an entity may comprise or consist of a bispecific antibody in which one antigen-binding site specifically recognizes MASP-1 and blocks LEA-1, while a second antigen-binding site specifically recognizes MASP-2 and blocks LEA-2. Alternatively, such an entity may consist of a bispecific monoclonal antibody in which one antigen-binding site specifically recognizes MASP-3, thereby blocking LEA-1, while a second antigen-binding site specifically recognizes MASP-2, thereby blocking LEA-2. Optimally, such an entity may consist of a bispecific monoclonal antibody in which one antigen-binding site specifically recognizes both MASP-1 and MASP-3, thereby blocking LEA-1, while a second antigen-binding site specifically recognizes MASP-2, thereby blocking LEA-2.
[0279] The MASP-2 inhibitory agent can be administered to the subject systemically, for example, by intra-arterial, intravenous, intramuscular, inhalation, nasal, subcutaneous or other parenteral administration, or, for non-peptidergic agents, possibly oral administration. Administration can be repeated as determined by the physician until the condition is resolved or controlled.
[0280] Administration of the MASP-3 inhibitory compositions and / or MASP-2 inhibitory compositions of the invention can be performed by a single administration of the composition (e.g., a single composition containing a MASP-2 and / or MASP-3 inhibitory agent or a bispecific or dual inhibitory agent, or co-administration of separate compositions), or by limited sequential administration, for treating, preventing, or reducing the severity of microimmunonecrotizing crescentic glomerulonephritis. Alternatively, the compositions can be administered at periodic intervals, such as daily, biweekly, weekly, every other week, monthly, or bimonthly, over an extended period of time to treat a subject in need thereof.
[0281] XII. The Role of MASP-2 and MASP-3 in Traum...
Claims
1. Use of a composition comprising an amount of a MASP-3 inhibitory agent effective to inhibit MASP-3-dependent complement activation in the preparation of a medicament for treating a subject suffering from or at risk for developing a disease or condition selected from the group consisting of disseminated intravascular coagulation, asthma, dense deposit disease, microimmunonecrotizing crescentic glomerulonephritis, traumatic brain injury, aspiration pneumonia, endophthalmitis, neuromyelitis optica, age-related macular degeneration, and Behcet's disease, wherein the MASP-3 inhibitory agent is a MASP-3 monoclonal antibody or fragment thereof that specifically binds to the serine protease domain of human MASP-3 (aa 450-711 of SEQ ID NO:8) and inhibits factor D maturation.
2. The use of claim 1, wherein the MASP-3 monoclonal antibody or fragment thereof is at least one of the following: (i) a MASP-3 inhibitory antibody that binds to a portion of MASP-3 (SEQ ID NO:8) and does not inhibit MASP-1 or MASP-2; (ii) a MASP-3 inhibitory antibody that specifically binds to a portion of MASP-3 with an affinity that is at least 10 times greater than its binding affinity to MASP-1 (SEQ ID NO: 10); and / or (iii) a MASP-3 inhibitory antibody that specifically binds to the serine protease domain of MASP-3 (aa 450-711 of SEQ ID NO: 8).
3. The use of claim 1, wherein the composition further comprises at least one of the following: a MASP-1 inhibitory agent, a MASP-2 inhibitory agent, or a combination of a MASP-1 inhibitory agent and a MASP-2 inhibitory agent.
4. The use of claim 3, wherein the MASP-1 inhibitor is at least one of: (i) a MASP-1 monoclonal antibody or a fragment thereof, which specifically binds to a portion of SEQ ID NO: 10; (ii) a MASP-1 inhibitory agent that specifically binds to a portion of MASP-1 with an affinity that is at least 10 times greater than its binding affinity to MASP-3 (SEQ ID NO: 8); and / or (iii) a MASP-1 inhibitory agent that specifically binds to the serine protease domain of MASP-1 (aa 449-694 of SEQ ID NO: 10).
5. The use of claim 3, wherein the MASP-2 inhibitory agent is a MASP-2 monoclonal antibody or a fragment thereof, which specifically binds to a portion of SEQ ID NO:
5.
6. The method of claim 1, wherein the disseminated intravascular coagulation is selected from disseminated intravascular coagulation secondary to sepsis, trauma, infection (bacterial infection, viral infection, fungal infection, parasitic infection), malignancy, transplant rejection, transfusion reaction, obstetric complications, vascular aneurysm, liver failure, heat stroke, burns, radiation exposure, shock or severe toxic reaction.
7. The use of claim 1, wherein the composition is administered systemically.
8. The use of claim 7, wherein the composition is administered subcutaneously, intramuscularly, intravenously, intraarterially or as an inhalant.
